AMC 098 (Version 4 .0) 08DEC2020 i 
NCI Version Date 08DEC2020  SUMMARY OF CHANGES  
A Pi[INVESTIGATOR_634937] 4.0 
 
NCI Protocol #: AMC -098 
Local Protocol #: AMC -098 
 NCI Version Date: 08DEC2020 Protocol Date: 08DEC2020  
I. Scientific and Substantive Changes:  
# Section  Comments  
1.  4.5 
5.1 
5.1.2  The protocol was updated to clarify that participants who experience a 
cumulative dose delay of > [ADDRESS_848289] also been included, and requirements for US 
sites to complete a separate DARF documenting drug accountability for each protocol using nelfinavir has been removed as sites are permitted document using a single DARF. 
 
In addition, l ocally sourced supplies of FDA -approved Viracept® 
(nelfinavir mesylate) 625 mg tablets may be sourced by [CONTACT_635000]
e AMC with prior approval from the AMC 
ODMC , as permitted by [CONTACT_635001] . 
3.  [IP_ADDRESS]  
Appendix X  Prolonged storage in formalin may affect biopsy tissue specimen 
viability and result in the inability to perform immunohistochemistry 
(IHC) studies. To ensure specimen viability , the protocol has been 
updated to require that tissue for ICH studies be processed locally to a FFPE block and shipped at ambient temperature 
to the AMC 
Biorepository. Centers are instructed to refer to the MOP for processing 
requirements.  If the previously submitted baseline tissue samples are 
inadequate to perform IHC studies, [ADDRESS_848290] treatment discontinuation, if in the 
AMC 098 (Version 4 .0) 08DEC2020 ii 
NCI Version Date 08DEC2020  # Section  Comments  
opi[INVESTIGATOR_634938]. All participants must complete the follow 
up evaluations prior to starting alternative therapy.  
5.  9.0 This section has been revised to allow CTEP -registered physician 
investigators and CTEP- registered advanced practice clinicians who are 
non-physician investigators (i.e., NP or PA) to perform toxicity 
assessment per local licensure requirements.  Delegation of these tasks 
must be recorded on the institution’s AMC delegation of task log (D TL) 
or local equivalent.  
6.  Appendix XI  Sulfamethoxazole and trimethoprim (Bactrim) have been removed 
from Appendix XI as drugs that may potentially interact with nelfinavir, 
as there is limited scientific evidence sug gesting potential interactions. 
Clinically, Bactrim and nelfinavir are often taken concurrently when 
nelfinavir is the primary ART regimen.  
 
II. Administrative and Editorial Changes : 
# Section  Comments  
7.  Global  Version number and version date has been updated  from v3 .0 / 
13FEB2019 to v4 .0 / 08DEC 2020.  
8.  Global  Grammar and spelling have  been  updated throughout.  
9.  Title Pa ge CTEP IVR numbers have been  added for the chairs/co -chairs.  
10.  Protocol 
Roster  The protocol roster has been  updated to accurately ref lect investigator 
qualifications , credentials, address/contact [CONTACT_3031], and titles.  In 
addition, [EMAIL_12106] has replaced [EMAIL_1741]  as 
the contact [CONTACT_635002].  
11.  Protocol 
Schema  
10.1 Phrasing  that the study will need to enroll 18 HIV positive and 18 HIV 
negative participants to achieve sufficient power when completing the primary analysis  has been removed from Section 10.1. and the protocol 
schema has been revised to indicate approxima tely 18 participants HIV 
positive and 18 HIV negative participants will be enrolled. Th ese 
updates w ere 
made for consistency throughout the protocol as the 
enrollment of 18 HIV positive and 18 HIV negative participants is the 
enrollment goal (see “Populati on” under the Protocol S ynopsis ).  
12.  2.4.[ADDRESS_848291] been replaced  with 
the AMC core lab  title, the AMC Pharmacology Core Lab at Johns 
Hopkins University  (Lab PI: [INVESTIGATOR_634939]) . 
13.  3.1.[ADDRESS_848292] 
AMC 098 (Version 4 .0) 08DEC2020 iii 
NCI Version Date 08DEC2020  # Section  Comments  
been clarified. A negative result on any of the nationally approved tests 
(including rapid tests) is sufficient to satisfy inclusion the criterion.  
14.  3.[ADDRESS_848293] of 
Abbreviations 
8.1.10 
8.2.5 
[IP_ADDRESS] 
[IP_ADDRESS] 
Appendix I  The individual chemistry tests required throughout the course of the 
study (based on a typi[INVESTIGATOR_2855] U.S. chemistry panel) and timepoints for 
collection were clarified . CBCs and chemistries performed for 
eligibil ity must be completed within 4 weeks prior to enrollment, while 
baseline/screening chemistries must be collected within [ADDRESS_848294] of 
Abbreviations.  
16.  [IP_ADDRESS]  
[IP_ADDRESS]  Blood collections for PK analysis  have been removed  from the  
baseline/screening evaluations, as the first timepoint of collection is 
included in the during treatment evaluations per  Section [IP_ADDRESS] and 
Appendix II . 
17.  [IP_ADDRESS]  
Appendix II 
Appendix IX  Added clarification that b lood collection for  PKs may occur  within  3 
days before dose administration  (i.e., - 3 day window) , and listed the 
cycle  numbers  corresponding to the study week . 
18.  [IP_ADDRESS]  
[IP_ADDRESS]  The requirement that KS tumor assessments must be completed at each 
study visit (every 2 weeks) and at the early  treatment discontinuation 
and follow -up visits has been clarified. Because there is only one early 
treatment discontinuation visit and one follow -up visit, KS response 
assessment will only be completed once for each timepoint.  
19.  12.[ADDRESS_848295] be updated 
contemporaneously as personnel are added or removed and/or study roles and delegated tasks change. Changes must be approved by [CONTACT_150894], 
and documented by [CONTACT_5657]/her initials and date, before they are 
implemented.  
20.  Appendix II  Specimen handling instructions for IHC studies has been replaced with 
a reference/link to Appendix X.  
21.  Appendix VI  The AMC Data and Safety Monitoring plan was updated from version 
6.0 to the current version ( 9.0). Key revisions include the addition of an 
introduction to address the variety of systems the AMC uses for 
individual trials, changes to the data entry systems used by [CONTACT_635003] (OPEN/Rave), participation with NCI CIRB for ne
w AMC 
protocols, procedures for data reporting,  administrative changes 
AMC 098 (Version 4 .0) 08DEC2020 iv 
NCI Version Date 08DEC2020  # Section  Comments  
(updates to document organization, external links, and group 
terminology) , and to state that the IRB review plan is identified in the 
protocol , as the AMC is opening international studi es subject to 
review/requirements per their respective regions.  
22.  Appendix VII  The study diary was reorganized for clarity. “ Capsules ” were updated 
to “tablets. ” 
23.  Appendix X  This Appendix has been updated to indicate that RNA later for gene 
expression profiling may be sourced locally or provided by [CONTACT_229345].  
 
AMC 098 (Version 4 .0) 08DEC2020 1 
NCI Version Date 08DEC2020   
 
AIDS MALIGNANCY CONSORTIUM  
 
AMC PROTOCOL #098  
A Pi[INVESTIGATOR_634940]  
A Trial of the AIDS Malignancy Consortium (AMC)  
 Sponsored by:  [CONTACT_241212] (OHAM)  
 NCT Registration Number:  [STUDY_ID_REMOVED]  
 Pharmaceutical Support 
Provided by:  [CONTACT_3954].  
IND Status: Exempt  
 Commercially Available 
Agents:  Viracept® (nelfinavir mesylate)  
NSC #: 722664  
 Protocol Chair:  Soren Gantt, MD, PhD  (IVR -[ZIP_CODE] ) 
 Protocol Co -Chairs:  Rich Ambinder, MD  (IVR-[ZIP_CODE] ) 
Rachel Bender Ignacio, MD, MPH  (IVR-609501) 
Warren Phipps, MD, MPH  (IVR-615161) 
Version 4 .0, 08DEC20202 
NCI Version Date 08DEC2020  
 

 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848296] and follow 
this protocol: AMC Protocol # 098 – A Pi[INVESTIGATOR_634941] (Version 4.0, 08DEC2020 ), as written according to AMC, NCI, and FDA guidelines. I 
understand that no deviations from the protocol eligibility criteria or waivers for protocol 
deviations will be permitted.  
  _________________________________  ______________________ 
PI [INVESTIGATOR_31325] ( DDMMMYYYY) 
 
AMC 098 (Version 4 .0) 08DEC2020 3 
NCI Version Date 08DEC2020  TABLE OF CONTENTS  
SUMMARY OF CHANGES  ......................................................................................................... i  
I. Scientific and Substantive Changes:  ........................................................................... i  
II. Administrative and Editorial Changes: ...................................................................... ii 
AMC PROTOCOL SIGNATURE [CONTACT_1783]  .................................................................................. [ADDRESS_848297] oratory Objectives  ............................................................................................ 12  
2.0 BACKGROUND  ............................................................................................................. 13  
2.1 Study Disease ........................................................................................................... 13  
2.2 Study Agent ............................................................................................................. 14  
2.3 Study Design and Rationale ..................................................................................... 15  
2.4 Correlative Studies  ................................................................................................... 17  
3.0 PARTICIPANT SELECTION  ...................................................................................... 19  
3.1 Eligibility Criteria  .................................................................................................... 19  
3.2 Exclusion Criteria  .................................................................................................... 21  
3.3 Number of Participants to be Enrolled  ..................................................................... 23  
3.4 Participant Enrollment Procedures  .......................................................................... 23  
3.5 Enrollment at International Sites  ............................................................................. 24  
4.0 TREATMENT PLAN  ..................................................................................................... 25  
4.1 Agent Administration ............................................................................................... 25  
4.2 General Concomitant Medication and Supportive Care Guidelines ........................ 26  
4.3 Duration of Therapy  ................................................................................................. 26  
4.4 Duration of Follow Up ............................................................................................. 26  
4.5 Criteria for Removal from Treatment ...................................................................... 26  
5.0 DOSING DELAYS/DOSE MODIFICATIONS  ........................................................... 28  
5.1 Dose Modifications for Nelfinavir  ........................................................................... 28  
6.0 ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS  ...................... 32  
 
AMC 098 (Version 4 .0) 08DEC2020 4 
NCI Version Date 08DEC2020  6.1 Comprehensive Adverse Events and Potential Risks Lists...................................... 32  
6.2 Classification of AEs by [CONTACT_635004] 32  
6.3 Expedited Adverse Event Reporting ........................................................................ 33  
6.4 Routine Adverse Event Reporting ........................................................................... 36  
6.5 Secondary Malignancy  ............................................................................................. 36  
6.6 Second Malignancy .................................................................................................. 36  
7.0 PHARMACEUTICAL INFORMATION  ..................................................................... 37  
7.1 Nelfinavir (Viracept®, nelfinavir mesylate) ............................................................. 37  
7.2 Drug Orders, Transfers, Returns, and Accountability ............................................. 39  
8.0 CLINICAL AND LABORATORY EVALUATIONS  ................................................. 41  
8.1 Screening/Baseline Evaluations  ............................................................................... [ADDRESS_848298]  ................................................................................... 45  
9.1 Definition of Response ............................................................................................ 45  
10.0  STATISTICAL CONSIDERATIONS  .......................................................................... 48  
10.1  Study Design/Endpoints........................................................................................... 48  
10.2  Sample Size/Accrual Rate ........................................................................................ 50  
10.3  Reporting and Exclusions ........................................................................................ 50  
10.4  Stoppi[INVESTIGATOR_634942]  ................................................................................... 51  
11.0  ROLE OF DATA MANAGEMENT  ............................................................................. 52  
11.1  CRF Instructions  ...................................................................................................... 52  
11.2  Data Qu ality ............................................................................................................. 52  
11.3  Data Monitoring  ....................................................................................................... 52  
12.0  ETHICAL AND REGULATORY CONSIDERATIONS  ........................................... 53  
12.1  IRB Approval and Informed Consent ...................................................................... 53  
12.2  Changes to the Protocol ........................................................................................... 53  
12.3  Women and Minorities  ............................................................................................ 53  
12.4  Investigator and Research Associate Registration with CTEP  ................................ 55  
12.5  Protocol Registration and Delegation of Tasks Log ................................................ 56  
13.0  REFERENCES  ................................................................................................................ 57  
APPENDIX I: SCHEDULE OF PROCEDURES  .................................................................... 61  
 
AMC 098 (Version 4 .0) 08DEC2020 5 
NCI Version Date 08DEC2020  APPENDIX II: BIOMARKERS AND CORRELATIVE STUDIES  ..................................... 64  
APPENDIX III: PERFORMANCE STATUS SCALES  ......................................................... 65  
APPENDIX IV: AIDS AND CANCER SPECIMEN RESOURCE (ACSR) SPECIMEN 
PREPARATION AND SHIPPI[INVESTIGATOR_86883]  ............................................................ 66  
APPENDIX V: ACSR INFORMED CONSENT  ..................................................................... 69  
APPENDIX VI: AMC DATA AND SAFETY MONITORING PLAN ................................. 74  
APPENDIX VII: PARTICIPANT DRUG DIARY  .................................................................. 79  
APPENDIX VIII: CENTRAL PATHOLOGY REVIEW  ....................................................... 82  
APPENDIX IX: SPECIMEN PREPARATION AND SHIPPI[INVESTIGATOR_634943]  ........................... 83
 
APPENDIX X: AMC BIOREPOSITORY SPECIMEN PREPARATION AND SHIPPI[INVESTIGATOR_634944]  .............................................................. 85
 
APPENDIX XI: DRUGS KNOWN TO BE METABOLIZED BY [CONTACT_584383]450 ISOENZYMES  ............................................................................................................................ 93
 
APPENDIX XII: DRUGS KNOWN OR SUSPECTED TO INHIBIT KSHV REPLICATION....................................................................................................................................................... 99
 
APPENDIX XIII: PARTICIPANT INSTRUCTIONS FOR ORAL SWABS  ..................... 100  
APPENDIX XIV: PARTICIPANT DRUG INFORMATION HANDOUT AND WALLET CARD  ......................................................................................................................................... 103
 
 
AMC 098 (Version 4 .0) 08DEC2020 6 
NCI Version Date 08DEC2020  PROTOCOL ROSTER  
AMC Protocol # 098 
A Pi[INVESTIGATOR_634945] : 
Soren Gantt, MD, PhD  
Centre de recherche du CHU Sainte-Justine 
3175 Côte Sainte-Catherine 
Montréal Qc H3T 1C5 
Canada  
Tel: (514 ) 345-4931  
Email:[EMAIL_12107]  Protocol Statistician : 
Jeannette Lee, PhD  
Department of Biostatistics  
University of Arkansas for Medical Sciences  
[ADDRESS_848299], Ed III, Room 3212
 
Little Rock, AR [ZIP_CODE]  
Tel: (501) 526 -6712  
Fax: ([PHONE_13219]  
Email: [EMAIL_4639]  
Protocol Co -Chair : 
Rich Ambinder, MD  
Johns Hopkins University Oncology Center  
Bunting- Blaustein Cancer Research Bldg.  
[ADDRESS_848300], Room 389  
Baltimore, MD [ZIP_CODE]  
Tel: (410) 955 -8839  
Fax: (410) 955 -0960  
Email: [EMAIL_12108]  AMC Data Management/Operations : 
AMC Operations and Data Management Center
 
The Emmes Co mpany, LLC  
[ADDRESS_848301]  
Rockville, MD [ZIP_CODE]  
Tel: (301) 251 -1161  
Fax: ([PHONE_2020]  
Email: [EMAIL_12106]  
Protocol Co -Chair : 
Rachel Bender Ignacio, MD, MPH  
[ADDRESS_848302] N Mailstop E2- 112 
Fred Hutchinson Cancer Research Center  
Seattle, WA [ZIP_CODE]  
Tel: (206) 667 -4628  
Fax: (206) 667 -6366  
Email: [EMAIL_12109] 
 AMC Biorepository Director : 
Sylvia Silver, DA  
George Washington University Medical Center
 
[ADDRESS_848303], NW Ross Hall, Room 118
 
Washington, DC [ZIP_CODE]  
Tel: (202 ) 994 -2945  
Fax: ([PHONE_2030]  
Email: [EMAIL_12110]  
Protocol Co -Chair:  
Warren Phipps, MD, MPH  
Fred Hutchinson Cancer Research Center  
[ADDRESS_848304]. N., M1-B140 
Seattle, WA  [ZIP_CODE] 
Tel: (206) 667 -4600 
Email: [EMAIL_12111]
 
 
  
 
AMC 098 (Version 4 .0) 08DEC2020 7 
NCI Version Date 08DEC2020  AMC Kaposi Sarcoma Working Group 
Chair : 
Lee Ratner , MD, PhD  
Washington University School of Medicine  
Division of Oncology 
[ADDRESS_848305]. Louis, MO [ZIP_CODE]
 
Tel: (314 ) 362 -8836  
Fax: ( 314) 747 -2120  
Email: [EMAIL_7842] 
 AMC Core Laboratory Director : 
: 
Jeffrey Bethony , PhD  
George Washington University Medical Center  
[ADDRESS_848306] NW Washington, DC [ZIP_CODE]
 
Tel: ([PHONE_13220]  
Fax: ([PHONE_2030]  
Email: [EMAIL_12112]  
AMC  Pharmacologist : 
Michelle A. Rudek, PharmD, PhD Analytical Pharmacology Core Laboratory  
Johns Hopkins Oncology Center Bunting- Blaustein Cancer Research Bldg.  
[ADDRESS_848307], Room 1M52 Baltimore, MD [ZIP_CODE] Tel: (410) 614 -6321 
Fax: ([PHONE_13221] Email: [EMAIL_12113]
 Sub-Saharan Africa AMC Biorepository 
Director : 
Johann Schneider, MMed Anat Path  
Division of Anatomical Pathology  
National Health Laboratory Service  
10th Floor Green Avenue, Room 52 Tygerberg Hospi[INVESTIGATOR_634946] 7535 South Africa Tel: 27 -21-938-4041 
Fax: 27-21-938-6559 Email: [EMAIL_12114]  
 
AMC Path ology Core  Laboratory : 
Ethel Cesarman, MD, PhD Weill Medical College of Cornell University  
Department of Pathology [ADDRESS_848308], Room C410 [LOCATION_001], NY [ZIP_CODE] Tel: (212 ) 746 -8838 
Fax: ([PHONE_13222] 
Email:  [EMAIL_12115]  Uganda Cancer Institute Local  PI: 
[INVESTIGATOR_634947], MBChB , MMed, PhD 
Uganda Cancer Institute [PO_BOX] Kampala, Uganda Tel: [PHONE_13225]/680467 Mobile: [PHONE_13226] Fax: [PHONE_13227] 
Email: [EMAIL_12116]  
 
 
AMC 098 (Version 4 .0) 08DEC2020 8 
NCI Version Date 08DEC2020  PROTOCOL SYNOPSIS  
Title:  A Pi[INVESTIGATOR_634948]:  Phase II  
Participating Institutions:  This protocol will be open to all AMC domestic member sites and 
AMC sub -Saharan A frica sites.  
Accrual Target:  36 participants  
Population:  Participants with Kaposi sarcoma (KS) . Enrollment will target  
but will not be limited to  18 participants with HIV infection and 
18 without HIV infection.  
Regimen:  Nelfinavir 1250 mg twice daily for up to 8 weeks, followed by 
[CONTACT_635005] 312 5 mg twice daily for up to 16 weeks 
(up to 24 weeks of treatment). Participants will be followed for 
up to 8 weeks following treatment discontinuation.  
Anticipated Trial 
Dura tion: Up to 3 years  
Primary Objective:  To determine the efficacy of a therapeutic escalation strategy 
consisting of standard dose nelfinavir, followed by [CONTACT_635006], for the treatment of KS tumor lesions.  
Secondary Objectives:  1. To evaluate the safety of high dose nelfinavir among 
participants with KS.  
2. To assess the effect of nelfinavir on Kaposi s arcoma-
associated herpesvirus (KSHV) lytic gene expression in 
tumor tissue.  
3. To correlate nelfinavir and the primary active metabolite, M8, 
concentrations with tumor response, antiviral response, and adverse effects in participants with KS.
 
4. To assess the effect of nelfinavir on KSHV copy number in 
saliva.  
Exploratory Objectives:  1. To assess the effect of nelfinavir on KSHV and Epstein -Barr 
virus (EBV) copy number in peripheral blood mononuclear 
cells (PBMC) and plasma.  
2. To assess the effect of nelfinavir on herpes simplex virus 
(HSV), cytomegalovirus (CMV) , and EBV copy number in 
saliva.  
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848309] dose nelfinavir, (1250 mg twice daily); high dose nelfinavir, (3125 mg twice daily); PD, progressive disease; CR, complete response; SD, stable disease; PR, partial response.  
Baseline viral measurements 
for [ADDRESS_848310] dose nelfinavir  
High dose nelfinavir  
 Stop nelfinavir 4 weeks 
after CR  
Stop nelfinavir  
PD after 4 weeks 
or SD/PR at  
8 weeks  
CR at any time  
SD/PR : continue  
for up to16 
weeks  
CR at any time  
Stop nelfinavir  
4 weeks after CR  
Approximately 18 
HIV-positive  persons  
Approximately 18 
HIV-negative  persons  
PD after 
4 weeks  
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848311] OF ABBREVIATIONS  
ACSR  ................................................................................... AIDS and Cancer Specimen Resource 
ACTG  .................................................................................................... AIDS Clinical Trials Group  
AE ................................................................................................................................ adverse event  
AIDS  .................................................................................. Acquired Immunodeficiency Syndrome 
ALT (SGPT)  .................................................................................................... a lanine t ransaminase  
AMC  ................................................................................................ AIDS Malignancy Consortium 
ART .................................................................................................................. antiretroviral therapy  
AST  (SGOT)  ................................................................................................. a spartate transaminase  
AUC  .................................................................................................................. area under the curve 
BID ................................................................................................................ bis in die (twice a day)  
BUN  ................................................................................................................... blood urea n itrogen  
CBC ................................................................................................................. complete blood count 
CDC  ............................................................................. Centers for Disease Control and Prevention  
CDUS  .................................................................................................. Clinical Data Update System  
CMV  ....................................................................................................................... cytomegalovirus  
CO2  ............................................................................................................................ carbon dioxide 
CR ........................................................................................................................ complete response 
CRF  ......................................................................................................................... case report form  
CTCAE  ............................................................ Common Terminology Criteria for Adverse Events  
CTEP  ....................................................................................... Cancer Therapy Evaluation Program 
CTEP- AERS  ..................................................................... CTEP Adverse Event Reporting System 
DARF  ......................................................................................... Drug Accountability Record Form 
DHHS  ............................................................................ Department of Health and Human Servic es 
DLT  ................................................................................................................. dose- limiting toxicity  
DNA  ............................................................................................................... deoxyribonucleic acid 
DSMB  ............................................................................................... Data Safety Monitoring Board 
EBV ..................................................................................................................... Epstein -Barr Virus  
EIACD  ................................................................................. enzyme inducing anti -convulsant drug 
EKG  ..................................................................................................................... electrocardiogram  
ELISA  .................................................................................... enzyme-linked immunosorbent assay 
ER ................................................................................................................. endoplasmic reticulum  
FIAU  ................................................................................................................................. fialuridine  
FDA .................................................................................................. Food and Drug Administration 
GEE  ............................................................................................... generalized estimating equations  
HD-NF V  ............................................................................................................high dose nelfinavir 
HHV-8.............................................................................................................. human herpesvirus-8 
HIV ............................................................................................... Human Immunodeficiency Virus HSV .................................................................................................................. herpes simplex virus 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848312] ............................................................................................. National Clinical Trials [Registry]  
NFV .................................................................................................................................... nelfinavir 
NIH ...................................................................................................... National Institutes of Health  
NRTI  .............................................................. nucleoside/nucleotide reverse transcriptase inhibitor 
NNRTI  ...................................................................... non- nucleoside reverse transcriptase inhibitor  
ODMC ............................................................................. Operations and Data Management Center  
OHAM  ......................................................................................... Office of HIV AIDS Malignancy  
PBMC  ....................................................................................... peripheral blood mononuclear cells 
PD…  ...................................................................................................................progressive disease  
PI ........................................................................................................................... protease inhibitor  
PIO ........................................................................................................ Protocol Information Office  
PK ......................................................................................................................... pharmacokinetics 
PR ............................................................................................................................. partial response 
qPCR  .................................................................................... quantitative polymerase chain reaction  
RNA  ..................................................................................................................... ribose nucleic acid  
SAE  ................................................................................................................. serious adverse event  
SD ................................................................................................................................ stable disease 
SD-NFV  ...................................................................................................... standard dose nelfinavir 
SOC  ......................................................................................................................system organ class  
SOP ..................................................................................................... standard operating procedure 
S[LOCATION_003]R  ..................................................... serious and unexpected suspected adverse drug reaction  
ULN  ................................................................................................................ upper limit of normal  
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848313] of nelfinavir on HSV, CMV, and EBV copy number in saliva. 
 
AMC 098 (Version 4 .0) 08DEC2020 13 
NCI Version Date 08DEC2020  2.0 BACKGROUND  
2.1 Study Disease  
Kaposi sarcoma is a vascular inflammatory tumor of endothelial origin caused by [CONTACT_635007]- associated herpesvirus, also known as human herpesvirus 8 (HHV -8)1. HIV 
infection and immunosuppression dramatically increase the risk of KS among people infected with KSHV. KS is the most common AIDS -defining malignancy. Due to in part 
to the low prevalence of KSHV infection, KS is rare among HIV -uninfected individual s in 
the U.S. However, in parts of East Africa where KSHV is endemic, KS is common among people with and without HIV infection
2. Like all herpesviruses, HHV -8 infection of cells 
results in one of two discrete viral programs, latency and lytic replication. 
During latent infection, few viral genes are expressed and the HHV -8 genome is 
maintained as an epi[CONTACT_67166]. KS tumor (“spi[INVESTIGATOR_86853]”) cells are predominately (~99%) latently 
infected with KSHV. However, a portion of spi[INVESTIGATOR_634949]
3-5. Most infected cell types in culture display a progressive loss of the 
HHV- [ADDRESS_848314] spi[INVESTIGATOR_634950]7-9. This indicates that persistence of KSHV within KS tumors 
requires ongoing lytic replication and infection of new cells6. In addition, numerous lytic 
viral gene products detected in KS tumors appear central to KS pathogenesis. Proteins expressed by [CONTACT_15209][INVESTIGATOR_634951]; including inflammation (vGPCR, vIL -6, K15), angiogenesis 
(vIL-6, vGPCR, K1, vCCL1, vCCL2), cell growth (vIL -6, vGPCR, K1), and inhibition of 
apoptosis (vCCL1, vCCL2, vBcl2, vIRF1, K1), among others
10, 11. Of note, lytically 
infected cells are destroyed, and thus, their effects in KS lesions should be limited to either 
increasing the number of infected cells or paracrine effects of lytic viral gene products.  
KSHV DNA is detected more frequently and at higher copy numbers in blood of KS patients compared to controls with asymptomatic KSHV infection
12-15. A large proportion 
of KSHV DNA in plasma is encapsidated in virions14, 16, indicating an association between 
KS and systemic viral replication and dissemination. KSHV viremia appears to be in the causal pathway for KS, rather than a consequence, since KSHV viremia predicts subsequent KS in cohorts of asymptomatic people with KSHV and Human Immunodeficiency Virus (HIV) co-infection
17, 18. In addition, ganciclovir, which inhibits 
KSHV lytic replication, prevents incident KS (see below). Therefore, inhibiting KSHV 
replication may interfere with KS progression.  
A large number of drugs that block herpesvirus DNA synthesis have been reported to inhibit HHV -8 replication
19-23. Of these agent s, ganciclovir (or its oral pro -drug 
valganciclovir) is the only one proven to either suppress HHV -8 replication in vivo  or 
prevent the development of KS in randomized trials. In a randomized, placebo-controlled, cross- over trial, valganciclovir was shown to reduce HHV -8 oral shedding frequency by 
46% and quantity by 0.44 log copi[INVESTIGATOR_014]/mL
24. In a randomized trial, Ganciclovir treatment of 
cytomegalovirus retinitis in HIV -infected patients statistically significantly reduced the 
incidence of KS by 75% when given orally and 93% when given intravenously compared to intraocular treatment alone
25. Numerous observational studies have also suggested that 
ganciclovir and foscarnet, but not acyclovir, may prevent KS26-29. The efficacy of antivirals 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848315] on progression or HHV -8 
viremia35. 
2.2 Study Agent  
2.2.1 Nelfinavir mesylate (Viracept®) 
Nelfinavir is an orally adminis tered aspartyl -protease inhibitor (PI) approved for 
the treatment of HIV. More recently off- target effects have led investigators to 
repurpose nelfinavir as a potential anticancer agent36-38. Several early phase clinical 
trials have resulted. In a phase I dose escalation trial in lung cancer, nelfinavir was studied in combination with combination chemotherapy (cisplatin and etoposide)/radiation therapy
39. Two dose levels were studied, 625 mg bis in die 
(BID [twice daily]) and 1250 mg BID. No dose limiting t oxicities (DLTs) were 
seen at either dose level and there was no grade 3 or 4 diarrhea reported.  
In a National Cancer Institute  (NCI) phase I trial in participants with refractory 
solid tumors, 3125 mg BID was found to be the maximum tolerated dose (MTD)40. 
The [ADDRESS_848316]
41, diarrhea was unusual in this study40. 
Additionally, there were no cumulative toxicities noted, and no participants developed greater than grade 2 changes in lipi[INVESTIGATOR_634952], despi[INVESTIGATOR_040] 11 participants receiving the MTD of 312 5 mg BID for a median of 6.6 months. Two 
of three participants receiving 3750 mg BID of nelfinavir experienced grade 4 neutropenia, but the drug was well tolerated at other doses. It should also be noted that in previous HIV treatment trials of nelfinavir in Sub -Saharan Africa, the 
frequency with which diarrhea was reported ranged from 2 -11% and did not require 
discontinuation of treatment
42-45. While non- linearity in the pharmacokinetics was 
noted at doses above 1875 mg, greater than 50% of the patients at  3125 mg had 
higher maximal (Cmax) and total area under the curve (AUC) exposure compared with the [ADDRESS_848317] evaluated dose of 4250 mg BID
46. In that study, epis odes of diarrhea 
occurred in a minority of courses, all epi[INVESTIGATOR_634953], and were not associated with higher nelfinavir doses. However, there was no measurable increase (and perhaps a slight decrease) in the peak plasma levels of nelfinavir or the prima ry 
active metabolite, M8, between 3000 mg BID and 4250 mg BID, suggesting that higher levels may not be achievable, perhaps due to autoinduction of metabolism
46. 
Therefore, in this trial of nelfinavir for KS, we will cap the high dose at 3125 mg BID and obtain trough levels to account for the potentially large variability in nelfinavir exposure.  
 
AMC 098 (Version 4 .0) 08DEC2020 15 
NCI Version Date 08DEC2020  2.3 Study Design and Rationale  
The off -target effects of nelfinavir are highly relevant for KS47. Several studies show that 
nelfinavir can inhibit PI3K/Akt signa ling and  induce endoplasmic reticulum (ER) stress 
with activation of the unfolded protein response38, 48- 50. In addition, antiangiogenic effects 
of nelfinavir are well documented, including down regulating hypoxia -inducible factor 1 
alpha (HIF -1-α), VEGF a nd matrix metalloprotease 2 (MMP2) activity, and inhibition of 
STAT3 signaling and of γ -secretase activity50,51. Nelfinavir has activity against a broad 
range of cancer cell lines and in animal models36,37. These diverse tumors include 
liposarcoma52,53, multiple myeloma48, primary effusion lymphoma and Burkitt lymphoma. 
All of these activities suggest the possibility of a direct antitumor effect in KS.  
In addition, nelfinavir both reactivates lytic KSHV gene expression and inhibits production 
of infectious KSHV in vitro . Consistent with activation of the unfolded protein response, 
nelfinavir activates KSHV lytic gene expression54. Activation of viral lytic gene expression 
might directly result in tumor cell killing as viral replication activates DNA damage pathways and apoptosis or  might lead to increased viral antigen expression and increased 
susceptibility to immune killing. Although viral lytic gene expression is induced in latently infected cells, nelfinavir potently blocks in vitro  production of infectio us KSHV, and other 
herpesviruses, at concentrations that are achieved in plasma of patients after oral administration
55. Thus, we hypothesize that nelfinavir will decrease measurable viral loads. 
Protease inhibitor- based antiretroviral therapy (ART) has re cently been shown to decrease 
shedding of KSHV, though this study was not able to demonstrate a superior effect of nelfinavir compared with other PIs
56. In herpes simplex virus 1 (HSV -1), nelfinavir 
prevents envelopment and release of mature virus from infected cells54,57, suggesting that 
that nelfinavir may act similarly against KSHV. Although initial induction of KSHV lytic gene expression by [CONTACT_635008], 
which we will monitor for, we expect that the c ombination of antitumor and antiviral 
activities will result in KS responses.  
Proposals to evaluate the effects of nelfinavir on KSHV infection and KS in HIV -infected 
individuals have focused on the potential confounding by [CONTACT_635009]; even with adjustment for HIV viral load and CD4 counts, any effect of nelfinavir might still be due to enhanced control of HIV infection. By [CONTACT_635010], we have the ability to definitively examine the direct c linical antitumor 
and antiviral effects of nelfinavir, which may provide valuable clinical information regarding the treatment of KS in HIV -negative individuals, as well as those who are HIV -
infected. Additionally, because all prior studies in reducing incident KS or treating KS with PIs have focused on ART -naïve persons, it is difficult to compare studies of persons 
receiving modern highly- active ART regimens, that do or do not include PIs, directly for 
their effects on KS and KSHV, because it is known that PIs provide more rapid virologic and immunologic responses than triple nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) regimens or non- nucleoside reverse transcriptase inhibitor (NNRTI) 
regimens (unclear vs. recently utilized integrase inhib itors). Therefore, in this study, we 
propose to add nelfinavir to stable complete ART regimens in HIV -infected persons and in 
HIV- negative KS participants, in order to remove the HIV virologic and immunologic 
confounding implied in PI [CONTACT_3225]. This is distinct from modern trials, which evaluate cytotoxic 
chemotherapy plus ART -initiation in previously ART -naïve persons. Thus, we expect we 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848318] responses in persons with stable disease (SD) despi[INVESTIGATOR_634954]58-60. Comparable trials of novel agents, such as valproic acid or VEGF inhibitors in 
persons already on stable ART at enrollment, showed much smaller effect sizes between 20-30%
61-64. 
The proposed trial is based on the hypothesis that nelfinavir might be repurposed as an anticancer agent,  and that among all cancers that might be targeted, the effects of nelfinavir 
on Akt signaling, angiogenesis pathways, viral gene expression, and infectious virion production seem almost tailored to the treatment of KS. And, save for (likely undue) concern s about diarrhea, the side effect profile is gentler than for any of the approved 
treatments (paclitaxel, liposomal doxorubicin) or those presently being investigated by [CONTACT_229345] (bortezomib, lenalidomide). Therefore, we propose to evaluate a treatment stra tegy 
of nelfinavir in AIDS -associated and in HIV -negative KS participants to determine tumor 
response and virologic suppression. The strategy starts with standard dose (1250 mg BID) nelfinavir to determine whether KS patients may demonstrate a tumor respon se and to 
determine the antiviral activity of the FDA -approved regimen. Those participants with 
tumor progression or no response to standard dose nelfinavir will receive high dose (3125 mg BID) nelfinavir therapy, which has been found to be well tolerated in clinical trials of cancer patients. In addition to tumor and virologic outcomes, these participants will be assessed for the possibility of bone marrow suppression and other toxicities that can occur with nelfinavir, especially in combination with a full ART regimen.  
Clinical tumor responses would pave the way for further evaluation of nelfinavir alone as an antitumor agent. Given the possibility of activation of viral lytic gene expression, evaluation of the combination of nelfinavir with an agent such as ganciclovir or fialuridine (FIAU) that would kill infected cells might be pursued. This study will evaluate the safety and efficacy of nelfinavir to treat KS. Furthermore, findings regarding the tumor and 
virologic response in participants may provide valuable insights into KS pathogenesis and 
the mechanism(s) of action of nelfinavir, which may translate into knowledge to guide therapy of KS worldwide. Finally, if nelfinavir was found to have an antiviral effect on KSHV in vivo , the drug may play a role in strategies to prevent the development of KS 
among persons deemed to be at high risk. 
High -Dose Safety Review  
As outlined in  Section 3.[ADDRESS_848319] three domestic participants on high -dose nelfinavir 
treatment were evaluated for safety on November 29, 2017. In accordance with the 
protocol, the Protocol Chair, AMC Medical Monitor, and Protocol Statistician  participated 
in this review, along with the protocol co- chairs . All participants experienced grade 2 or 3 
diarrhea ; however, several participants continued treatment during the AE and did not 
report diarrhea until the next visit , and the providers continu ed treatment with appropriate 
medical management in some cases without holding the dose for resolution to grade [ADDRESS_848320] significant toxicities or toxicity that requires 
supportive care exceeding capabilities of the international sites, and that the protocol 
stoppi[INVESTIGATOR_634955]. The protocol team’s recommendation to 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848321] of nelfinavir on KSHV lytic gene expression in tumor 
tissue.  
As described in Section 2.1 , KSHV lytic gene expression may contribute to tumor 
development and progression. We hypothesize that nelfinavir will  decrease lytic 
gene expression in tumors. This will be ascertained by [CONTACT_635011] (IHC) on a subset of viral proteins at the AMC Pathology Core  Laboratory. 
2.4.2 Correlation of nelfinavir and the primary active metabolite, M8, concentrations 
with tumor response, antiviral response, and adverse effects in participants with KS. 
The pharmacokinetics (PK) of nelfinavir are non- linear and show considerable 
inter- patient  variability. We hypothesize that higher drug levels will be associated 
with tumor response, as well as lower levels of viral lytic gene expression in tumors (Section 2.4.1) and KSHV copy number in saliva, PBMC, and plasma (
Sections 
2.4.3  and 2.4.4 ). Because nelfinavir is metabolized by [CONTACT_097]3A and CYP2C19, 
genotypi[INVESTIGATOR_634956]. Nelfinavir/M8 concentrations will be performed at the AMC Pharmacology Core Lab at Johns Hopkins Universit y and genotypi[INVESTIGATOR_634957]. 
2.4.[ADDRESS_848322] of nelfinavir on KSHV copy number in saliva. 
KSHV lytic replication is common in the oropharynx15 and decreases with active 
antiviral treatment24. As such, KSHV copy number will be measured in saliva using 
quantitative polymerase chain reaction (qPCR) as a convenient estimate o f antiviral 
activity. KSHV qPCR will be conducted at the AMC Genomics Core Laboratory . 
2.4.4. Exploratory: Assessment of the effect of nelfinavir on KSHV and EBV copy 
number in PBMC and plasma; and HSV, CMV, and EBV viral load in saliva. 
KSHV replication in blood may be a more relevant predictor of response to 
nelfinavir than oral replication. As such, qPCR may be used to measure KSHV in stored PBMC and plasma from participants. EBV viral load will also be evaluated in these samples.  
Additionally, HSV, CMV, and EBV viral load will be assessed in saliva at the  AMC 
Virology Core . KSHV qPCR for plasma  and PBMC  viral load will be performed at 
the AMC Virology Core. 
PBMC/Plasma viremia: Because KSHV can reactivate sporadically, and viremia is not always persistent in persons with KS (present on median of 20% of days in 
endemic KS and on 67% of days in HIV -associated KS in Uganda1 the more 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848323] e, 2 samples can be achieved 
through weekly sampling during the 4 weeks pre -treatment. Eight samples on 
treatment can be obtained twice monthly in order to coordinate the blood draw 
schedule with clinical/tumor assessment visits and safety lab blood draws,  which 
will also occur on this schedule (safety labs monthly but  coordinated with bi -
weekly visits); this will reduce burden on participant and maximize study resources. 
Effect of the study drug on KSHV replication is an important outcome of this study.  
 
AMC 098 (Version 4 .0) 08DEC2020 19 
NCI Version Date 08DEC2020  3.0 PARTICIPANT SELECTION  
A rostered AMC  investigator (CTEP -registered physician investigator)  must document that 
each protocol participant meets all stated eligibility criteria. Participating sites must have 
documentation that each eligibility requirement is satisfied prior to participant enrollment. In compliance with CTEP policy, no exceptions to eligibility criteria will be granted under any circumstance.  
NOTE: Institutions may use this section of the protocol as an eligibility checklist for source docum entation if it has been reviewed, signed, and dated before registration/randomization 
by [CONTACT_1704]. If used as source documentation, this checklist must be printed, the investigator must check each item to document their assessment that the pa rticipant 
meets each eligibility criterion, and the completed checklist must be maintained in the participant’s chart.  
Participant ID Number: 098  - ___ ___ ___ - ___ ___ ___ ___ ___ 
Patient’s Initials (F, M  (optional), L): ___ ___ ___ 
3.1 Eligibility Crite ria 
__ 3.1.1 Biopsy- proven KS involving skin (with or without visceral involvement) without 
need for urgent cytotoxic therapy. There should be no evidence of improvement in KS in the [ADDRESS_848324] performed in conjunction with screening (or enzyme -linked 
immunosorbent assay [ELISA] test kit) and  confirmed by [CONTACT_635012]
1. 
U.S. participants only: Alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 
1. Approved diagnostic tests, or 
2. The referring physician's written record th at HIV infection was documented, 
with supporting information on the participant's relevant medical history and/or 
current management of HIV infection.  
Participants enrolled outside the U.S. must have a confirmatory diagnostic test sequence as appropriate p er national standards, detailed as above, performed 
regardless of prior documented HIV status.  
 
1 NOTE: The term “licensed” refers to a U.S. FDA -approved kit or for sites located in countries other than the United 
States, a kit that has been certified or licensed by [CONTACT_163394].  
 WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that 
confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by [CONTACT_68387] E/CIA that is based on a 
different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a 
plasma HIV -1 RNA viral load.  
 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848325] be 
performed no more than 4 weeks before enrolling to the treatment segment 
__ 3.1.3 Participant may be either previously untreated for KS or refractory to or intolerant 
of any one or more prior KS therapi[INVESTIGATOR_014].  
__ 3.1.4 Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of high dose nelfinavir in participants < 18 years of age, children are excluded from this study. 
__ 3.1.5 ECOG performance status ≤ 2 (Karnofsky ≥ 50%, see Appendix III
). 
__ 3.1.[ADDRESS_848326] organ and marrow function within the following parameters (within 4 weeks before enrolling  for study treatment): 
• Leukocytes: ≥ 3,000/mm
3 
• Absolute neutrophil count: ≥ 1,500/mm3 
• Platelets: ≥ 100,000/mm3 
• Total bilirubin: within normal limits at each study site local laboratory  
• AST (SGOT) / ALT (SGPT): ≤ 2.5 X institutional upper limit of no rmal (ULN) 
• Creatinine:  
o Creatinine levels ≤  upper limit of institutional normal; or  
o Creatinine clearance ≥ 60 mL/min/1.[ADDRESS_848327] be on ART with the following criteria:  
• A complete ART regimen that adheres to the current DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV (https://aidsinfo.nih.gov/guidelines/html/1/adult-and- adolescent -arv/0) or any 
co-formulated combination that is FDA approved for the t reatment of HIV . See 
Section 3.2.5
 for details regarding eligible antiretroviral drugs.  
• The ART regimen must not include PIs  (including nelfinavir) ; participants must 
not have received a PI -based regimen for at least 4 weeks prior to  study 
enrollment.  
• Modification of ART regimen limited to eligible antiretroviral drugs while on 
study is allowable.  
• Participants must either have an undetectable HIV plasm a RNA, or if plasma 
RNA detectable, it must be decreasing while on the same stable regimen for a 
minimum of 12 weeks prior to study enrollment. 
• No evidence of incomplete virologic response or virologic failure (two consecutive HIV RNA levels > 200 copi[INVESTIGATOR_014]/m L after 24 weeks on a stable 
regimen or after achieving an undetectable viral load) within 12 weeks before 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848328] agree to use adequate 
contraception (barrier or other non -hormonal method of birth control, or 
abstinence) prior to study enrollment and for the duration of study participation. Hormonal contraception alone is contraindicated for pregnancy prev ention in this 
study due to potential loss of efficacy from drug interactions with nelfinavir. Should 
a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. 
__ 3.1.10 Ability to understand and the willingness to sign a written informed consent document. 
3.2 Exclusion Criteria  
Participants who do not fulfill the criteria as listed in Section 3.1
 above, are ineligible. 
Additionally, the presence of any of the following conditions will exclude a participant from study enrollment: 
__ 3.2.[ADDRESS_848329] had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin -C) prior to study enrollment or those who have not 
recovered from adverse events due to agents administered more than [ADDRESS_848330] KSHV or that are strong inhibitors or inducers of CYP3A or 2C19 are ineligible. Nelfinavir ( NFV) also inhibits CYP3A4 and therefore sensitive 
substrates should be avoided. Of the antiretroviral drugs, only delaviridine, nevirapi[INVESTIGATOR_050] , cobicistat -boosted antiretrovirals (strong CYP3A4 inhibitor), 
maraviroc (sensitive CYP3A4 substrate) , and protease inhibitors (strong CYP3A4 
inhibitor) are excluded. For women of child -beari ng potential, h ormonal 
contraception is permitted if the participant agrees to use  barrier or non-hormonal 
methods of birth control or abstinence prior to enrollment and for the duration of the study, due to the effect of nelfinavir on contraceptive effectiv eness. The 
following drugs are also prohibited: 
Strong Inhibitors of CYP3A4:  
• Antibiotics : clarithromycin, erythromycin, telithromycin, troleandomycin  
• HIV: non -nucleoside reverse transcriptase inhibitors (delaviridine, nevirapi[INVESTIGATOR_050]), 
protease inhibitors (ri tonavir, indinavir, lopi[INVESTIGATOR_054]/ritonavir, saquinavir), 
 
AMC 098 (Version 4 .0) 08DEC2020 22 
NCI Version Date 08DEC2020  cobicistat -boosted antiretrovirals (e.g., elvitegravir). NOTE: Clinical trials 
have demonstrated that there are no clinically significant drug -drug interactions 
between nelfinavir and the following antiretrovirals: efavirenz (strong CYP3A4 
inhibitor), etravirine (strong CYP3A4 inhibitor). Therefore, these antiretrovirals will not be excluded.  
• Antifungals : itraconzaole, ketoconazole, voriconazole, fluconazole, 
posaconazole 
• Antidepressants: nefazodone 
• Antidiuretic : conivaptan 
• GI: cimetidine , aprepi[INVESTIGATOR_053] 
• Hepatitis  C: boceprevir, telaprevir  
• Miscellaneous: Seville oranges, grapefruit, or grapefruit juice and/or pummelos, star fruit, exotic citrus fruits, or grapefruit hybrids  
Strong Inducers of CYP3A4:  
• Glucocorticoids: cortisone (> 50 mg), hydrocortisone (> 40 mg), prednisone (> 10 mg), methylprednisolone (> 8 mg), dexamethasone (> 1.5 mg) 
• Anticonvulsants: phenytoin, carbamazepi[INVESTIGATOR_050], primidone, phenobarbital and 
other enzyme inducing anti-convulsant drugs (EIACD) 
• Antibiotics: rifampin (rifampi[INVESTIGATOR_2513]), rifabutin, rifapentine  
• Miscellaneous: St. John’s Wort, modafinil  
Strong Inhibitors of CYP2C19: 
• Antifungals: fluconazole 
Strong Inducers of CYP2C19:  
• Antibiotic s: rifampin (rifampi[INVESTIGATOR_2513])  
Lists i ncluding medications and substances known or with the potential to interact 
with the CYP3A or 2C19, isoenzymes are provided in Appendix XI
. 
Drugs with KSHV antiviral activity: • Participants receiving any medications or substances that may interfere with 
KSHV replication are ineligible.  
Because the lists of these agents are constantly changing, it is important to regularly consult a frequently -updated list such as 
http://medicine.iupui.edu/clinpharm/ddis. Medical reference t exts such as the 
Physicians’ Desk Reference may also provide this information.  Sites are 
encouraged to contact  [CONTACT_635013].  
As part of the enrollment/informed consent procedures, the participant will be  
counseled on the risk of interactions with other agents, and what to do if new 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848331].  
Lists including medications and substances known or wi th the potential to interfere 
with KSHV replication, are provided in Appendix XII . 
__ 3.2.6 Uncontrolled intercurrent illness including, but not limited to, hepatitis C infection 
requiring treatment during th e study, symptomatic congestive heart failure, 
unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that in the opi[INVESTIGATOR_634958].  
__ 3.2.7 Pregnant women are excluded from this study because nelfinavir is a Pregnancy Category B agent that has not been studied at high doses in pregnant women. Because there is an unknown but potential risk for adverse events in nursing infants secondary t o treatment of the mother with high dose nelfinavir, breastfeeding 
should be discontinued if the mother is treated with high dose nelfinavir. 
__ 3.2.8 Chronic diarrhea as defined by [CONTACT_635014] 3 times daily at base line lasting more than 4 weeks or not abating on condition -appropriate 
therap y prior to study enrollment.  
__ 3.2.9 Participant is < 2 years free of another primary malignancy. Exceptions include basal cell skin cancer, Stage 0 -I squamous cell cancer of the skin, cer vical 
carcinoma in situ, anal carcinoma in situ.  
__ 3.2.10 Use of systemic corticosteroid therapy (except for replacement doses of glucocorticoid and/or mineralocorticoid for adrenal insufficiency). Inhaled or intranasal corticosteroids for allergic or bro nchospastic conditions are permitted. 
Physician Signature: ______________________________ Date: ___________________ 
(Optional unless this section is used as an eligibility checklist)  
3.3 Number of Participants to be Enrolled  
3.3.1 Proposed s ample s ize 
This study will enroll a minimum of 3 participants and a maximum of 36 
participants ( planned enrollment of 18 participant s with HIV infection and 18 
participants without HIV infection).  
3.3.[ADDRESS_848332] this protocol approved by [CONTACT_241251] (IRB) and be 
registered for study participation with the AIDS Malignancy Consortium (AMC)  
Operations and Data Management Center (ODMC) before they may enro ll participants. 
Enrollment and data collection will occur via Advantage eClinical . 
3.4.1 Registration for s creening  
After an informed consent form has been signed by [CONTACT_635015] -
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848333] be registered for screening (AMC -098, Segment A, Screening Enrollment) 
on-line via Advantage  eClinical. After successful registration into screening, the 
participant will receive a n eleven -digit participant ID and will then enter the 
screening process ( screening and pre -entry visits). A system generated 
confirmation email will be sent to the enroller upon successful completion of the 
participant enrollment into Segment A. If the on -line system is inaccessible, the site 
should notify the AMC ODMC (via email at [EMAIL_1741] or via phone at 
301-251- 1161) for further instructions.  
3.4.[ADDRESS_848334] been obtained and the participant is determined to be eligible, the participating site will enroll the participant into AMC -
098 Segment B (Treatment Enrollment) on -line via Advantage eClinical . 
Enrollment into Segment B should occur no more than [ADDRESS_848335] dose of the protocol agent (enrollment 1 day prior to or on the day of treatment is strongly encouraged). 
Participants must be enrolled into AMC -098 Segment B (Treatment 
Enrollment) prior to receiving the first dose of the protocol agent.  
3.5 Enrollment at International Sites  
Enrollment is open at all sub- Sahar an Africa AMC international sites contingent upon site 
satisfaction of all regulatory and site activation requirements.  
  
 
AMC 098 (Version 4 .0) 08DEC2020 25 
NCI Version Date 08DEC2020  4.0 TREATMENT PLAN  
4.1 Agent Administration  
The protocol agent will be administered on an outpatient basis. A c ycle is 2 weeks of 
continuous treatment  (+/- 3 days according to timing of study visit/evaluations within 
window). Reported adverse events and potential risks for nelfinavir are described in 
Section 6.0. Appropriate dose modifications for nelfinavir are described in Section 5.0 . No 
investigational or commercial agents or therapi[INVESTIGATOR_634959] t hose described below may be 
administered with the intent to treat the participant's malignancy.  
All participants will initiate protocol treatment with nelfinavir [ADDRESS_848336] dose, advance to high 
dose nelfinavir at 3125 mg BID continuously (i.e., intrapatient dose escalation)  for up to 
16 weeks (up to 24 weeks of treatment). 
NOTES: The participant will be requested to maintain a medication diary of each dose of 
medication (See Appendix VII ). The medication diary will be returned to clinic staff at the 
end of each cycle (every two -week study visit). 
The site will be required to document study agent return by [CONTACT_635016]. Non- compliance with study agent administration should be noted at the time 
of diary collection and the participant should be instructed again regarding dosing instructions.  
Dose delays and modifications for participants experiencing toxicity are  described in 
Section 5.[ADDRESS_848337] be consumed with a moderately-high fat meal, to increase absorption and decrease pharmacokinetic variability, and that acidic foods/fruit juices are avoided at time of administration.  
Treatment intensification will depend on the response at each treatment lev el: 
4.1.[ADDRESS_848338] dose nelfinavir (1250 mg BID) 
• Each participant must be observed for a minimum period of at least [ADDRESS_848339] dose nelfinavir before escalation to the high dose nelfinavir treatment 
level.  
• If after 4 weeks there is progressive disease (PD), the participant will advance to the high dose nelfinavir level. 
• If by 8 weeks there is stable disease (SD) or partial response (PR) at the standard dose, the participant will advance to the high dose level. 
• If there is complete response (CR) at any time at the standard dose level, 
nelfinavir will be discontinued 4 weeks after documentation of complete 
response.  
• Because dosing of study drug is continuous both during and between cycles, care should be taken to avoid study drug interruption. Therefore, if the study visit/study evaluations occur within the +/ - 3 day visit window, the appropriate 
 
AMC 098 (Version 4 .0) 08DEC2020 26 
NCI Version Date 08DEC2020  amount of drug should be provided at that visit for the study interval (i .e., if the 
study visit occurs [ADDRESS_848340] 17 days, or until the date of next scheduled 
visit)  
4.1.2 High dose nelfinavir (3125 mg BID) 
• High dose nelfinavir treatment will be continued for at least 4 weeks.  
• If there is progressive disease (PD) documented  after 4 weeks at the high dose 
level, nelfinavir will be discontinued.  
• If there is stable disease (SD) or partial response (PR) at the high dose level, high dose nelfinavir will be continued for up to 16 weeks.  
• If there is a complete response (CR), high d ose treatment will be discontinued 
[ADDRESS_848341] for potential drug -interactions will be provided 
to participants (See Appendix XIV
). The site Principal Investigator [INVESTIGATOR_634960]450 isoenzymes. Questions regarding ART regimens may be directed to Michelle Rudek. 
Appendix XI  presents guidelines for identifying medications/substances that could 
potentially interact with the study agent. 
Antiretroviral therapy is required for HIV -infected participants, with the stipulations 
detailed in Section 3.1.[ADDRESS_848342] be documented in the  case report form ( CRF ). 
4.3 Duration of Therapy  
In the absence of treatment delays due to adverse event(s), treatment may continue for a minimum of [ADDRESS_848343]. Participants removed from study for unacceptable adverse event(s) (see Section 4.5
) will be followed until resolution or stabilization of the adverse event(s).  
4.[ADDRESS_848344] 
be documented in the Case Report Form in Advantage eClinical . 
 
AMC 098 (Version 4 .0) 08DEC2020 27 
NCI Version Date 08DEC2020  • Disease progression after 4 weeks on high dose nelfinavir;  
• Rapid progression of disease that is deemed to be life -threatening; 
• Intercurrent illness that prevents further administration of treatment;  
• Unacceptable adverse event(s);  
• Participant decides to withdraw from the study;  
• General or specific changes in the participant's condition render the participant 
unacceptable for further treatment in the judgment of the investigator;  
• Participants who become pregnant or need to breast- feed;  
• The Investigator has the right to remove participants from the study for clinical reasons 
which he/she believes are life threaten ing to the participant even if such reasons do not 
fall into the toxicity classifications discussed in Section 5.0 ; 
• Participants requiring a cumulative delay of > 2 weeks  (i.e., across cycles)  or, 
participants  requiring > two dose reduction (i.e., requiring reduction to < 1875 mg BID)  
throughout the duration of the study. 
 
AMC 098 (Version 4 .0) 08DEC2020 28 
NCI Version Date 08DEC2020  5.0 DOSING DELAYS/DOSE MODIFICATIONS  
5.[ADDRESS_848345] dose nelfinavir 
(1250 mg BID) as this dose is currently FDA approved for treatment of HIV infection and 
has been studied extensively in Phase I -IV studies, with clinical experience over the last 
two decades65-67. 
If at any t ime during administration of standard dose nelfinavir (1250 mg BID) the 
participant experiences an adverse event at a severity ( grade ) that requires dose 
interruptions per the tables below, study treatment will be terminated.  
Unless noted otherwise for a specific event, i f at any time during administration of high 
dose nelfinavir (3125 mg BID) the participant experiences an adverse event grade that requires dose interruptions per the tables below, study drug will be held until the event 
resolves or improves to the specified grade, and then reduced by 625 mg BID (at 2500 mg BID) and continued as above unless the adverse event recurs, in which case the dose is reduced by [CONTACT_20904] 625 mg to a minimum of 1875 mg BID if required. If the participant experiences an adverse event on high dose nelfinavir that does not resolve or improve to the specified grade after reducing the dose to 1875 mg BID, study treatment will be terminated.  
If any participant requires a  cumulative  treatment  delay of > 2 weeks  throughout the 
duration of the study (i.e. total across cycles) , then the participant must discontinue study 
treatment. 
5.1.1 Table of N elfinavir D ose L evels and N umber of T ablets  
 
Dose Level  Nelfinavir Dose  Number of 625 mg Tablets  
1 (Standard Dose)  1250 mg, BID  2 tablets BID  
2 1875 mg, BID  3 tablets BID  
3 2500 mg BID  4 tablets BID  
4 (High Dose)  3125 mg, BID  5 tablets BID  
 
5.1.2 Tables of adverse events, and indications for dose modifications and management 
The AEs and corresponding severity definitions below are as classified in the NCI 
Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, as required in protocol Section 6.0
. 
 
AMC 098 (Version 4 .0) 08DEC2020 29 
NCI Version Date 08DEC2020  Event Name  [CONTACT_635052]/Next Dose for 
Standard Dose -Nelfinavir  Management/Next Dose for 
High Dose -Nelfinavir  
≤ Grade 1  No change in dose  No change in dose  
Grade 2  No change in dose  No change in dose  
Grade 3  Hold* until ≤ Grade 1. 
Resume at same dose level.  Hold* until ≤ Grade 1 . 
Resume at one dose level 
lower, if indicated.** 
Grade 4  Off protocol therapy  Off protocol therapy  
*Participants requiring a cumulative delay of > 2 weeks should go off protocol 
therapy.  
**Participants req uiring > two dose reductions should go off protocol therapy.  
Recommended management: antiemetics.  
 
Event Name  [CONTACT_635053]/Next Dose for 
Standard Dose -Nelfinavir  Management/Next Dose for 
High Dose -Nelfinavir  
≤ Grade 1  No change in dose  No change in dose  
Grade 2  Hold until ≤ Grade 1. 
Resume at same dose level.  Hold until ≤ Grade 1. 
Resume at same dose level.  
Grade 3  Hold* until < Grade 2. 
Resume at same dose level.  Hold* until < Grade 2. 
Resume at one dose level 
lower, if indicated.** 
Grade 4  Off protocol therapy  Off protocol therapy  
*Participants requiring a cumulative delay of > 2 weeks shall go off protocol 
therapy.  
**Participants requiring > two dose reductions shal l go off protocol therapy.  
Recommended management: antiemetics.  
 
 
AMC 098 (Version 4 .0) 08DEC2020 30 
NCI Version Date 08DEC2020  Event Name  [CONTACT_54977]/Next Dose 
for Standard Dose -
Nelfinavir  Management/Next Dose for 
High Dose- Nelfinavir  
≤ Grade 1  No change in dose  No change in dose  
Grade 2  
considered 
tolerable or 
easily managed  Add supportive care as 
indicated. No change in dose.
 Add supportive care as 
indicated. No change in dose.  
Grade 2 
considered intolerable to participant  or 
deemed unacceptable in the investigator’s 
judgment  Hold until ≤ Grade 1. 
Resume at same dose level.  Hold until ≤ Grade 1. 
Resume at same dose level . 
Grade 3  Hold* until ≤ Grade 2  if 
tolerable, or ≤ Grade 1 if considered intolerable at Grade 2. Resume at same 
dose level.  Hold* until ≤ Grade 2  if 
tolerable, o r ≤ Grade 1 if 
considered intolerable at Grade 2 . Resume at one dose 
level lower, if indicated.** 
Grade 4  Off protocol therapy  Off protocol therapy  
*Participants requiring a cumulative delay of >2 weeks shall go off protocol 
therapy.  
**Participants requiring > two dose reductions shall go off protocol therapy.  
Recommended management: loperamide antidiarrheal therapy . 
Dosage schedule: [ADDRESS_848346] onset, followed by 2 mg with each loose motion 
until diarrhea -free for 12 hours (maximum dosage: 16 mg/24 
hours).  
Adjunct anti -diarrheal therapy is permitted and shall be recorded when used.  
 
Event Name  [CONTACT_635054]/Next Dose for 
Standard Dose -Nelfinavir  Management/Next Dose for 
High Dose -Nelfinavir  
≤ Grade 1  No change in dose  No change in dose  
Grade 2  No change in dose  No change in dose  
 
AMC 098 (Version 4 .0) 08DEC2020 31 
NCI Version Date 08DEC2020  Event Name  [CONTACT_635054]/Next Dose for 
Standard Dose -Nelfinavir  Management/Next Dose for 
High Dose -Nelfinavir  
Grade 3  Hold* until < Grade 2. 
Resume at same dose level.  Hold* until < Grade 2. 
Resume at one dose level 
lower, if indicated.** 
Grade 4  Off protocol therapy  Off protocol therapy  
*Participants requiring a  cumulative  delay of > 2 weeks shall go off protocol 
therapy.  
**Participants requiring > two dose reductions shall go off protocol therapy.  
 
Event Name  [CONTACT_635055]/Next Dose for 
Standard Dose -Nelfinavir  Management/Next Dose for 
High Dose -Nelfinavir  
≤ Grade 1  No change in dose  No change in dose  
Grade 2  Hold until ≤ Grade 1. 
Resume at same dose level.  Hold until ≤ Grade 1. 
Resume at same dose level.  
Grade 3  Hold* until ≤ Grade 1. 
Resume at same dose level.  Hold* until ≤ Grade 1 . 
Resume at one dose level 
lower, if indicated.** 
Grade 4  Off protocol therapy  Off protocol therapy  
*Participants requiring a cumulative delay of > 2 weeks shall go off protocol 
therapy.  
**Participants requiring > two dose reductions shall go off protocol therapy.  
 
AMC 098 (Version 4 .0) 08DEC2020 32 
NCI Version Date 08DEC2020  6.0 ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS  
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial. The 
following list of AEs (Section 6.1) and the characteristics of an observed AE ( Section 6.2 ) 
will determine whether the event req uires expedited reporting via the CTEP Adverse Event 
Reporting System (via CTEP -AERS) in addition  to routine reporting. 
CTEP- registered physician investigators and CTEP -registered advanced practice clinicians 
who are non- physician investigators ( i.e.,, NP or PA) may perform toxicity assessment per 
local licensure requirements.  
The CTEP Version 5.0 of the NCI Common Terminology Criteria for Adverse Events 
(CTCAE) will be utilized for AE reporting. The CTEP Version 5.0 of the CTCAE is identified and located on the CTEP website at  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
All appropriate treatment areas should have access to a copy of the CTEP Version 5.0 of 
CTCAE.  
This study will be monitored by [CONTACT_470] (CDUS). Cumulative 
CDUS data will be submitted quarterly to CTEP by [CONTACT_10075]. Reports are due January 31, April 30, July 31, and October 31. 
6.[ADDRESS_848347] for nelfinavir  
Agent not supplied by [CONTACT_472] : Refer to Section 7.0
 or the Viracept® package 
insert(s) for the comprehensive list of adverse events . 
Listed below are adverse events occurring in > 2% of participants receiving standard dose nelfinavir (Viracept
®). 
• Diarrhea  
• Nausea 
• Flatulence  
• Rash  
With high dose nelfinavir, neutropenia has been observed. 
6.2 Classification of AEs by [CONTACT_635017]  
6.2.1 Adverse Event: Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure regardless of whether it is considered related to the medical treatment or procedure (attribution of unre lated, unlikely, possible, 
probable, or definite).  
6.2.2 Life-threatening Adverse Event: Any AE that places the participant or participant, 
in view of the Investigator, at immediate risk of death from the reaction.  
6.2.3 Serious Adverse Event (SAE): Any AE  occurring at any dose that results in any of 
the following outcomes: Death, a life -threatening AE, inpatient hospi[INVESTIGATOR_634961] 098 (Version 4 .0) 08DEC2020 33 
NCI Version Date 08DEC2020  prolongation of existing hospi[INVESTIGATOR_059], a persistent or significant disability/ 
incapacity, or a congenital anomaly/birth def ect. 
6.2.4 Please note for hospi[INVESTIGATOR_059] – All hospi[INVESTIGATOR_602] (or prolongation of existing 
hospi[INVESTIGATOR_059]) for medical events equivalent to CTCAE Grade 3, 4, [ADDRESS_848348] be reported regardless of the requirements for Phase of study, expected or unexpected,  
and attribution. For example, do not report an admission for pharmacokinetic sampling, but do report an admission for a myocardial infarction.  
6.2.5 Toxicity: Toxicity is a term NOT clearly defined by [CONTACT_86946]. Toxicity has been described as an AE that has an attribution of possibly, probably 
or definitely related to investigational treatment. To minimize confusion the NCI would recommend that the term toxicity NOT be utilized for AE reporting purposes. The CTCAE continues to use the term ‘toxicity’ because of familiarity.  
6.2.6 Unexpected Adverse Event: Any AE that is not listed in available sources including the package insert, the Investigator’s Brochure, or the protocol. 
6.2.7 CTEP Adverse Event Reporting System (CTEP -AERS): An electron ic system for 
expedited submission of AE reports. 
6.2.8 Attribution: The determination of whether an AE is related to a medical treatment or procedure. Attribution categories:  
Definite – The AE is clearly related to the investigational agent.  
Probable – The AE is likely related to the investigational agent.  
Possible – The AE may be related to the investigational agent.  
Unlikely – The AE is doubtfully related to the investigational agent.  
Unrelated – The AE is clearly NOT related to the investigational agent . 
6.[ADDRESS_848349] use CTEP -AERS (CTEP Adverse Event 
Reporting System), accessed via the CTEP home page (http://ctep.cancer.gov). The reporting procedures to be followed are presented in the “CTEP, NCI Guidelines: 
Adverse Event Reporting Requirements” which can be downloaded from the CTEP home page (http://ctep.cancer.gov). These requirements are briefly outlined in the table below ( Section 6.3.3
). 
A [ADDRESS_848350] be entered electronically into 
CTEP-AERS by [CONTACT_635018].  
6.3.2 CTEP- AERS is programmed for automatic electronic distribution of reports to the 
following individuals: Study Coordinator of the Lead Organization, Principal Investigator, and the local treating physician. CTEP -AERS provides a copy fe ature 
for other e -mail recipi[INVESTIGATOR_840].  
6.3.3 Expedited reporting guidelines  
Use the NCI protocol number and the protocol -specific participant ID assigned 
during trial registration on all reports.  
 
AMC 098 (Version 4 .0) 08DEC2020 34 
NCI Version Date 08DEC2020  Note: A death  on study requires both routine and expedited reporting regardless of 
causality, unless as noted below. Attribution to treatment or other cause must be 
provided. 
Death due to progressive disease should be reported as Grade 5 “General 
disorders and administ ration site conditions  – Disease Progression. ” Evidence 
that the death was a manifestation of underlying disease ( e.g., radiological changes 
suggesting tumor growth or progression: clinical deterioration associated with a 
disease process) should be submitt ed.  
Expedited Reporting Requirements for Adverse Events that Occur in a Non -IND/IDE trial 
within [ADDRESS_848351] Administration of a Commercial Agent 1, 2 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)  
NOTE:  Investigators MUST  immediately report to the sponsor (NCI) ANY Serious Adverse Events, whether or 
not they are considered related to the investigational agent(s)/intervention (21 CFR 312.64)  
An adverse event is considered serious if it results in ANY  of the following outcom es: 
• Death  
• A life -threatening adverse event  
• An adverse event that results in inpatient hospi[INVESTIGATOR_1328] ≥ 24 hours  
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
• A congenital anomaly/birth defect.  
Important Medical Events (IME) that may not result in death, be life threatening, or require hospi[INVESTIGATOR_5186] n may be 
considered serious when, based upon medical judgment, they may jeopardize the participant or participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and IC H E6).
 
ALL SERIOUS  adverse events that meet the above criteria MUST  be immediately reported to the NCI via CTEP -
AERS within the timeframes detailed in the table below.  
Hospi[INVESTIGATOR_15164] 1  
timeframes  Grade 2  
Timeframes  Grade 3  
Timeframes  Grade 4 & 5  
Timeframes  
Resulting in Hospi[INVESTIGATOR_059]  
≥ 24 hrs. 10 Calendar Days  24-Hour 5  
Calendar Days  Not resulting in  
Hospi[INVESTIGATOR_059] ≥ 24 hrs. Not required  10 Calendar Days  
Expedited AE reporting timelines are defined as:  
● “24-Hour; 5 Calendar Days” - The AE must initially be reported via CTEP -AERS within 24 hours of learning 
of the AE, followed by a complet e expedited report within 5 calendar days of the initial 24 -hour report.  
● “10 Calendar Days” - A complete expedited report on the AE must be submitted within [ADDRESS_848352] administration of investigational 
agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:  
Expedited 24- hour notification followed by [CONTACT_432] 5 calendar days for:  
All Grade 4, and Grade 5 AEs  
Expedited 10 calendar day reports for:  
Grade [ADDRESS_848353] agent s, the AE reporting period is limited to 10 radioactive half -lives, rounded 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848354] whole day, after the agent/intervention was last administered. Footnote “1” above applies after 
this reporting period.  
Effective Date: May 5, 2011  
6.3.4 Additional protocol-s pecific expedited a dverse event r eporting exclusions 
For this protocol only, the AEs/grades listed below do not require expedited 
reporting via CTEP -AERS. However, they still must be reported through the 
routine reporting mechanism ( Section 6.4 ): 
 
CTCAE SOC  Adverse Event  Grade  Hospi[INVESTIGATOR_059]/ Prolongation 
of Hospi[INVESTIGATOR_634962]  ≤ 2 Prolongation of Hospi[INVESTIGATOR_634963]  ≤ 2 Prolongation of Hospi[INVESTIGATOR_634964]  ≤ 2 Prolongation of Hospi[INVESTIGATOR_059]  
*AEs considered with an attribution to NFV of possible or greater  
6.3.5 For Uganda Cancer Institute Only: SAE reporting to the Ugandan National Drug 
Authority  
Once the trial is opened in Uganda, this protocol will also comply with the National Drug Authority’s requirements for safety reporting.  
The requirement for the investigator to notify the sponsor of any serious adverse event that occurs in a participant during a clinical trial will occur via Adverse Event 
form in Advantage eClinical (see Section 6.4
), which will include any suspected 
unexpected serious adverse reactions.  
The sponsor shall, within seven days of becoming aware, report to the Authority and the Uganda National Council of Science and Technology or an institution authorized to receive the report by [CONTACT_635019], any suspected unexpected serious adverse react ions. 
Where urgent safety measures are taken to protect the participants against any 
immediate hazard to the health or safety of trial participants due to participation in this investigation, the sponsor shall within three working days from the date the safety measures are taken, give written notice to the Authority of the measures taken and the circumstances that give rise to the measures.  
6.3.6 SAE reporting to [COMPANY_007] Inc.  
The following incidents will be reported to [COMPANY_007] Inc. within 24 hours of the AMC 
ODMC’s awareness, in accordance with the agent supply agreement : 
• All deaths  
• Non-fatal SAEs in reporting period assessed as related to nelfinavir and 
unexpected 
• Related SAEs that occur after the rep orting period 
 
AMC 098 (Version 4 .0) 08DEC2020 36 
NCI Version Date 08DEC2020  • Exposure during pregnancy or lactation, occupational exposure, or lack of 
effect  
As the manufacturer of the agent, [COMPANY_007] will be responsible for reporting any serious and unexpected suspected adverse drug reactions (S[LOCATION_003]R) to the FDA in accordance with [ADDRESS_848355] be entered in an Adv erse Event form within 24 hours of the investigator’s awareness.  
In assessing laboratory results, an abnormal laboratory value will be considered clinically significant if it is characterized by [CONTACT_167664]:  
1. Is judged by [CONTACT_8127] a causal relationship to the investigational agent 
2. Requires clinical intervention or monitoring, such as: close observation, more frequent follow -up assessments, further diagnostic intervention, treatment/therapeutic 
intervention, or protocol therapy dose modification  
3. Is associated with clinical signs or symptoms, which may suggest a disease and/or organ toxicity, or may represent a new condition or worsening of a baseline condition 
4. Is associated with a serious adverse event, or is otherwise judged by [CONTACT_635020].  
In general, a laboratory abnormality that is not clinically significant will be consistent with 
CTCAE grade 1 (mild) or 2 (moderate) severity, as categorized by [CONTACT_241260] (SOC) or Metabolism and Nutrition Disorders SOC. Investigators may not designate laboratory abnormalities that are consistent with grade 3 or greater severity as not clinically significant.  
All laboratory values deemed clinically significant will be subsequently reported as AEs unless the result is a sign of a clinical diagnosis that is reported as an AE. For example, clinically relevant laboratory results for electrolyte abnormalities would not require separate reporting as AEs if they are signs of a clinical diagnosis and reported AE for dehydration. 
6.5 Secondary Malignancy 
Not relevan t for nelfinavir.  
6.6 Second Malignancy  
A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a metastasis from the initial malignancy). Second malignancies require ONLY routine 
adverse event reporting.  
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848356] of the adverse events and potential risks associated with the investigational or 
commercial agents administered in this study can be found in Section 6.1 . 
7.1 Nelfinavir (Viracept®, nelfinavir mesylate)  
[NOTE: Please refer to the commercial package insert for more information.] 
7.1.1 Other Names: Viracept®; 159989-64- 7; VRX496; UNII -HO3OGH5D7.  
The chemical name [CONTACT_399086]  
[3S-[2(2S*, 3S*), 3 α, 4aβ, 8aβ]]-N-(1, 1- dimethylethyl)decahydro -2-[2-hydroxy-3-
[(3-hydroxy2- methylbenzoyl)amino] -4-(phenylthio)butyl] -3-isoquinoline 
carboxamide monomethanesulfonate (salt) and the molecular weight is 663.90 
(567.79 as the free base). 
 
7.1.2 Classification: human immunodeficiency virus (HIV -1) protease inhibitor. 
7.1.[ADDRESS_848357] a number of 
tumor types and herpesvirus replication in vitro  (see Section 2.2.1 ). 
7.1.4 Ingredients 
Nelfinavir tablets are available for oral administration as a white oval tablet with a clear film coating in 625 mg strength (as nelfinavir free base).  
Each tablet contains the following common inactive ingredients: calcium silicate, crospovidone, magnesium stearate, hypromellose, and triacetin. In addition, the 625 mg tablet contains colloidal silicon dioxide.  
7.1.5 Storage and s tability  
Nelfinavir tablets and should be stored at 15° to 30°C (59° to 86°F) away from sources of heat and moisture. 
Keep container tightly closed.  

 
AMC 098 (Version 4 .0) 08DEC2020 38 
NCI Version Date 08DEC2020  7.1.6 Dose s pecifics and a dministration  
Nelfinavir should be taken with a meal. Participants unable to swallow the 625 mg 
tablets should dissolve the tablets in a small amount of water. Once dissolved, participants should mix the cloudy liquid well, and cons ume it immediately. The 
glass should be rinsed with water and the rinse swallowed to ensure the entire dose is consumed.  
7.1.7 Preparation: 625 mg tablets.  
7.1.8 Route of administration: Oral  
7.1.9 Incompatibilities: Not applicable (oral).  
7.1.10 Availabil ity: VIRACEPT ® (nelfinavir mesylate) 625 mg: White oval tablet with a 
clear film coating engraved with "V" on one side and "625" on the other. Bottles of 120 (625 mg) tablets – NDC [ZIP_CODE]-027- 70 VIRACEPT ® (nelfinavir mesylate).  
7.1.11  Side Effects: Most co mmon adverse reactions (≥ 2%) of moderate or severe 
intensity in adults and adolescents (13 years and older) are diarrhea, nausea, rash, and flatulence.  
Adverse events occurring in less than 2% of participants receiving VIRACEPT
® in 
all phase II and III clinical trials and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below. 
Body as a Whole : abdominal pain, accidental injury, allergic reaction, asthenia, 
back pain, fever, headache, malaise, pain, and redistribution/accumulation of body fat. 
Digestive System : anorexia, dyspepsia, epi[INVESTIGATOR_50684], gastrointestinal bleeding, 
hepatitis, mouth ulceration, pancreatitis, and vomiting. 
Hemic/Lymphatic System: anemia, leukopenia, and thrombocytopenia. 
Metabolic/Nutritional System : increases in alkaline phosphatase, amylase, creatine 
phosphokinase, lactic dehydrogenase, SGOT, SGPT, and gamma -glutamyl 
transpeptidase; hyperlipemia, hyperuricemia, hyperglycemia, hypoglycemia, dehydration, and live r function tests abnormal.  
Musculoskeletal System : arthralgia, arthritis, cramps, myalgia, myasthenia, and 
myopathy. 
Nervous System: anxiety, depression, dizziness, emotional lability, hyperkinesia, 
insomnia, migraine, paresthesia, seizures, sleep disorder, somnolence, and suicide ideation. 
Respi[INVESTIGATOR_43548]: dyspnea, pharyngitis, rhinitis, and sinusitis. 
Skin/Appendages : dermatitis, folliculitis, fungal dermatitis, maculopapular rash, 
pruritus, sweating, and urticaria.  
Special Senses: acute iritis and eye disorder. 
Urogenital System : kidney calculus, sexual dysfunction, and urine abnormality. 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848358] -approval use of 
VIRACEPT®. Because these reactions are reported voluntarily from a population 
of unce rtain size, it is not always possible to reliably estimate their frequency or 
establish a causal relationship to drug exposure.  
Body as a Whole: hypersensitivity reactions (including bronchospasm, moderate to 
severe rash, fever, and edema).  
Cardiovascular System : QTc prolongation, torsades de pointes. 
Digestive System: jaundice.  
Metabolic/Nutritional System: bilirubinemia, metabolic acidosis.  
7.1.12 Nursing Implications: Women receiving high dose nelfinavir should not breastfeed.  
7.1.13 Refer ences: PubChem: Open Chemistry Database; VIRACEPT® Highlights of 
Prescribing Information (ViiV Healthcare Company, updated 05/2013) 
7.2 Drug Orders, Transfers, Returns, and Accountability  
Nelfinavir mesylate is being supplied by [CONTACT_4618], Inc. for this trial. Locally -sourced supplies 
of a FDA-approved Viracept ( nelfinavir mesylate ) 625 mg tablets may be sourced by [CONTACT_635021] . The principal investigator (or his/her authorized designee) 
at each study site will request study agent from the AMC’s vendor for study agent distribution. International sites must consult the Ma nual of Procedures for drug ordering 
instructions . Information and forms for ordering study agent will be maintained in the 
password -protected section of the AMC Operations website for protocol AMC -098 
(www.AIDSCancer.org ). 
Medication should be kept in a secured locked area at the study site in accordance with applicable regulatory requirements. Participants should be instructed to keep medication in 
its original container and stored at room temperature (15- 30°C), away from heat and 
moisture. The site is responsible for the destruction of study agent returned by [CONTACT_635022].  
The Investigator, or a responsible party designated by [CONTACT_737], must maintain a careful record of the inventory and disposition of all drugs received using the NCI Drug Accountability Record Form (Oral DARF) (available on the CTEP h ome page 
(http://ctep.cancer.gov) or contact[CONTACT_635023] [EMAIL_8889]).  The DARFs document the drug delivery date to the site, 
inventory at the site, use by [CONTACT_241264], and disposal of the drug (if applicable). A site -specific accountability record, either manual or electronic, may be used if it includes 
all the information required on the NCI Investigational Drug Accountability Record and if the paper printout is identical to the NCI account ability record. Institutional pharmacists 
must only supply participants  enough study drug to last until their subsequent study visit  
(i.e., no extra study drug should be given. T he pharmacist must dispense nelfinavir in the 
original container.  The nelfinavir removed from the bottle prior to dispensing should be 
destroyed according to local policy. Pharmacists must log the number of capsules be ing 
dispensed on the first line of the oral DARF. On the next line, record the number of capsules wasted and connect the two lines with a bracket (either ‘{‘ or ‘[’) outside of the table on 
 
AMC 098 (Version 4 .0) 08DEC2020 40 
NCI Version Date 08DEC2020  the left side .  
  
 
AMC 098 (Version 4 .0) 08DEC2020 41 
NCI Version Date 08DEC2020  8.0 CLINICAL AND LABORATORY EVALUATIONS  
Schedules shown in the Study Calendar below are provided in Appendix I . 
8.1 Screening/Baseline Evaluations  
Baseline evaluations (including scans and x- rays) are to be conducted within 4 weeks prior 
to study enr ollment into Segment B (Treatment Enrollment), unless otherwise specified 
below. 
8.1.1 Recording of demographics, medical history, history of Centers for Disease Control 
and Prevention ( CDC) HIV risk group and AIDS defining illnesses, physical 
examination (including vital signs, height, and weight), nutrition assessment,  
ECOG or KPS score,  assessment of KS sign and symptoms, and medication review.  
8.1.2 Diagnostic KS biopsy if not previously done at any time (can be the same biopsy collected for immunohisto chemistry correlative studies). Any biopsy report is 
sufficient for the domestic sites; participants at the international sites require 
diagnosis by [CONTACT_229345] -approved pathologist identified for that site . 
8.1.[ADDRESS_848359] mus t be performed prior to initiating 
treatment. These may be performed on Day 0, but no earlier than 7 days before initiating study treatment. Tumor assessments and photographs should be performed as outlined in the Kaposi’s Sarcoma (KS) Tumor Assessment Man ual of 
Procedures (MOP).  
8.1.4 Staging criteria (to be done within 4 weeks prior to study enrollment): KS staging will be based on the modified AIDS Clinical Trials Group (ACTG) Oncology Committee Staging Criteria as outlined in the KS Tumor Assessment MOP . 
8.1.[ADDRESS_848360] dose nelfinavir  (on Day 0 ) if 
previously performed within the 4 weeks before Day 0. 
8.1.9 Electrocardiogram ( EKG ). 
8.1.10 Complete blood count  (CBC)  with differential and chemistries must be  performed 
within 4 weeks before starting treatment. Chemis tries include  calcium, sodium, 
potassium, carbon dioxide ( CO2 ), chloride, AST ( SGOT )/ALT(  SGPT ), BUN, 
creatinine, direct and total bilirubin, fasting glucose, and triglycerides. 
8.1.11 Optional donation to the AIDS and Cancer Specimen Resource (ACSR). (See 
Appendix V  for ACSR Informed Consent Form and Appendix IV
 for ACSR 
Speci men Preparation and Shippi[INVESTIGATOR_335]) ( for U.S. participants only ). 
8.1.12 Correlative Studies (see Section 2.4, Appendix II, Appendix IX , and Appendix X ) 
[IP_ADDRESS] Oral swabs for KSHV, HSV, EBV, and CMV qPCR collected on 14 
separate days pre- treatment (14 samples total) between weeks - 4 and 0. 
Sample collection will be performed between study visits and will be self-
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848361] 
be documented in the participant’s study record.  
[IP_ADDRESS] Baseline biopsies: two biopsy specimens will be obtained prior to 
initiating nelfinavir: one 3 mm KS biopsy for immunohistochemistry (collected in formalin) AND one 3 mm for viral gene expression arrays (collected in RNA later ). For IHC, the same biopsy may be used for those 
participants that require a diagnostic KS biopsy for study entry (see Section 8.1.2
). If biopsy specimens for ICH studies are deemed u nusable 
or are inadequate to perform IHC studies, 6 additional slides  from the 
diagnostic biopsy may be collected for analysi s. 
[IP_ADDRESS] Blood ( 8.5 mL in a yellow top ACD tube ) sample collected once per week 
during pre -treatment for a total of 2 samples for KSHV  and EBV qPCR 
of PBMC and plasma. PBMC DNA from this sample will also be used for genotypi[INVESTIGATOR_634965]3A /CYP2C19 will be performed to assess 
nelfinavir/M8 metabolism/pharmacogenomics.  
The timing of these  samples  is based on feasibility. For example, [ADDRESS_848362] ( Appendix XIV
), Participant Instructions for Oral Swabs 
(Appendix XIII ), and Participant Drug Diary (see Appendix VII ). Nutritional 
counseling is required to ensure that participants are consuming nelfinavir with the appropriate foods. The site must query the participant regarding this information 
(open- ended questions are recommended) and capture the response in the source. 
The AMC -098 Documentation of Nutrition Assessment and Counseling source 
document provided on the AMC member’s only website or an equivalent document 
may be used for this purpose. 
8.2 Evaluations during Treatment  
Efforts should be made to keep participants  on the proper study visit schedule. Each study 
visit while on treatment may be conducted +/- 3 days from the evaluation schedule. 
8.2.1 Medical history, physical exam (including vital signs and weight), medication 
review (adherence review), nutrition assessment, and assessment of KS sign and symptoms. 
8.2.[ADDRESS_848363] X -ray should be performed to evaluate tumor response  only for participants 
with pulmonary KS or new pulmonary symptoms. 
8.2.3 Pregnancy testing by [CONTACT_57134]- HCG if female of childbearing age immediately prior to 
starting high -dose nelfinavir. 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848364] dose nelfinavir, and 2 weeks after starting high 
dose nelfinavir. 
8.2.8 Correlative Studies (see Section 2.4, Appendix II , Appendix IX , and Appendix X ) 
[IP_ADDRESS] Oral swabs for KSHV, HSV, EBV, and CMV, qPCR collected twice weekly 
for 7 weeks (14 samples) starting one week after initiation of high dose 
nelfinavir treatment. Sample collection between study visits will be self -
collected by [CONTACT_2299]. See Appendix XIII  for participant instructions 
for the oral swab collection.  
[IP_ADDRESS] On -treatment biopsies  
• Two weeks after initiating standard dose nelfinavir, two 3 mm KS biopsies will be obtained: one for immunohistochemistry (collected in formalin) AND one for viral gene expression arrays (collected in RNAlater ). 
• Two weeks after initiating high dose nelfinavir, two 3 mm KS biopsies will be obtained: one for immunohistochemistry (collected in formalin) AND one for viral gene expression arrays (collected in RNA later ). 
[IP_ADDRESS] Blood (6 mL  in a lavender top EDTA tube ) for assessment of nelfinavir/M8 
concentrations (pharmacokinetics),  prior to dosing  at each study visit (eve ry 
2 weeks) while on treatment , starting on Week 1/cycle 1  through the 
completion of Week 15/cycle 9  (a total of 9 samples will be collected) A -3 
day window is permitted. 
[IP_ADDRESS] Blood ( 8.5 mL in a ye llow top ACD tube ) sample collected at each clinic 
visit (every 2 weeks) while on high dose nelfinavir for KSHV  and EBV 
qPCR of PBMC and plasma. 
The timing of these samples is basing the timing on feasibility . The e ight 
samples on treatment can be obtained twice monthly in order to coordinate 
the bl ood draw schedule with clinical/tumor assessment visits and safety lab 
blood draws, which will also occur on this schedule (safety labs monthly 
but coordinated with bi -weekly visits); this will reduce burden on 
participant and maximize study resources.  
8.2.9 Provide study drug, nutritional counseling, Participant Instructions for Oral Swabs (one week after initiation of high dose nelfinavir, Appendix XIII
), and Participant 
Drug Diary (see Appendix VII ). Sufficient drug to provide continuous dosing 
between cycles/study visits should be provided as long as visits lie within the visit window. 
8.3 Early Treatment Discontinuation Evaluations  
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848365] the following evaluations and laboratory tests  within  7 days 
after discontinuation of nelfinavir: 
[IP_ADDRESS] Medical history, physical exam (including vital signs and weight), 
medication review (adherence review), nutrition assessment.  
[IP_ADDRESS] KS tumor assessment with photographic documentation as outlined in the 
KS Tumor Assessment MOP. Response of KS to treatment is described  in 
Section 9.[ADDRESS_848366] X -ray should be performed to evaluate tumor response  only for 
participants with pulmonary KS or new pulmonary symptoms. 
[IP_ADDRESS] Complete blood count with differential, and chemistries  as described in 
Section 8.1.10 . 
[IP_ADDRESS] Fasting glucose and triglycerides. 
[IP_ADDRESS] HIV plasma viral load and CD4 count if HIV-positive. 
8.[ADDRESS_848367] the following evaluations and laboratory tests 8 weeks (± 
7 days) after discontinuation of nelfinavir . Follow- up evaluations  must occur before 
beginning a lternative thera py. If in the opi[INVESTIGATOR_634966] , then the follow up 
visit may occur earlier th an 8 weeks (± 7 days) after discontinuation of nelfinavir. 
[IP_ADDRESS] Medical history, physical exam (including vital signs and weight). 
[IP_ADDRESS] KS tumor assessment with photographic documentation as outlined in the 
KS Tumor Assessment MOP. Response of KS to treatment is described in 
Section 9.[ADDRESS_848368] X -ray should be performed to evaluate tumor response  only for 
participants with pulmonary KS or new pulmonary symptoms. 
[IP_ADDRESS] Complete blood count with differential, and chemistries  as described in 
Section 8.1.10 . 
[IP_ADDRESS] Fasting glucose and triglycerides. 
[IP_ADDRESS] HIV plasma viral load and CD4 count if HIV -positive. 
8.5 Final Evaluations, Off Study  
At the completion of all follow -up evaluations described in Section 8.4 , the Off -Study 
Summary Form should be completed in Advantage eClinical. 
8.5.1 Participants completing  study per-protocol. 
8.5.2 Participants who discontinue the study early. 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848369]  
For the purposes of this study, participants should be re -evaluated for response every 2 
weeks. See Appendix I  for the KS Tumor Assessment schedule.  
CTEP- registered physician investigators and CTEP -registered advanced practice clinicians 
who are non -physician investigators (i.e ., NP or PA) may perform toxicity and response 
assessment per local licensure requirements.  
Evaluable for Toxicity : All participants will be evaluable for toxicity from the time of their 
first treatment with nelfinavir.  
Evaluable for Objective Response : Only those participants who have measurable disease 
present at baseline and  have received study drug will be considered evaluable for response.  
Response status will be classified as complete response (CR), partial response (PR) , stable 
disease ( SD), or progressive disease ( PD). 
9.1 Definition of Respons e 
Response and progression will be evaluated in this study using the AIDS Clinical Trials 
Groups (ACTG) response criteria for Kaposi sarcoma.  
9.1.1 Complete response: Complete response (CR) is defined as the absence of any detectable residual disease, incl uding tumor -associated edema, persisting for at 
least 4 weeks. In participants with pi[INVESTIGATOR_49194] (brown or tan) macular skin lesions persist after apparent complete response, biopsy of at least one representative lesion is required in order to document the absence of malignant cells. In participants known to have had visceral disease, an assessment at restaging with appropriate endoscopic or radiographic procedures should be made. 
9.1.2 Partial response (PR) is defined as no new lesions (skin or oral), or new visceral sites of involvement (or the appearance or worsening of tumor -associated edema or 
effusions); AND  
• A 50% or greater decrease in the number of all previously existing lesions lasting for at least 4 weeks; OR  
• Complete flattening of at least 50% of all previously raised lesions (i.e., 50% of all previously nodular or plaque- like lesion become macules); OR  
• A 50% decrease in the sum of the products of the largest perpendicular diameters of the marker lesions.  
Note: Participants with residual tumor -associated edema or effusion who otherwise 
meet the criteria for complete response will be classified as having a partial response.  
9.1.3 Stable disease is defined as any response not meeting the criteria for CR, PR, or progressive disease.  
9.1.4 Progressive disease (PD) is defined as follows:  
For participants with ≤ 50 cutaneous lesions  
• 25% increase in the sum of perpendicular diameters of the indicator lesions, OR  
 
AMC 098 (Version 4 .0) 08DEC2020 46 
NCI Version Date 08DEC2020  • ≥ 25% increase in the total lesion count, or a minimum of 5 new lesions, 
whichever is greater, OR  
• ≥ 25% increase in the number of raised lesions (minimum of 5 new raised 
lesions if there are very few raised lesions, for example ≤  8), whichever is 
greater.  
Note: There are body sites where disease is particularly difficult to evaluate, and  a 
few new lesions may be counted in spi[INVESTIGATOR_86872] a participant is not actually 
progressing. For example, lesions of the foot, particularly those which are flat, are difficult to evaluate because their intensity may be variable based on how much edema is present, how much the person walked the  day before, how long their feet 
have been in a dependent position prior to the physical exam, etc. 
For participants with > 50 cutaneous lesions  
• ≥ 25% increase in the sum of the perpendicular diameters of the  indicator 
lesions, OR 
• ≥ 25% increase in the total number of lesions in the prospectively defined 
anatomic sites containing representative numbers of lesions, OR 
• A total of 5 new lesions in anatomic sites which were previously documented 
as having no evidence of cutaneous disease on the whole body diagram, OR  
• ≥ 25% increase in the number of raised lesions (minimum of 5 raised lesions if 
there are very few raised lesions, for example < 8) whichever is greater. Photographic documentation of “gross” or significant progression, particularly in areas that were not being followed, will be of particular value.  
In order to classify a response as PR, the participant must have at least a PR in either the cutaneous or noncutaneous sites of disease, and no evidence of progression as defined in the above criteria. In order to classify a response as a CR, 
the participant must have a CR in both the cutaneous (if applicable) and noncutaneous (if applicable) sites of disease, and no evidence of progression as defined by [CONTACT_86950]. 
9.1.[ADDRESS_848370] 1 week, which interferes with the participant’s normal activities. Progressive visceral disease, for measurable and evaluable disease, should be analogous to non- KS response criteria.  
9.1.[ADDRESS_848371] dose of chemotherapy until 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848372] progression. 
 
AMC 098 (Version 4 .0) 08DEC2020 48 
NCI Version Date 08DEC2020  10.0 STATISTICAL CONSIDERATIONS  
10.1 Study Design/Endpoints  
Currently approved cytotoxic chemotherapy regimens result in a roughly 40% partial or 
complete response (total response) rate in persons who are not ART -naïve (who initiate 
ART and chemotherapy concurrently). Our hypothesis is that the dos e-escalation regimen 
will result in at least a 20% improvement in PR or CR above the historically defined rate of spontaneous KS regression, which is 20%. We chose to evaluate a 20% improvement in total response rate because we felt that this would be both  a clinically significant 
improvement and at least equivalent to current chemotherapy. Because NFV has many fewer toxicities and requires less monitoring, oral administration, and less cost and potential for better access compared to chemotherapy, a findin g of at least equivalence 
could be considered an improvement over the standard -of-care. Because the cost and 
feasibility of using an all- oral NFV regimen in resource -limited settings would provide a 
significant implementation and access benefit over cytotoxic chemotherapy, we feel strongly that NFV should be proven similarly efficacious to current chemotherapy, rather than superior to it. Therefore,  we have chosen a design with 90% power at a one -sided 10% 
significance level to test the hypothesis that 40% of participants receiving NFV at standard followed by [CONTACT_5019]- dosing regimens will be able to attain PR or CR. The null hypothesis is 
that we will fail to detect a response superior to the rate of spontaneous tumor regression (20%). Participants from both the international and domestic protocol will contribute t o the 
single analysis plan, which is based on HIV status and not site of recruitment.  
Primary objective  
To determine the efficacy of a therapeutic escalation strategy consisting of standard dose nelfinavir, followed by [CONTACT_635024], for the treatme nt of Kaposi sarcoma (KS) 
tumor lesions.  The binomial proportion and its exact 95% confidence interval will be used 
to estimate the response rate in the study. With [ADDRESS_848373] 95% confidence interval separately for HIV positive and HIV negative participants.  
Secondary objectives  
• To evaluate the safety of high dose nelfinavir among participants with KS.  
• The frequency of adverse events and their severity will be tabulated to evaluate tolerance of high dose NFV in the treatment of KS in both HIV -negative  and HIV -
positive  participants.  
• To correlate nelfinavir and the primary active metabolite, M8, c oncentrations with 
tumor response , antiviral response, and adverse effects in participants with KS. Trough 
nelfinavir/M8 concentrations will be summarized using descriptive statistics and 95% confidence intervals. This outcome will also be displayed graphically as a trend in drug levels over time. The relationship between dose and drug exposure of nelfinavir/M8 and the pharmacodynamic effects will be determined using Pearson’s correlation coefficient (r
2) or appropriate non -parametric statistics for dichoto mous and categorical 
variables (e.g., Mann –Whitney U -test or Kruskal -Wallis analysis of variance by [CONTACT_635025]).  
 
AMC 098 (Version 4 .0) 08DEC2020 49 
NCI Version Date 08DEC2020  • To assess the effect of nelfinavir on KSHV lytic gene expression in tumor tissue. 
Descriptive statistics will be used for changes in the relative abundance of all latent and lytic viral mRNA relative to cellular mRNA by [CONTACT_635026], and changes in the percentage of cells staining for K8.1 (lytic) and LANA (laten cy-associated nuclear 
antigen ) antigens by [CONTACT_9064]. Generalized estimating equations will be 
used to evaluate these changes over time. Normalizing transformations will be used as needed. 
• To assess the effect of nelfinavir on KSHV copy number in saliva. Prior studies 
demonstrate stability of estimates of herpesvirus shedding rat e in mucosal swabs with 
14 or more samples. Therefore, pre -treatment oral samples and oral samples during 
treatment will be collected from each participant. The sampling frequency is irrelevant 
as long as the quantity is sufficient. With 36 participants, a  decrease in the proportion 
of participants with detectable KSHV DNA from 50% at baseline to 1% on treatment can be detected at the one -sided 0.05 significance level with 0.99 power using 
McNemar's test.  
• K8.1 will be measured by [CONTACT_9064]. A study participant’s K8.[ADDRESS_848374] 20% and has increased at least 50% from baseline measures. With 36 study participants, the null hypothesis that the proportion of study participants who demonstrate an increase is 1% and can be tested against the alternative that it is 20% or greater at the one -sided significance level of 0.[ADDRESS_848375] for a single proportion (REF: Chernick MR, Liu CY: The saw -
toothed behavior of power versus sample size and software solutions: single binomial proportion using exact methods. The American Statistician 56: 149- 155, 2002.) Thus, 
the proportion of study participants who demonstrate an increase in K8.[ADDRESS_848376] 95% confidence interval.
 
Exploratory objectives  
• To assess the effect of nelfinavir on KSHV  and EBV  copy number in PBMC and 
plasma.  
• To assess the effect of nelfinavir on HSV, CMV, and EBV in saliva. 
• KSHV detection in plasma (viremia) and oral shedding will be calculated at baseline and on NFV treatment. An analysis will also be performed for shedding of HSV, CMV, and EBV. Kaplan- Meier curves will also be created to demonstrate percent of 
participants demonstrating the presence of each of the above viruses in blood and saliva as a function of time and stage of treatment. For each herpesvirus and source of samples (oral or plasma), the following analyses will be  done: 
• McNemar’s chi -square test will be used to evaluate the detection of the herpesvirus 
prior to treatment and during treatment.  
• Generalized estimating equations (GEE) using a binomial distribution will be used to 
evaluate the detection of KSHV in plasma and oral specimens over time. Log10 
transformations will be applied to the viral load data, and the median log viral load will be estimated for each participant prior to treatment and at time points post treatment. Generalized estimating equations (GEE) will be used to assess change over time with 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848377] to these measures.  
10.2 Sample Size/Accrual Rate  
The study is designed to test the null hypothesis that the response rate is less than or equal 
to 20% against the alternative that it is 40% or greater with 90% power at a one -sided 10% 
significance level which will require a sample size of [ADDRESS_848378] for a single proportion
3,4. 
The plan is to enroll 18 participants who are HIV -positive and 18 who are HIV -negative, 
at an estimated accrual rate of 1 -2 participants/month. Participants from both the 
international and domestic sites will contribute to the single analysis plan, which is based on HIV status and not site of recruitment. 
Evaluable participants for all endpoints ar e defined as participants who meet all the 
eligibility criteria, enroll on the study, and receive at least one dose of treatment. 
Participants who enroll but are not treated will be replaced.  
10.3 Reporting and Exclusions  
10.3.1 Evaluation of toxicity  – All participants will be evaluable for toxicity from the 
time of their first treatment with nelfinavir.  
10.3.2 Evaluation of response  – All participants included in the study must be assessed 
for response to treatment, even if there are major protocol treatment deviations or if they are ineligible. Each participant will be assigned one of the following categories: 1) complete response, 2) partial response, 3) stable disease, 4) progressive disease, 5) early death from malignant disease, 6) early death from toxicity, 7) early death because of other cause, or 9) unknown (not assessable, insufficient data).  
All of the participants who met the eligibility criteria (with the possible exception of those who received no study medication) should be included in the main 
analysis of the response rate. Participants in response categories [ADDRESS_848379] a treatment failure (disease progression). Thus, an incorrect 
treatment schedule or drug administration does not result in exclusion from the  
analysis of the response rate. Precise definitions for categories [ADDRESS_848380] been identified (e.g., early death due to other reasons, early discontinuation of treatment, major protocol violations, etc.). However, these subanalyses may not serve as the basis for drawing conclusions concerning treatment efficacy, and the reasons for excluding participants from the analysis should be clearly reported. The 95% confidence intervals should also be provided.  
 
AMC 098 (Version 4 .0) 08DEC2020 51 
NCI Version Date 08DEC2020  10.4 Stoppi[INVESTIGATOR_634967] 0.05. Thus, the stoppi[INVESTIGATOR_634968] ≤ 5% of the time of the true und erlying rate of treatment terminations due to 
adverse events was 0.05. The trial will be stopped if the number of participants who terminate treatment due to adverse events is greater than  or equal to X out of N participants:  
X N 
2 3-7 
3 8-16 
4 17-28 
5 29-36 
 
AMC 098 (Version 4 .0) 08DEC2020 52 
NCI Version Date 08DEC2020  11.0 ROLE OF DATA MANAGEMENT  
11.1 CRF Instructions  
Access to the internet data entry system for this study, Advantage eClinical , and 
instructions for recording of study data on CRFs will be provided by [CONTACT_635027].AIDSCancer.org . Participating institutions are responsible for submitting data and/or 
data forms via Advantage eClinical  in accordance with the AMC Data Entry Guide and 
specific form instructions, within the timelines specified by [CONTACT_229345]’s Standards of Procedure for Site Performance Measures.  
11.2 Data Quality  
It is the responsibility of the AMC ODMC to assure the quality of data for the study (See Appendix VI
, AMC Data and Safety Monitoring Plan) . This role extends from protocol 
development to generation of the final study database. 
11.3 Data Monitoring 
This study will be monitored in compliance with AMC policies and by [CONTACT_470] (CDUS) Version 3.0. Cumulative protocol- and participant -specific CDUS 
data will be submitted electronically to CTEP on a quarterly basis. Reports are due January 31, April 30, July 31, and October 31. Instructions for submitting data using the CDUS can be found on the CTEP Web site (http://ctep.cancer.gov/reporting/cdus.html). The AMC ODMC is responsible for compi[INVESTIGATOR_372303].  
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848381] (IRB) approval and informed consent 
described in the Food and Drug Administration (FDA) regulations (21 CFR Part 50 and 56) and Department of Health and Human Services (DHHS) regulations for the Protection of Human Subjects regulations (45 CFR Part 46) must be followed. IRB approval of the protocol and the informed consent form must be given in writing. 
The sponsor’s designee (AMC ODMC) must receive a copy of the letter of appro val from 
the IRB, which specifically approves the protocol and informed consent, before participant 
enrollment. The IRB must also approve any significant changes to the protocol and documentation of this approval must be sent to the AMC ODMC. The IRB must review the research project at least once every [ADDRESS_848382] be explained to the participant. The informed 
consent will describe the purpose of the study, the procedures to be followed, the risks and benefits of participation, all risks of th e investigational agent(s) and/or study participation 
as listed in the model informed consent form, and all other elements of informed consent 
as required by [CONTACT_5151]. A copy of the consent form will be given to the participant to 
keep. 
In addition, any institution(s) conducting research according to the guidelines of this 
protocol is required to adhere to local and national laws and regulations governing the 
confidentiality and disclosure of health information. 
12.[ADDRESS_848383] 
be approved by [CONTACT_635028]. All amendments require approval by [CONTACT_1201]/IEC of the treating institution. A copy of the written approval o f the 
IRB/IEC and the national regulatory body (if applicable) must be sent to the ODMC.  
12.3 Women and Minorities  
This study is being conducted by [CONTACT_6812] -sponsored AIDS Malignancy Consortium 
(AMC). As part of their contractual obligations, each participa ting site within the AMC 
and the AMC as a whole is required to assure that the participation of women and minority participants reflects the percentage representation of these populations in their geographic region and, for the AMC, the [LOCATION_002] as a whole. As such, it is expected that the representation of participants on this trial will reflect the constitution of the respective 
 
AMC 098 (Version 4 .0) 08DEC2020 54 
NCI Version Date 08DEC2020  populations. 
Accrual Targets  
DOMESTIC  PLANNED ENROLLMENT REPORT  
Racial Categories  Ethnic Categories  
Total  Not Hispanic or Latino  Hispanic or Latino  
Female  Male  Female  Male  
American Indian/ Alaska Native  0 0 0 0 0 
Asian  0 0 0 0 0 
Native Hawaiian or Other Pacific 
Islander  0 0 0 0 0 
Black or African American  3 12 0 1 16 
White  1 5 1 3 10 
More Than One Race  0 0 0 0 0 
Total  4 17 1 4 26 
 
INTERNATIONAL  PLANNED ENROLLMENT REPORT  
Racial Categories  Ethnic Categories  
Total  Not Hispanic or Latino  Hispanic or Latino  
Female  Male  Female  Male  
American Indian/ Alaska Native  0 0 0 0 0 
Asian  0 0 0 0 0 
Native Hawaiian or Other Pacific 
Islander  0 0 0 0 0 
Black or African American  3 7 0 0 10 
White  0 0 0 0 0 
More Than One Race  0 0 0 0 0 
Total  3 7 0 0 10 
 
  
 
AMC 098 (Version 4 .0) 08DEC2020 55 
NCI Version Date 08DEC2020  12.4 Investigator and Research Associate Registration with CTEP  
Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) 
policy require all individuals contributing to NCI- sponsored trials to register and to renew 
their registration annually. To r egister, all individuals must obtain a Cancer Therapy 
Evaluation Program (CTEP) Identity and Access Management (IAM) account at https:// ctepcore.nci.nih.gov/iam. In addition, persons with a registration type of 
Investigator (IVR), Non -Physician Investigator (NPI[INVESTIGATOR_6731]), or Associate Plus (AP) (i .e., 
clinical site staff requiring write access to the electronic data entry system for this protocol  
or acting as a primary site contact) must complete their annual registration using CTEP’s web-based Registration and Credential Repository (RCR) at 
https://ctepcore.nci.nih.gov/rcr.  
RCR utilizes five -person registration types.  
• IVR: MD, DO, or international equivalent,  
• NPI[INVESTIGATOR_6731]: advanced practice providers ( e.g., NP or PA) or graduate level researchers 
(e.g., PhD), 
• AP: clinical site staff (e .g., RN or CRA) with data entry access to CTSU  and/or AMC  
applications (e .g., Roster Update Management System [ RUMS], OPEN, Rave ; 
Advantage eClinical for this protocol ), 
• Associate (A): other clinical site staff involved in the conduct of NCI- sponsored trials, 
and 
• Associate Basic (AB): individuals ( e.g., pharmaceutical company employees) with 
limited access to NCI -supported systems. 
Table 12- B: CTEP investigator registration documentation requirements  
Documentation Required  IVR NPI[INVESTIGATOR_6732] A 
FDA Form 1572      
Financial Disclosure Form      
NCI Biosketch (education, training, employment, 
license, and certification)      
HSP/GCP training      
Agent Shipment Form (if applicable)      
CV (optional)      
An active CTEP -IAM user account and appropriate RCR registration is required to access 
all CTEP and Cancer Trials Support Unit (CTSU) websites and applications. In addition, 
IVRs and NPI[INVESTIGATOR_634969] 098 (Version 4 .0) 08DEC2020 56 
NCI Version Date 08DEC2020  on the FDA Form 1572 in RCR to allow the following: 
• Added to a site roster 
• Act as the site-protocol PI [INVESTIGATOR_6734] 
• Assigned the Clinical Investigator (CI) role on the Delegation of Tasks Log (DTL; the 
AMC DTL template will be used for th is study; see Section 12.5 ). 
Additional information can be found on the CTEP website at https://ctep.cancer.gov/investigatorResources/default.htm. For questions, please contact 
[CONTACT_280548] [EMAIL_088]. 
12.[ADDRESS_848384] complete a protocol -specific registration packet, including an AMC DTL  
using the provided AMC template or local equival ent. The Clinical Investigator (CI) is 
required to review and sign the AMC DTL prior to the site receiving an a pproved site 
registration status and enrolling participants to the study. The AMC DTL template is 
provided in the protocol registration packet for this protocol, located on the AMC Operations web site at www.AIDSCancer.org. Any individual at the enrolling site on a participating roster may initiate the site DTL. Instructions on completing the DTL are embedded in the AMC DTL template . 
The AMC DTL  must be updated contemporaneously as personnel are added or removed 
and/or study roles and delegated tasks change. Changes must be approved by [CONTACT_150894], and documented by [CONTACT_5657]/her initials and date, before they are implemented. 
 
 
AMC 098 (Version 4 .0) 08DEC2020 57 
NCI Version Date 08DEC2020  13.0 REFERENCES  
1. Chang Y , et al.  (1994) Identification of herpesvirus -like DNA sequences in AIDS -associated 
Kaposi's sarcoma. Science 266(5192):1865-1869. 
2. Parkin DM & Cancer IAfRo (2003) Cancer in Africa: epi[INVESTIGATOR_222288]. In,  IARC 
Sci Publ  (IARC Press, Lyon, [LOCATION_009]), p 414. 
3. Staskus KA , et al. (1997) Kaposi's sarcoma- associated herpesvirus gene expression in 
endothelial (spi[INVESTIGATOR_86853]) tumor cells. J Virol  71(1):715-719. 
4. Parravicini C , et al. (2000) Differential viral protein expression in Kaposi's sarcoma -
associated h erpesvirus- infected diseases: Kaposi's sarcoma, primary effusion lymphoma, 
and multicentric Castleman's disease. Am J Pathol  156(3):743-749. 
5. Katano H, Sato Y, Kurata T, Mori S, & Sata T (2000) Expression and localization of human 
herpesvirus 8- encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and 
multicentric Castleman's disease. Virology  269(2):335-344. 
6. Grundhoff A & Ganem D (2004) Inefficient establishment of KSHV latency suggests an 
additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin 
Invest  113(1):124-136. 
7. Flamand L, Zeman RA, Bryant JL, Lunardi -Iskandar Y, & Gallo RC (1996) Absence of 
human herpesvirus 8 DNA sequences in neoplastic Kaposi's sarcoma cell lines. J Acquir 
Immune Defic Syndr Hum Retrovirol  13(2):194-197. 
8. Dictor M, Rambech E, Way D, Witte M, & Bendsoe N (1996) Human herpesvirus 8 
(Kaposi's sarcoma -associated herpesvirus) DNA in Kaposi's sarcoma lesions, AIDS 
Kaposi's sarcoma cell lines, endothelial Kaposi's sarcoma simulators, and t he skin of 
immunosuppressed patients. Am J Pathol  148(6):2009-2016. 
9. Aluigi MG , et al. (1996) KSHV sequences in biopsies and cultured spi[INVESTIGATOR_634970], 
iatrogenic and Mediterranean forms of Kaposi's sarcoma. Res Virol  147(5):267-275. 
10. Ganem D  (KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and 
medicine. J Clin Invest  120(4):939-949. 
11. Mesri EA, Cesarman E, & Boshoff C (2010) Kaposi's sarcoma and its associated herpesvirus. 
Nature reviews. Cancer 10(10):707-719. 
12. B roccolo F , et al.  (2002) Detection of DNA of lymphotropic herpesviruses in plasma of 
human immunodeficiency virus -infected patients: frequency and clinical significance. 
Clin Diagn Lab Immunol  9(6):1222-1228. 
13. Cannon MJ , et al. (2003) Risk factors for Kaposi's sarcoma in men seropositive for both 
human herpesvirus 8 and human immunodeficiency virus. AIDS  17(2):215-222. 
14. Lin L, et al. (2009) Effects of chemotherapy in AIDS -associated non -Hodgkin's lymphoma 
on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol  27(15):2496-2502. 
15. Johnston C , et al. (2009) Impact of HIV infection and Kaposi sarcoma on human herpesvirus -
8 mucosal replication and dissemination in Uganda. PLoS One  4(1):e4222. 
16. Campbell TB , et al. (2000) Relationship of human herpesvirus 8 peripheral blood virus load 
and Kaposi's sarcoma clinical stage. Aids 14(14):2109-2116. 
17. Whitby D , et al. (1995) Detection of Kaposi sarcoma associated herpesvirus in peripheral 
blood of HIV -infected individuals and progression to Kaposi's sarcoma. Lancet  
346(8978):799-802. 
18. Engels EA , et al.  (2003) Detection and quantification of Kaposi's sarcoma -associat ed 
herpesvirus to predict AIDS- associated Kaposi's sarcoma. AIDS  17(12):1847-1851. 
 
AMC 098 (Version 4 .0) 08DEC2020 58 
NCI Version Date 08DEC2020  19. Neyts J & De Clercq E (1997) Antiviral drug susceptibility of human herpesvirus 8. 
Antimicrob Agents Chemother  41(12):2754-2756. 
20. Medveczky MM, Horvath E, Lund T, & Medveczky PG (1997) In vitro  antiviral drug 
sensitivity of the Kaposi's sarcoma-associated herpesvirus. Aids  11(11):1327-1332. 
21. Kedes DH & Ganem D (1997) Sensitivity of Kaposi's sarcoma -associated herpesvirus 
replication to antiviral drugs. Implications for potential therapy. J Clin Invest  99(9):2082-
2086. 
22. Friedrichs C, Neyts J, Gaspar G, De Clercq E, & Wutzler  P (2004) Evaluation of antiviral 
activity against human herpesvirus 8 (HHV -8) and Epstein- Barr virus (EBV) by a 
quantitative real -time PCR assay. Antiviral Res 62(3):121-123. 
23. Zhu W , et al. (2005) Potent antiviral activity of north -methanocarbathymidin e against 
Kaposi's sarcoma- associated herpesvirus. Antimicrob Agents Chemother  49(12):4965-
4973. 
24. Casper C , et al. (2008) Valganciclovir for suppression of human herpesvirus -8 replication: a 
randomized, double -blind, placebo- controlled, crossover trial. J Infect Dis  198(1):23- 30. 
25. Martin DF , et al. (1999) Oral ganciclovir for patients with cytomegalovirus retinitis treated 
with a ganciclovir implant. [COMPANY_002] Ganciclovir Study Group. N Engl J Med 340(14):1063-
1070. 
26. Jones JL, Hanson DL, Chu SY, Ward J W, & Jaffe HW (1995) AIDS -associated Kaposi's 
sarcoma. Science 267(5201):1078-1079. 
27. Mocroft A , et al.  (1996) Anti -herpesvirus treatment and risk of Kaposi's sarcoma in HIV 
infection. Royal Free/Chelsea and Westminster Hospi[INVESTIGATOR_634971]. AID S 
10(10):1101-1105. 
28. Glesby [INVESTIGATOR_370684], et al. (1996) Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from 
the Multicenter AIDS Cohort Study. J Infect Dis  173(6):1477-1480. 
29. Spector SA , et al. (1996) Oral ganciclovir for the prevention of cytomegalovirus disease in 
persons with AIDS. [COMPANY_002] Cooperative Oral Ganciclovir Study Group. N Engl J Med 
334(23):1491-1497. 
30. Fife K , et al.  (1999) Cidofovir for the treatment of Kaposi's sarcoma in an HIV -negative 
homosexual man. Br J Dermatol  141(6):1148-1149. 
31. Mazzi R , et al. (2001) Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's 
sarcoma progression in two patients with AIDS. Aids  15(15):2061-2062. 
32. Morfeldt L & Torssander J (1994) Long- term remission of Kaposi's sarcoma followin g 
foscarnet treatment in HIV -infected patients. Scand J Infect Dis  26(6):749-752. 
33. Robles R, Lugo D, Gee L, & Jacobson MA (1999) Effect of antiviral drugs used to treat 
cytomegalovirus end -organ disease on subsequent course of previously diagnosed 
Kapos i's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol  
20(1):34-38. 
34. El Amari EB , et al. (2008) Predicting the evolution of Kaposi sarcoma, in the highly active 
antiretroviral therapy era. AIDS  22(9):1019-1028. 
35. Little RF , et al. (2003) A pi[INVESTIGATOR_634972]. J Infect 
Dis 187(1):149-153. 
36. Gills JJ, Lopi[INVESTIGATOR_2399] J, & Dennis PA (2008) Nelfinavir, a new anti -cancer drug with pleiotropic 
effects and many paths to autophagy. Autophagy  4(1):107-109. 
 
AMC 098 (Version 4 .0) 08DEC2020 59 
NCI Version Date 08DEC2020  37. Gills JJ , et al. (2007) Nelfinavir, A lead HIV protease inhibitor, is a broad -spectrum, 
anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in 
vitro  and in vivo . Clin Cancer Res 13(17):5183-5194. 
38. Bernstein WB & D ennis PA (2008) Repositioning HIV protease inhibitors as cancer 
therapeutics. Curr Opin HIV AIDS  3(6):666-675. 
39. Rengan R , et al. (2012) A phase I trial of the HIV protease inhibitor nelfinavir with 
concurrent chemoradiotherapy for unresectable stage III A/IIIB non -small cell lung 
cancer: a report of toxicities and clinical response. J Thorac Oncol  7(4):709-715. 
40. Blumenthal GM , et al. (2014) A phase I trial of the HIV protease inhibitor nelfinavir in adults 
with solid tumors. Oncotarget  5(18):8161-8172. 
41. Rufo PA , et al. (2004) Diarrhea -associated HIV -1 APIs potentiate muscarinic activation of 
Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. Am J Physiol 
Cell Physiol  286(5):C998-C1008. 
42. Pujades-Rodriguez M, O'Brien D, Humblet P, & Calmy A (2008) Second- line antiretroviral 
therapy in resource -limited settings: the experience of Medecins Sans Frontieres. AIDS  
22(11):1305-1312. 
43. Sanne I, Pi[INVESTIGATOR_634973] P, Squires K, Thiry A, & Schnittman S (2003) Results of a phase 2 clinical 
trial a t 48 weeks (AI424 -007): a dose -ranging, safety, and efficacy comparative trial of 
atazanavir at three doses in combination with didanosine and stavudine in antiretroviral -
naive subjects. J Acquir Immune Defic Syndr  32(1):18-29. 
44. Idoko JA , et al. (2002) A multicentre study to determine the efficacy and tolerability of a 
combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. West Afr J Med  21(2):83-86. 
45. Kilewo C, et al.  (2009) Prevent ion of mother -to-child transmission of HIV -1 through 
breastfeeding by [CONTACT_635029], 
Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr  52(3):406-416. 
46. Pan J , et al.  (2012) Phase I study of  nelfinavir in liposarcoma. Cancer Chemother Pharmacol . 
47. Gantt S, Casper C, &  Ambinder RF (2013) Insights into the Broad Cellular Effects of 
Nelfinavir and the HIV Protease  Inhibitors Supporting their Role in Cancer Treatment 
and Prevention. Curr Opin Oncol  25(5). 
48. Bono C , et al.  (2012) The human immunodeficiency virus -1 protease inhibitor nelfinavir 
impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in 
vitro  and in vivo . Haematologica 97(7):1101-1109. 
49. Chow WA, Jiang C, & Guan M (2009) Anti -HIV drugs for cancer therapeutics: back to the 
futur e? Lancet Oncol  10(1):61-71. 
50. Pore N , et al. (2006) Nelfinavir down- regulates hypoxia -inducible factor 1alpha and VEGF 
expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res  
66(18):9252-9259. 
51. Lan X , et al. (2012) The effect of HIV protease inhibitors on amyloid- beta peptide 
degradation and synthesis in human cells and Alzheimer's disease animal model. J 
Neuroimmune Pharmacol  7(2):412-423. 
52. Chow WA, Guo S, & Valdes-Albini F (2006) Nelfinavir induces liposarcoma apoptosis and 
cell cycle arrest by [CONTACT_635030] l regulatory element binding protein-1. Anticancer 
Drugs  17(8):891-903. 
 
AMC 098 (Version 4 .0) 08DEC2020 60 
NCI Version Date 08DEC2020  53. Guan M , et al. (2011) Nelfinavir induces liposarcoma apoptosis through inhibition of 
regulated intramembrane proteolysis of SREBP -1 and ATF6. Clin Cancer Res  
17(7):1796-1806. 
54. K alu NN, et al. (2014) Nelfinavir inhibits maturation and export of herpes simplex virus 1. 
J Virol  88(10):5455-5461. 
55. Gantt S , et al. (2011) The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma -
associated herpesvirus replication in vitro . Antimicrob Agents Chemother  55(6):2696-
2703. 
56. Gantt S , et al.  (2014) Reduced human herpesvirus -8 oropharyngeal shedding associated with 
protease inhibitor- based antiretroviral therapy. J Clin Virol 60(2):127-132. 
57. Gantt S , et al. (2015) Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope 
proteins and blocks virus maturation. Adv Virol  2015:687162. 
58. Mosam A , et al. (2012) A randomized controlled trial of highly active antiretroviral therapy 
versus highly active antiretroviral therapy an d chemotherapy in therapy -naive patients 
with HIV -associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr  
60(2):150-157. 
59. Gbabe OF, Okwundu CI, Dedicoat M, & Freeman EE (2014) Treatment of severe or 
progressive Kaposi's sarcoma in HIV -infected adults. Cochrane Database Syst Rev  
9:CD003256. 
60. Cianfrocca M, et al. (2010) Randomized Trial of Paclitaxel Versus Pegylated Liposomal 
Doxorubicin for Advanced Human Immunodeficiency Virus -Associated Kaposi 
Sarcoma Evidence of Symptom Palliation from Chemotherapy. Cancer  116(16):3969-
3977. 
61. Uldrick TS , et al. (2013) Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma. 
Journal of Clinical Oncology  31(15). 
62. Uldrick TS , et al.  (2012) Phase II Study of Bevacizumab in Patients With HIV -Associated 
Kaposi's Sarcoma Receiving Antiretroviral Therapy. Journal of Clinical Oncology  
30(13):1476-1483. 
63. Lechowicz M, et al. (2009) Molecular and Clinical Assessment in the Treatment of AIDS 
Kaposi Sarcoma with Valproic Acid. Clinical Infectious D iseases 49(12):1946-1949. 
64. Rudek MA , et al.  (2014) A phase 1/pharmacokinetic study of sunitinib in combination with 
highly active antiretroviral therapy in human immunodeficiency virus -positive patients 
with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer  120(8):1194-1202. 
65. Casado JL , et al. (2001) Efficacy, tolerance, and pharmacokinetics of the combination of 
stavudine, nevirapi[INVESTIGATOR_050], nelfinavir, and saquinavir as salvage regimen after ritonavir or 
indinavir failure. AIDS Res Hum Retroviruses 17(2):93-98. 
66. Moyle GJ , et al. (1998) Safety, pharmacokinetics, and antiretroviral activity of the potent, 
specific human immunodeficiency virus protease inhibitor nelfinavir: Results of a phase I/II trial and extended follow -up in patients infected with human immunodeficiency 
virus. J Clin Pharmacol  38(8):736-743. 
67. Anonymous (1997) Anti- HIV effects of nelfinavir reported after ten months of combination 
therapy. AIDS Patient Care STDS 11(4):289-290. 
 
 
AMC 098 (Version 4 .0) 08DEC2020 61 
NCI Version Date 08DEC2020  APPENDIX I: SCHEDULE OF PROCEDURES  
The schedule of evaluations below applies to all participants on study. Baseline evaluations (including scans and x- rays) are to be 
conducted within 4 weeks prior to study enrollment into Segment B (Treatment Enrollment), unless specified below. 
Assessment  Type  Study 
Stage  Baseline/  
Screening  Treatment 
Start  SD-NFV1 HD-NFV1 Early Discontinuation 
and Follow -Up 
Study 
Visit  Up to 4 Weeks 
Before NFV 
Unless Noted  Treatment 
Day 0 Every 2 Weeks 
Through Week 8 
Unless Noted  Every  2 Weeks 
Through Week 24 
Unless Noted  Within  7 Days After 
Stoppi[INVESTIGATOR_634974].  
+8 Weeks (± 3 days) After 
Stoppi[INVESTIGATOR_634975] -Up 
Informed Consent  (2 to 4 weeks before NFV)  X     
Optional ACSR Donation  X     
Demographics, Height, Diagnostic KS 
Biopsy2, ECOG/KPS score   X     
Medical History  (including documentation 
of HIV diagnosis if positive) , Concurrent 
meds, Physical Exam, Vital Signs, Weight   X  X X X 
Confirmatory HIV Test if Previously HIV -
negative   X     
Chest X -Ray  X  X7 X7 X7 
CBC w/ Differential  
Safety Labs /Chemistries : calcium, sodium, 
potassium, CO2, chloride, AST 
(SGOT)/ALT(, SGPT), BUN, creatinine, 
direct and total bilirubin, fasting glucose, 
and triglycerides.   X   X (every 4 wks.) X 
Fasting Glucose and Triglycerides   X   X (every 8 wks.) X 
 
AMC 098 (Version 4 .0) 08DEC2020 62 
NCI Version Date 08DEC2020  Assessment  Type  Study 
Stage  Baseline/  
Screening  Treatment 
Start  SD-NFV1 HD-NFV1 Early Discontinuation 
and Follow -Up 
Study 
Visit  Up to 4 Weeks 
Before NFV 
Unless Noted  Treatment 
Day 0 Every 2 Weeks 
Through Week 8 
Unless Noted  Every  2 Weeks 
Through Week 24 
Unless Noted  Within  7 Days After 
Stoppi[INVESTIGATOR_634974].  
+8 Weeks (± 3 days) After 
Stoppi[INVESTIGATOR_634975] -Up 
Adherence Review  Nutrition Assess. KS 
Sign/Symp. Assessment   X  X X X3 
KS Staging   X     
Standardized Assessment of Tumor  
Response  with Photograph s   X8 X X X 
If HIV -positive : CD4 Count, and %   X    X 
If HIV -positive : HIV Plasma Viral Load   X  X (every 8 wks.) X (every 8 wks.) X 
beta-HCG if of Childbearing Potential   X X5  X5  
EKG   X  X6 X6  
Provide and Review Drug Diary, Provide 
Study Drug, and Nutritional Counseling    X X4 X4  
Provide Participant I nstructions for Oral 
swabs   X   X4 (once after 
starting HD -NFV)   
1. Study weeks and timing of standard dose nelfinavir ( SD-NFV ) and high dose nelfinavir ( HD-NFV) may vary based on response; see Section  4.1. Scheduled 
study visits will be every 2 weeks  +/- 3 days. Sufficient drug to provide continuous dosing between cycles/study visits should be provided as long as visits lie 
within the visit window.  
2. Can be the same biopsy collected for immunohistochemistry correlative studies.  May be performed any time  prior to  study enrollment.  
3. Medication adherence review and nutrition assessment not required at Early Discontinuation or Follow -up visit.  
4. Providing drug diary, study drug , participant instructions for oral swabs,  and nutritional counseling not required if pa rticipant is discontinued.  
5. Pregnancy testing for females of childbearing potential immediately prior to starting SD -NFV (day 0) and again immediately prior to starting HD -NFV. 
6. EKG only required once 2 weeks after starting SD -NVF and once 2 weeks afte r starting HD -NFV. 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848385] X -Ray should be performed to evaluate tumor response only for participants with pulmonary KS or new pulmonary symptoms.  
8. Tumor assessment with photographs may be performed on Day 0, but no earlier than 7 days before initiating study treatment.  
 
AMC 098 (Version 4 .0) 08DEC2020 64 
NCI Version Date 08DEC2020  APPENDIX II: BIOMARKERS AND CORRELATIVE STUDIES  
Sample  Collected in  Baseline/Screening  
Weeks  
-4 to 0  Treatment start/  
Day 0 SD-NFV1 HD-NFV1 Special Handling  Where to 
Send  
3mm skin biopsies for 
immunohistochemistry 
expression of LANA 
and 3 lytic gene 
products; KSHV gene 
expression arrays  1 biopsy in 
formalin (for 
IHC); 1 biopsy in 
RNAlater  (for 
gene expression)  Weeks -4 to 0, once  -- 2 weeks after 
starting SD -NFV 2 weeks after starting 
HD-NFV  See 
Appendix X  See 
Appendix X  
Whole blood for 
separation into plasma and PBMCs for KSHV 
and EBV qPCR  One 8.5 ml ACD 
(yellow top) tube  2 total blood 
samples during 
weeks  
-4 to 0  -- -- Each visit  
(every 2 weeks) after 
starting HD -NFV 
(8 samples total)  See 
Appendix X  See 
Appendix X  
Oral swabs for KSHV, 
EBV, CMV, and HSV  Study -specific 
swabs/tubes 14 total daily 
swabs, collected 
during weeks -4 to 
0 -- -- 2 swabs per week 
while on HD-NFV 
for a total of 14 
swabs  Stored at room 
temperature. Ship in 
batches bi -weekly 
(Sun-Wed); See 
Appendix X  
Genotypi[INVESTIGATOR_634976]  -- -- -- See 
Appendix X  See 
Appendix X  
Peripheral blood for 
PK ~6 ml of whole 
blood processed as 
plasma (one 6 ml 
potassium EDTA 
lavender top tube) -- Immediately  (- 3 days)  pre-dose at each visit (every 2 weeks) 
starting on Week 1/cycle 1 through the completion of Week 
15/cycle 9  (9 total samples)  Stored on ice, 
plasma separated 
within 30 minutes 
and frozen at ~ -70. 
Ship in batches 
(Mon -Wed)  See 
Appendix 
IX 
1. Study weeks and timing of SD-NFV and HD-NFV may vary based on response; see Section 4.1 . Scheduled study visits will be every 2 weeks.  
  
 
AMC 098 (Version 4 .0) 08DEC2020 65 
NCI Version Date 08DEC2020  APPENDIX III: PERFORMANCE STATUS SCALES  
Karnofsky Performance Scale  ECOG Performance Status Scale  
Percent  Description  Grade  Description  
100 Normal, no complaints, no 
evidence of disease.  0 Normal activity. Fully active, able 
to carry on all pre- disease 
performance without restriction.  
90 Able to carry on normal activity; 
minor signs or symptoms of 
disease.  
80 Normal activity with effort; some 
signs or symptoms of disease.  1 Symptoms, but ambulatory. 
Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work).
 [ADDRESS_848386] of his/her 
needs.  2 In bed < 50% of the time. 
Ambulatory and capable of all self -
care, but unable to carry out any work activities. Up and about more than 50% of waking hours.
 50 Requires considerable assistance and frequent medical care.
 
40 Disabled, requires special care 
and assistance.  3 In bed > 50% of the time. Capable 
of only limited self-care, confined to bed or chair more than 50% of waking hours.
 30 Severely disabled, hospi[INVESTIGATOR_373]. Death not imminent.  
20 Very sick, hospi[INVESTIGATOR_373]. Death not imminent.  4 100% bedridden. Completely 
disabled. Cannot carry on any self-care. Totally confined to bed or chair.
 10 Moribund, fatal processes 
progressing rapi[INVESTIGATOR_375].  
0 Dead.  5 Dead.  
 
 
AMC 098 (Version 4 .0) 08DEC2020 66 
NCI Version Date 08DEC2020  APPENDIX IV: AIDS AND CANCER SPECIMEN RESOURCE (ACSR) SPECIMEN 
PREPARATION AND SHIPPI[INVESTIGATOR_86883]  
A. GENERAL  
To ship blood specimens, use a diagnostic shipper approved for a volume of at least [ADDRESS_848387] shipper is recommended. These 
shippers may be ordered at the SAF -T-PAK website: www.saftpak.com. The following 
instructions below are for use with the recommended STP -210 shipper. If using another 
federally approved diagnostic shipper, please follow instructions provided for that specific shipper. 
NOTE:  Specimens MUST BE SHIPPED Monda ys through Thursdays  an OVERNIGHT 
PRIORITY shipment. Specimens are NOT ACCEPTED ON SATURDAYS  OR 
SUNDAYS  in the ACSR.  
B. SPECIMEN PREPARATION, PACKAGING,
 AND  SHIPMENT  
Blood specimens 
Draw two 8.5 cc (mL) yellow top [acid citrate dextrose (ACD)] tubes from study 
participant. With a black, water resistant, sharpie pen, label each specimen with the 
following information:  
• AMC Protocol # 098 
• AMC Participant ID#  
• Date and time of collection  
• Specimen type, i.e., WB=Whole Blood, P=Plasma, S=Serum, or Tissue  
• Specimen purpose: Donation 
Specimen shipment  
• Seal the tops of the two 8.5 cc yellow tops with Parafilm.  
• Place the two sealed tubes into bubble wrap (provided in STP-210 kit). 
• Tape around the bubble wrap so that the roll stays together and the tubes cannot fal l 
out or break. 
• Place absorbent material sheet around the bubble wrapped tubes and slip into a 
biohazard poly- bag and “self -seal.”  
• Place poly -bag containing tubes into the white TYVEK bag and seal. 
• Place the TYVEK bag into the STP -[ADDRESS_848388] shipper with clear packing/shippi[INVESTIGATOR_45295]. 
• Affix the FED -EX air bill on blank side of the shipper making sure that it is marked 
“FED -EX PRIORITY OVERNIGHT.”  
• Mark “OTHER” in the air bill under “Packaging.” Please use the FedEx #  available on 
the AMC member’s only website. 
 
AMC 098 (Version 4 .0) 08DEC2020 67 
NCI Version Date 08DEC2020  • Under air bill  section “Special Handling” indicate “YES -SHIPPERS DECLARATION 
NOT REQUIRED.”  
• Place “From/To” information onto areas provided on the shipper. 
Blood specimens should be shipped by [CONTACT_86973]:  
Sylvia Silver , DA 
AMC Biorepository  
George Washington Medical Center  
Ross Hall, Room [ADDRESS_848389], NW Washington, DC [ZIP_CODE] 
Phone: [PHONE_13223] 
Fax: 202- 994-5056 
Email: [EMAIL_12110]  
• Make certain that shipper is already either pre- labeled with ‘UN#3373’ stamp or  make 
a paper label with ‘UN#3373” and affix it to the shipper. 
• Make certain that the net volume of the specimen being shipped is written in the space provided on the shipper or  make a separate label with the volume in ml and affix to the 
shipper. 
• Affix air bill to shipper so that the ‘UN’ and ‘VOLUME’ labels are visible.  
• RETAIN THE TOP COPY OF THE AIRWAY BILL FOR YOUR RECORDS.  
• Place the box in the FedEx pi[INVESTIGATOR_86899] a package pi[INVESTIGATOR_9107]. 
Please Note: The shippers will be mailed back to each AMC site.  
INSTRUCTIONS
 FOR  BLOOD  SPECIMENS  COLLECTED  ON  FRIDAY  OR  
SATURDAY 
Preparation of plasma and mononuclear cells  
Refer to the ACSR’s Standard Operating Procedure ( SOP) on Separation of Plasma and 
Mononuclear Cells on the AMC Operations web site for instructions on preparing plasma and PBMC aliquots. It is preferable that separation occurs as soon as possible. If necessary, whole blood in ACD (yellow top tubes) can be held at room temperature for no more than 24 hours. 
Freeze the cell suspension in 0.5 mL aliquots in sterile NUNC vials by [CONTACT_407077] a room temperature, alcohol saturated, control rate freezer container and store in the - 80°C freezer overnight. Transfer the cell suspension into the liquid nitrogen 
temperature freezer for long -term storage the next working day. 
***PLEASE DOUBLE CHECK PACKAGING OF SHIPPER AND DO NOT DEVIATE FROM REQUESTED LABELING. Shippi[INVESTIGATOR_634977] 9 label with weight of dry ice written on package. 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848390] and then on dry ice 
immediately. The specimens may stay on dry ice until being transferred to a -80ºC freezer.  
Tissue specimens for donation may be batched for shippi[INVESTIGATOR_407003] - 80ºC freezer. 
*NOTE: Specimens can only be accepted Monday through Friday . Therefore, specimens 
can only be shipped Sunday -Thursday  for delivery the next day. Shippi[INVESTIGATOR_407004] 9 label with weight of dry ice written on package.  
TISSUE specimens should be shipped by [CONTACT_86974]: 
Sylvia Silver , DA 
George Washington Medical Center  
Ross Hall, Room [ADDRESS_848391], NW Washington, DC [ZIP_CODE] Phone: [PHONE_13223] Fax: ([PHONE_2030] 
C. RECORD OF SPECIMENS  
This study will track specimens via GlobalTrace
SM, a component of the AMC Advantage 
eClinical  system. The GlobalTrace shipment manifest must accompany all specimen 
shipments.  
 
AMC 098 (Version 4 .0) 08DEC2020 69 
NCI Version Date 08DEC2020  APPENDIX V: ACSR INFORMED CONSENT  
Study Title for Study 
Participants:  Collecting Blood and Tissue Sample Donations for 
Research for HIV/AIDS -Related Cancers  
Official Study Title:  Biospecimen Collection and Donation to the AIDS  
and Cancer Specimen Resource (ACSR)  
What is the usual approach to donate blood and/or tissue to the ACSR?  
You are being asked to donate blood and/or tissue for future research. You are  being asked to 
donate your blood and/or tissue samples to the ACSR because you have HIV infection and are 
being considered for participation in an AIDS Malignancy Consortium (AMC) clinical trial. The AMC works with the ACSR to collect donated samples from  persons with HIV infection for 
research studies. People who do not take part in an AMC clinical trial can also donate samples to the ACSR.  
What are my other choices if I do not take part in this study?  
It is your choice to donate or not donate your blood and/or tissue samples. You may still take part in the AMC clinical study if you choose not to donate blood or biopsy samples to the ACSR.  
You may also choose to donate: 
• Blood but not tissue, or 
• Tissue but not blood. 
What is the AIDS and Cancer Specimen Re source (ACSR)?  
The ACSR is a biorepository (biobank) that collects human biological specimens (samples) from 
persons who have HIV or cancers related to HIV/AIDS. The ACSR stores the samples and some of the donor’s medical information for use by [CONTACT_635031]. The National 
Cancer Institute (NCI) has set up the ACSR to assist researchers locate samples needed for their studies.  
The ACSR has an independent research panel that approves researchers’ requests to use the ACSR’s stored samp les for research studies. The ACSR only gives samples and medical 
information to researchers after their projects have been approved. Researchers may use the samples to study cancers and other diseases associated with HIV disease. This information may help us learn more about the causes of HIV -related diseases and cancers and to develop better 
ways to screen, diagnose, and treat them. 
Why is this study being done?  
The purpose of this study is to collect samples for the ACSR for future research studies. 
Researchers may study samples from the ACSR in combination with hundreds or thousands of other samples to explore how biologic or genetic factors may be related to HIV -related diseases 
and cancer. The information might help doctors in the future to identify who will or will not benefit from treatment. The samples may be used to learn more about how HIV -related diseases and 
cancers develop. The samples may also lead to new tests or discoveries. Finally, researchers may use the samples to study the genetic materi al from your cancer tissue and compare it to the material 
from your normal tissue (blood) to try to find the differences that exist. These studies could make it possible to identify many of the changes that are associated with diseases such as cancers. It may 
 
AMC 098 (Version 4 .0) 08DEC2020 70 
NCI Version Date 08DEC2020  also help us tailor treatments to a patient's unique genetic make -up and/or to the genetic markers 
of the tumors. 
What extra tests and procedures will I have if I take part in this study?  
1) If you agree to donate blood, the medical team will draw about 2 tablespoons of blood to give 
to the ACSR. This takes about 10 minutes. 
2) If you agree to donate tissue, your leftover tissue biopsy material will be donated to and stored by [CONTACT_635032].  
3) Some of your clinical information will be released to the AC SR and entered into their database. 
The information given to the ACSR will not include your name [CONTACT_635056]. 
We will only give the ACSR tissue that is left over after making decisions about your treatment or diagnosis. The study doctor will not take any extra biopsies just for the ACSR. 
We cannot tell you right now what future research these samples would be used for. Instead, we 
are asking that you give approval to give your samples for future testing without contact[CONTACT_635033]. The results of whatever research is done on your samples will not  be told to you or your 
doctor. The results of the tests will not  be placed in your study records. 
How long will ACSR keep my samples?  
Your blood and/or tissue sample will b e stored until it is used for research. The samples may be 
stored indefinitely.  
What possible risks can I expect from taking part in this study?  
• Blood Draw : The risks of drawing blood include temporary discomfort from the needle stick, 
bruising, and, rarel y, infection. 
• Confidentiality : The ACSR will receive study samples with code numbers. There will be no 
personal identifiers on the samples. Then the samples will be re- labeled with a barcode and 
stored for future testing. While the ACSR and researchers who  study ACSR samples will have 
no information that could identify you, there is a risk that someone could use information from genetic studies to trace your samples back to you. The researchers believe the chance that someone will identify you is very small, but the risk may change in the future as people come up with new ways of tracing information. In some cases, this information could be used to make it harder for you to get or keep a job. There are laws against misuse of genetic information, but they may not give full protection. The researchers believe the chance these 
things will happen is very small but cannot promise that they will not occur.  
Let your study doctor know of any questions you have about these possible risks. You can ask the study doctor questions about side effects at any time.  
What possible benefits can I expect from taking part in this study?  
This study is unlikely to help you. This study may help us learn things that may help people in the future.  
The information may help to identify those who are at increased risk and those who may benefit from targeted treatment and screening. In turn, these studies could help find ways to prevent or improve treatments for HIV -related diseases and AIDS -related cancers.  
 
AMC 098 (Version 4 .0) 08DEC2020 71 
NCI Version Date 08DEC2020  Can I stop taking part  in this study?  
Yes, you may withdraw your samples from the ACSR at any time. You may contact [CONTACT_635034]. The coordinator can ask in writing that your sample be removed from research use and that any identifiable sample and information still in their possession be destroyed. However, if any research has already been done using some of your samples, the data will be kept and analyzed as part of those studies. 
What are my rights in this study ? 
Taking part in this study is your choice. No matter what decision you make, and even if your 
decision changes, there will be no penalty to you. You will not lose medical care or any legal 
rights.  
For questions about your rights while in this study, call the ________________________ (insert 
name [CONTACT_29094]) Institutional Review Board at __________________ (insert telephone number). (Note to Local Investigator: Contact [CONTACT_539052] a local institution who are not on the IRB or research team but take calls regarding clinical trial questions can also be listed here.)  
What are the costs of taking part in this study?  
There will be no cost to you for donating your samples to the ACSR. You will not be paid for taking part in this study. 
What happens if I am injured or hurt because I took part in this study?  
If you are injured or hurt as a result of taking part in this study and need medical treatment, please 
tell your study doctor. The AMC will not offer to pay for med ical treatment for injury. Your 
insurance company may not be willing to pay for study -related injury. If you have no insurance, 
you would be responsible for any costs. 
If you feel this injury was a result of medical error, you keep all your legal rights to  seek payment 
for injury even though you are in a study. Who will see my medical information?  
Your privacy is very important to us and the researchers will make every effort to protect it. Your 
information may be given out if required by [CONTACT_2371]. For example, certain states require doctors to report to health boards if they find a disease like tuberculosis. However, the researchers will do their best to make sure that any information that is released will not identify you. Some of your health information, and/o r information about your specimen, from this study will be kept in a 
central database for research. Your name [CONTACT_122541] [CONTACT_305352].  
There are organizations that may inspect your records. These organizations are required to make 
sure your information is kept private, unless required by [CONTACT_139207]. Some of these organizations are:  
• The AIDS Malignancy Consortium (AMC) 
• The Institutional Review Board, IRB, is a group of people who review the research with the goal of protecting the people who take part in the study. 
• The Office for Human Research Protections and the National Cancer Institute in the U.S.  
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848392] HIV and cancer through these kinds of studies.  
Where can I get more information?  
You may visit the NCI Web site at http://cancer.gov/  for more info rmation about studies or 
general information about cancer. You may also call the NCI Cancer Information Service to get the same information at 1 -800-4- CANCER (1 -[PHONE_421]). 
Who can answer my questions about this study?  
You can talk to the study doctor about any questions or concerns you have about this study or to report side effects or injuries. Contact [CONTACT_39635] __________________ (insert name [CONTACT_99992][s])  at __________________ (insert telephone number). 
Please circle your answer to show whether or not you would like to take part in each option: 
1) I agree to donate my blood to the ACSR for future research that may be used to learn about, 
prevent, diagnose, or treat HIV- related diseases and cancer.  
YES  NO 
2) I agree to donate my blood to t he ACSR for future research that may include genetic testing to 
learn about, prevent, diagnose, or treat HIV- related diseases and cancer.  
YES  NO 
3) I agree to donate some of my tissue biopsy material that is not required for my treatment or diagnosis to the ACSR for future research that may be used to learn about, prevent, diagnose, or treat HIV -related diseases and cancer.  
YES  NO 
4) I agree to donate some of my tissue biopsy material to the ACSR for future research that may include genetic testing to learn about, prevent, diagnose, or treat HIV -related diseases and 
cancer.  
YES  NO 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848393] been answered. I will be given a signed copy of this form. I agree to take part in the optional study.  
 Participant’s signature________________________________  Date of signature_____________________________________  Signature [CONTACT_52943](s) conducting the informed consent discussion________________________  Date of signature_____________________________________ 
 
AMC 098 (Version 4 .0) 08DEC2020 74 
NCI Version Date 08DEC2020  APPENDIX VI: AMC DATA AND SAFETY MONITORING PLAN 
(Version 9.0   October 6, 2020) 
 
Introduction 
The AIDS Malignancy Consortium ( AMC) Data and Safety Monitoring Plan (DSMP) outlines the 
measures employed by [CONTACT_635035]. This includes methods to: 1 ) monitor the progress of 
trials and the safety of participants; 2) comply with regulatory requirements for adverse event (AE) 
reporting; 3) processes for trial termination or temporary suspension and major modifications; and 4) plans for ensuring data accuracy and protocol compliance. As the AMC conducts protocols of varying research phase, region of conduct (which may include trials conducted in the U.S., international sites, or both), IND sponsor (AMC investigator, CTEP, or industry- sponsored) and 
clinic al data entry system use, this plan addresses broad processes applying to the range of trial 
designs and requirements. R efer to the individual AMC protocol to identify the applicable study 
characteristics for the relevant requirements described in this plan. 
Monitoring the Progress of Trials and the Safety of Participants Routine and expedited AE reporting All AMC protocols that collect safety data adhere to  the National Cancer Institute (NCI), Cancer 
Therapy Evaluation Program (CTEP) Guidelines: Adverse Event Reporting Requirements 
(https ://ctep.cancer.gov/ protocolDevelopment/ adverse_effects.htm) , as applicable to the clinical 
protocol. AEs are to be recorded in the source documents, assessed by a clinical investigator for 
the AE reporting criteria, and promptly reported in the clinical data entry system as required by [CONTACT_241300]. For AMC trials conducted under a CTEP IND and AMC trials conducted within the U.S., a ll AEs that meet the NCI’s expedited reporting requirements are reported to the NCI via the 
CTEP Adverse Event Reporting System (CTEP -AERS) web application , either directly or through 
integration with Medidata Rave where this system is employed for AMC protocols. Use of this system ensures notification to the protocol chair and Investigational Drug Branch (IDB) at CTEP, as required for trials conducted under a  CTEP IND, and a uniform expedited reporting and safety 
review process for AMC domestic trials. The system may also be programmed to include sponsor notification as required for trials with industry support. Alternate process for expedited AE 
reporting to the AMC protocol chairs and AMC Operations and Data Management Center (ODMC) within the clinical data entry system ( AdvantageEDC or Advantage eClinical only) may 
be defined in the protocol for select trials (international studies and The ANCHOR Study).  
All serious adverse events (SAEs)  received by [CONTACT_241301], safe trial 
conduct, data reporting quality for AE term selection, and appropriate application of the regulatory criteria for se riousness, expectedness, and relatedness to the investigational therapy . If alternate 
procedures are followed for SAE review, the process for adequate medical monitoring will be defined in the  AMC protocol and the Transfer of Regulatory Obligations (TORO) with the sponsor. 
AMC medical monitor review includes review of the CTEP -AERS report before CTEP submission 
for IDB review (if applicable), or review of the SAE report in the data entry system for trials not using CTEP -AERS for expedited reporting. The IND  sponsor or its designee will issue the 
determination as to whether the AE requires IND safety reporting to FDA as a serious and 
 
AMC 098 (Version 4 .0) 08DEC2020 75 
NCI Version Date 08DEC2020  unexpected suspected adverse drug reaction (S[LOCATION_003]R).  For protocols not conducted under an IND , 
in the event of disagreement between the reporting physician and the AMC medical monitor 
regarding the relationship  of the AE  to the investigational agent(s) (i.e., determinatio n of whether 
the attribution  is unrelated  or unlikely, or possible, probable, or definite), the AMC medical 
monitor will provide the final determination of the relationship.  IND safety reporting to FDA is 
performed by [CONTACT_635036] a CTEP IND; IND safety reporting is performed 
by [CONTACT_4209]’s designee (AMC ODMC or other party defined in the study agreement or TORO) for IND studies sponsored by [CONTACT_241303]. 
Expedited reporting to the Institutional Review Board (IRB)  
The requirements for IRB review will be identified in the protocol section on ethical and regulatory 
obligations. All AMC trials initiated before September 1, [ADDRESS_848394]  to local IRB review; only U.S. sites are subject to the NCI requirement 
to use a single IRB for protocols initiated on or after September 1, 2020. For trials subject to local IRB review, the site principal investigator [INVESTIGATOR_634978], per the local IRB’s requirements for such 
reporting. For studies reviewed by [CONTACT_635037], the protocol chair will render a determination 
as to whether a SAE or other problem constitutes a trial -wide unanticipated problem that requires 
reporting to that I RB, in accordance with its standards of procedure.  
To comply with investigator  notification requirements for IND studies under [ADDRESS_848395]- protected section of the AMC Operations web site  (AMC 
trials subject to local IRB review only) or the CTSU website (U.S. trials subject to single IRB review/CTEP IND agents) . The site clinical investigator res ponsible for the applicable AMC 
protocol(s) is responsible for review ing any IND safety reports received and documenting 
submission to the IRB of record (if required by [CONTACT_37403])  within the timeline defined by  [CONTACT_635038] (CTM B) audit guidelines. 
Procedures for monitoring trial progress and pharmacovigilance 
For trials using AdvantageEDC or Advantage eClinical for clinical data entry, t he AMC ODMC 
provides on demand tabular listings of all reported AEs  and SAEs on a participant level  to the 
protocol chair and co- chair(s) for review via the password -protected section of the AMC 
Operations web site, www.AIDScancer.org . For trials using OPEN and Medidata Rave for clinical 
data collection, data listing will be made available using that system . Summary reports of AEs by 
[CONTACT_241305](s) are provided to all AMC investigators  
and their staff  It is the respo nsibility of each site to provide trial -specific AE listings  to their 
respective IRB, if required by [CONTACT_241306] . For blinded studies, the AE and SAE listings  are 
reviewed and tabulated without treatment assignment.  
Accrual summaries for each AMC trial are updated nightly on the password -protected section of 
the AMC web site. The progress o f each AMC trial is reviewed regularly by [CONTACT_760] c hair and 
also by [CONTACT_635039] (SWG) during scheduled conference calls  
(monthly SWG calls and as required, protocol -specific monitoring conference calls) . Summary 
accrual, summary AE, and individual SAE reports are provided to SWG leadership and protocol 
chairs to monitor participant safety during these monthly  calls. 
 
AMC 098 (Version 4 .0) 08DEC2020 76 
NCI Version Date 08DEC2020  The AMC medical monitor review s listings of all reported AEs  on a quarterly basis for assuring 
compliance with the protocol requirements for AE reporting and the identification of any safety 
concerns (individual AE or increased frequency/severity of expected AEs) for the agents under 
investigation. Findings from these reviews are communicated to the protocol chairs and all AMC 
investigators, and posted to the AMC O perations web site.  
Data and Safety Monitoring Board(DSMB) review  
The AMC has formed an independent Data and Safety Monitoring Board (DSMB ) for AMC trials 
and for the ANCHOR Study. As required by [CONTACT_241308], the AMC requires DSMB review for all 
phase II I randomized trials . All other clinical trials that the AMC initiates will be reviewed by [CONTACT_635040] a recommendation as to whether the study requir es DSMB  oversight , which will require the approval of the AMC 
Executive Committee. This determination will be based on the phase of the study, experimental design, risk posed by [CONTACT_241310], extent of data available on the safety of an investigational agent, risk posed by [CONTACT_241311], and 
the categories of vulnerable populations involved. The involvement of a DSMB in reviewing an 
AMC protocol will be identified in each clinical protocol as approved by [CONTACT_241312], as applicable , 
required by [CONTACT_60683]. 
Regarding the composition of the AMC DSMB, voting members usually include  physicians, 
statistician s, an ethicist , and a patient advocate. All voting members have no other affiliation to 
the AMC and are appointed by [CONTACT_635041]. Nonvoting members are the AMC group s tatistician, the protocol statistician, an AMC 
ODMC staff member, two representatives (norm ally a clinician or statistician) from CTEP, and 
the grant program directors from the NCI Office of HIV and AIDS Malignancy (OHAM ). 
The DSMB reviews all applicable AMC  studies in accordance with the National Cancer Institute’s 
Policy for Data and Safety Monitoring. Confidential reports of all trials  under review  are prepared 
by [CONTACT_635042] C group s tatistician with support from the AMC ODMC. A written report containing 
the current status of each trial monitored, and when appropriate, any toxicity and outcome data, 
are sent to DSMB members by [CONTACT_241315]. This report addresses specific toxicity issues and any other  concerns about the conduct of 
the trial, as defined by [CONTACT_241316] . The report may contain information 
for the DSMB to render determinations for participant safety, early trial termination , results  
reporting, or continuing accrual or follow -up. 
The results of each DSMB meeting are summarized in a formal repor t sent by [CONTACT_4318] c hair to 
the AMC group c hair and AMC ODMC. The DSMB report contains recommendations on whether 
to close each study reviewed, whether to report the results, and whether to continue accrual or follow -up. A primary recommendation (e.g., continue with no change; recommended or required 
modification; stop) must be included in the document. The group c hair or designee  is then 
responsible for notifying the protocol c hair and relevant SWG  chair before the recommendat ions 
of the DSMB are carried out. In the unlikely event that the protocol c hair does not concur with the 
DSMB, then  the OHAM program directors and the NCI division director or designee must be 
informed of the reason for the disagreement. The protocol c hair, relevant SWG  chair, group chair, 
DSMB chair, and NCI division d irector or designee will be responsible for reaching a mutually 
acceptable decision about the study. CTEP approval of a protocol amendment will be required 
prior to any implementation of a change to the study. 
 
AMC 098 (Version 4 .0) 08DEC2020 77 
NCI Version Date 08DEC2020  Following a DSMB meeting, t he DSMB’s recommendations are provided  to all AMC investigators 
and staff . It is each site principal investigator’s  responsibility for conveying this information to its  
local  IRB as relevant for its protocol participation . For trials reviewed by a single IRB, the AMC 
ODMC will support notification to the IRB as required per its procedures . 
Cohort trial reviews not subject to DSMB review  
For phase I dose escalation trials, dose escalation (or dose de -escalation) is based on the rules in 
the protocol and the protocol c hair, AMC m edical monitor, and protocol s tatistician determine 
whether these criteria have been met  based on a review of all safety data for the protocol -defined 
evaluation period. If applicable f or phase II trials, stoppi[INVESTIGATOR_241198], or 
suspending enrollment pending observation of responses in a multi -stage phase II trial, is based on 
meeting criteria stated in the protocol, and the protocol chair, AMC medical monitor, and protocol 
statistician determine whether these criteria have been met.  
Plans for Assuring Compliance with Requirements Regarding AE Reporting  
The protocol chair, AMC group c hair, and the AMC ODMC share responsibility in assuring that 
participating investigators comply with applicable regulatory and  protocol requirements for AE  
reporting. The AMC site principal investigator [INVESTIGATOR_634979] ; clinical investigators also certify compliance in 
completing  the protocol signature [CONTACT_241335], and Form FDA -1572 
for CTEP investigat or registration , and also for AMC IND studies sponsored by [CONTACT_635043]. Protocol compliance with AE  identification, assessment and  
reporting requirements is assessed by [CONTACT_241318]: 1) programmed 
system checks and messages to instruct the site to complete routine and/or expedited reporting when certain criteria are reported in the clinical data entry system; 2) programmed data reports provided to the protocol chairs that identify reports requiring expedited AE reporting; 3) remote 
review of data entry or data reports to ensure compliance with protocol and NCI AE reporting 
requirements; 4) AMC medical monitor review described in the section above; and, 5)  routine site 
audits by [CONTACT_241319]’s source documentation. 
The clinical data entry system s used for AMC studies  include the Oncology Patient Enrollment 
Network, OPEN for enrollment, and Medidata Rave for clinical data entry for enrolled 
participants; trials activated before September 1, 2020 or that involve only AMC international sites may be reported in  AdvantageEDC/Advantage eClinical , a web -based data entry and enrollment 
system . These data entry systems are programmed to notify the site investigator, protocol chair, 
AMC medical monitor, and AMC ODMC via email in the event that a site reports an AE  that 
meets expedited reporting criteria to NCI and/or FDA.  Additional reporting conditions may be 
programmed depending on the sponsor reporting requirements of a given protocol (e.g., adverse events of speci al interest [AESI]).  If the site does not follow with an expedited report, the AMC 
ODMC contacts sites to request compliance with reporting requirements. Additionally, the protocol chair, AMC ODMC, and the AMC m edical monitor review reported AEs  on a routine 
basis to identify AEs  reported by [CONTACT_241320]. The protocol chair, AMC 
SWG chairs, AMC group c hair, and IND sponsors have general oversight for assuring that routine 
and expedited adverse reporting requirements are met by [CONTACT_241321].  
For studies monitored by [CONTACT_241322][INVESTIGATOR_241200] (DMU), cumulative protocol - and 
patient -specific data will be submitted weekly to CTEP electronically via the DMU. For trials 
 
AMC 098 (Version 4 .0) 08DEC2020 78 
NCI Version Date 08DEC2020  monitored by t he NCI’s Clinical Data Update System (CDUS), AE  information is transmitted 
electronically to NCI on a quarterly basis. For trials monitored by [CONTACT_12134]’s Clinical Trials Monitoring 
Service (CTMS), AE information is transmitted electronically to NCI every two we eks. 
Plans for Assuring that any Action Resulting in a Temporary or Permanent Suspension of an NCI -Funded Clinical Trial is Reported to the NCI Grant Program Director Responsible 
for the Grant  
In the event that temporary or permanent suspension of a trial, or major modification to the 
protocol is under consideration, the protocol c hair will convene the AMC ODMC, AMC Statistical 
Center,  and SWG  chair by [CONTACT_407069]. Suspension actions will also be 
reviewed by [CONTACT_241324]. For phase III trials, closure decisions ar e typi[INVESTIGATOR_634980]; if the trial in question is under AMC DSMB oversight but rendered by [CONTACT_241325], the AMC DSMB will be notified of the suspension and the reason.  For 
phase I and II trials, the p rotocol chair also has the option of asking the DSMB to review the study. 
The AMC ODMC will inform the CTEP Protocol Information Office (PIO ), with copy to OHAM 
Directors,  when studies are temporarily or permanently closed. In the event of major trial 
modification, CTEP must approve all protocol amendments prior to distributing to the AMC sites.  
Plans for Assuring Data Accuracy and Protocol Compliance 
All study data for AMC clinical trials are entered directly by [CONTACT_241326]. During data entry, the system performs validation 
checks on many fields and performs consistency checks between select fields. Range checks are placed on each field to eliminate entry of out-of-range values. Edit check programs are run on the database on a set schedule to identify and resolve inconsistencies between forms or data collected at different points in time. Submitt ed data entry forms are reviewed for compliance with the 
protocol and data entry instructions according to the AMC ODMC’s standards for data quality 
processes. AMC ODMC staff routinely interacts with site staff to resolve any data  submission 
problems. 
In accordance with NCI guidelines, the AMC ODMC conducts audits at the AMC sites to evaluate 
compliance with regulatory issues, and to review data for specific cases by [CONTACT_86994]. These reports are sent to the site principal investigator [INVESTIGATOR_241202]. In the event 
that major violations are identified, sites are asked to provide a written corrective and preventative action plan to correct deficiencies. If needed, a repeat site audit is conducted. In the event that a site does not correct deficiencies in a pre- determined time frame, the AMC Executive Committee 
has the option to implement remedial action (s) for the site. Possible actions include, but are not 
limited to, suspending enrollment of new patients to AMC trials until deficiencies are corrected; recommending a decrease in funding to the site; and requiring specific training for site investigators or staff members.  
 
AMC 098 (Version 4 .0) 08DEC2020 79 
NCI Version Date 08DEC2020  APPENDIX VII: PARTICIPANT DRUG DIARY  
YOU MUST KEEP THIS DIARY AND BRING IT TO EVERY APPOINTMENT  
 
Instructions for part icipants:  
Please record the date and time that your nelfinavir dose was taken. Be sure to record the doses 
when you take them and avoid writing entries for several days at once.  
In the “Comments” section write any problems you are having with the medicines or if you missed 
a dose and why or if you only took part of the medicine. 
When you are finished, bring this diary with you when you next see the Doctor or Study Staff. Your nelfinavir tablets should be taken with a meal, twice daily (once in the morning and once in 
the evening).  Nelfinavir should be taken with a moderately high fat meal, for example that includes oil, butter, 
eggs, or meat.  
If you cannot swallow the tablet whole, you may dissolve the tablet in a small amount of water. 
Drink all of the mixture after the table dissolves. Then refill your glass with water and drink all of the water right away. Do not mix with acidic foods or juice (apple juice, applesauce, or orange juice) because it will make it taste bad. Someone in the clinic will talk to you about the diet requirements.  
Missed nelfinavir doses, regardless of reason, SHOULD be made up if it is within 6 hour s of the 
missed dose. Do not make up the missed dose if within an hour from the next dose. If you vomit, 
do not take more pi[INVESTIGATOR_634981]. 
 
 
AMC 098 (Version 4 .0) 08DEC2020 80 
NCI Version Date 08DEC2020  AMC-098 Drug Diary  Participant ID #: 098- ___ ___ ___ - ___ ___ ___ ___ ___ 
Day  Date  
DD/MMM/YYYY  Time  
Nelfinavir Taken  
(circle AM/PM)  # of 
Tablets  
Taken  Time  
Nelfinavir Taken  
(circle AM/PM)  # of 
Tablets  
Taken  Comments  
Week #: ______ ___ Take ________ tablets twice a day (morning and evening) with a moderately high fat meal.  
1 ___/______/_____ ___:___ AM  PM ________ ___:___ AM  PM ________  
2 ___/______/_____ ___:___ AM  PM ________ ___:___ AM  PM ________  
3 ___/______/_____ ___:___ AM  PM ________ ___:___ AM  PM ________  
4 ___/______/_____ ___:___ AM  PM ________ ___:___ AM  PM ________  
5 ___/______/_____ ___:___ AM  PM ________ ___:___ AM  PM ________  
6 ___/______/_____ ___:___ AM  PM ________ ___:___ AM  PM ________  
7 ___/______/_____ ___:___ AM  PM ________ ___:___ AM  PM ________  
Week #: ____ ____  Take ________ tablets twice a day (morning and evening) with a moderately high fat meal.  
1 ___/______/_____ ___:___ AM  PM _______ ___:___ AM  PM _______ _  
2 ___/______/_____ ___:___ AM  PM _______ ___:___ AM  PM ________  
3 ___/______/_____ ___:___ AM  PM _______ ___:___ AM  PM ________  
4 ___/______/_____ ___:___ AM  PM _______ ___:___ AM  PM ________  
5 ___/______/_____ ___:___ AM  PM _______ ___:___ AM  PM ________  
6 ___/______/_____ ___:___ AM  PM _______ ___:___ AM  PM ________  
7 ___/______/_____ ___:___ AM  PM _______ ___:___ AM  PM ________  
8 ___/______/_____ ___:___ AM  PM _______ ___:___ AM  PM ________  
9 ___/______/_____ ___:___ AM  PM _______ ___:___ AM  PM ________  
10 ___/______/_____ ___:___ AM  PM _______ ___:___ AM  PM ________  
Please return the unused tablet s to your doctor with your diary at your next appointment. 
FOR STUDY TEAM USE ONLY  
 
AMC 098 (Version 4 .0) 08DEC2020 81 
NCI Version Date 08DEC2020  AMC-098 Drug Diary    Participant ID #: 098- ___ ___ ___ - ___ ___ ___ ___ ___ 
 
Number of tablets dispensed   
Date returned   
Number of tablets returned   
Number of days in this cycle (14 days +/ - 3 days)   
Number of tablets that should have been taken   
Number of tablets reported taken   
Discrepancy Notes:  
  
 
    
 
Staff S ignature: ____________________________________  Date: _____________ (DDMMMYYYY)  
NOTE: Non -compliance with study agent administration and/or diary completion should be noted at the 
time of diary collection and the participant should be instructed again regarding dosing instructions.  
 
AMC 098 (Version 4 .0) 08DEC2020 82 
NCI Version Date 08DEC2020  APPENDIX VIII: CENTRAL PATHOLOGY REVIEW  
Requ ired Tissues  
Participants must have measurable cutaneous Kaposi sarcoma (KS) that has been pathologically 
confirmed by [CONTACT_635044]. Participants must have one of the following for the purposes 
of central  pathology review: 
• Diagnostic tissue block or H&E plus five blank FFPE s ections for LANA staining , or 
• High quality images of the LANA staining for electronic submission for pathology review and 
H&E is available on site  
Handling of Tissues  
Domestic tissues should be submitted to the following address: 
Sylvia Silver , DA 
George Washington University Medical Center 
Ross Hall, Room [ADDRESS_848396], NW Washington, DC [ZIP_CODE] Phone: [PHONE_13223] Fax: 202- 994-5056 
International tissues should be submitted to the following address: 
Johann Schneider, MMed Anat Path Division of Anatomical Pathology  
National Health Laboratory Service  
[ADDRESS_848397], Room 52 
Tygerberg Hospi[INVESTIGATOR_634946] 7535 South Africa Phone: 27- 21-938-4041 
Fax: 27-21-938-6559 Email: [EMAIL_12114]  
Record of Specimens: This study will track specimens via GlobalTrace
SM, a component of the 
AMC Advantage eClinical  system. The GlobalTraceSM shipment manifest must accompany all 
specimen shipments.  
Pathology Review  
Ethel Cesarman, MD  
Weill Medical College of Cornell University  
Department of Pathology 
 
AMC 098 (Version 4 .0) 08DEC2020 83 
NCI Version Date 08DEC2020  APPENDIX IX: SPECIMEN PREPARATION AND SHIPPI[INVESTIGATOR_634982] (- 3 day window) at week 1/cycle 1  through completion of w eek 15/cycle 9. A 
maximum of nine (9) specimens will be collected. .A window of - 3 days is allowed. The actual 
sample collection times should be recorded on a pharmacokinetic worksheet that also documents 
the time of nelfinavir administration (previous and current dose; along with the use of a participant dosing diary (See Appendix VII
). 
In addition, when feasible, samples will be requested from the participant at the time of disease progression and in the event of DLT or other persistent and severe toxicity. For these optional samples, a blood sample should be drawn as close as possible to the time of the event with documentation of the last nelf inavir dose administered.  
Collection, Processing and Storage (only 1 tube is necessary for the PK assessment for nelfinavir)  
1) Each sample will comprise ~ 6 mL of venous blood drawn into a 6- mL lavender top tube  with 
K
2-EDTA as the anticoagulant. Immediately after collection, the tube should be gently inverted 
8 to 10 times to mix the anticoagulant with the blood sample. The tube should be stored upright on ice until centrifugation; centrifugation and sample processing should be performed within 30 minutes of sample collection.  
2) The plasma fraction should be separated by [CONTACT_385078] a refrigerated centrifuge (4 to 8°C) in a horizontal rotor (with a swing -out head) for a minimum of 10 minutes 
at 1500 to 1800 rela tive centrifugal force (RCF).  
3) The plasma fraction will be withdrawn by [CONTACT_21173][INVESTIGATOR_634983] 3 polypropylene freezing tubes (with each tube receiving approximately equal aliquots and at least 0.5 mL volume). 
4) All sample collection and freezing tubes will be clearly labeled in a fashion that identifies the 
participant, the study period, and the collection date and time. Labels will be fixed to freezing 
tubes in a manner that will prevent the label from becoming detached after freezing.  
5) After processing, samples should be placed into a freezer at approximately –70°C.  
With a black, water resistant, fine- tipped sharpie pen, label each specimen label with the following 
information:  
• Protocol #: AMC -098 
• 11-digit Participant ID #  
• Specimen type: “Plasma”  
• Specimen purpose: “Pharmacokinetic Analysis” (for the 3 aliquots) 
• Date/Time collected:  
*The nominal time point of the blood draw should be written on the specimen label (e.g., day, and pre-dose, 1 hour, 2 hours , etc.) In GlobalTrace
SM, enter the time c ollected and be sure to indicate 
the nominal time point in the comments section when adding specimens.  
 
AMC 098 (Version 4 .0) 08DEC2020 84 
NCI Version Date 08DEC2020  If there were samples not  obtained at the required time points, please inform the Analytical 
Pharmacology Core (APC) Laboratory prior to shippi[INVESTIGATOR_007].  
Shipment  
Samples will be kept at the study site and shipped periodically during the study to the APC 
Laboratory. Unless otherwise stated, samples will be shipped to the APC Laboratory under the direction of Michelle A. Rudek, Pharm.D., Ph.D.  
Specimens should be stored through the duration of the PK study (through Week 15) and shipped as a batch by [CONTACT_3445] (more than one participant/shipment is acceptable if the site has > 1 participant on -study).  
A participant's samples should be shipped to the APC lab within  [ADDRESS_848398] sample's 
collection date. (i.e., if the Week 15 sample is collected on 1/1/2016, all of that participant's samples should be at the APC lab by 2/1/2016). If a second set of participant samples can be batched by [CONTACT_209617] 2 weeks (i.e., 1.5 months).  
Please ship [ADDRESS_848399]/back -up 
aliquot may be shipped (after 2 successful shipments, all 3 aliquots can be shipped at once).  
Overnight shipments should occur on Monday through Wednesday  (Tuesday  is the preferred day) 
except when the following day is a holiday. A fax or call should be place to the Analytical Pharmacology Core Laboratory prior to shipment providing the shipment tracking information.  
Samples should be shipped on dry ice to : 
Analytical Pharmacology Core Laboratory*  
Attn: AMC Nelfinavir Study Samples  
[ADDRESS_848400]. CRB1 Rm 184  
Baltimore, MD [ZIP_CODE]- 1000  
Phone: 410- 502-7192 or 410- 955-1129  
Fax: 410- 502-0895  
Email: [EMAIL_12117] 
Record of Specimens  
This study will track specimens via GlobalTrace
SM, a component of the AMC Advantage  eClinical  
system. The GlobalTraceSM shipment manifest must accompany all specimen shipments.  
 
AMC 098 (Version 4 .0) 08DEC2020 85 
NCI Version Date 08DEC2020  APPENDIX X: AMC BIOREPOSITORY SPECIMEN PREPARATION AND SHIPPI[INVESTIGATOR_634984]: Required study specimens are included in Appendix II . All specimens will be banked at 
the domestic or international AMC biorepository, which will serve as a tissue source site for 
processing samples for all AMC sites, for testing at AMC core labs and outside labs. Test will be conducted at the end of enrollment for each phase or within one year of acquisition of sample. 
Assays procedures are described in the AMC manual of operation(s) and available from the network core laboratories. Assays details may change as technology progresses.  
Assays as proposed in exploratory objectives ( Section 2.4
): 
• Plasma for h erpesvirus (KSHV) and EBV viral load (AMC Virology Core) 
• PBMC for herpesvirus (KSHV) latent virus (AMC Virology Core)  
• PBMC for drug metabolism profile (Genotypi[INVESTIGATOR_007]) (AMC Genomics Core) 
• Tissue (skin of KS) biopsies: RNA later  for gene expression profiling (AMC Genomics Core) 
• Tissue (skin of KS) biopsies: formalin for IHC (AMC Pathology Core)  
• Saliva swabs for multiple herpesvirus (KSHV, HSV, EBV, HCMV) (AMC Genomics Core)  
• Nelfinavir PK (AMC Pharmacology Core) (See Appendix IX ) 
GENERAL  
A. To ship blood specimens, use a diagnostic shipper approved for a volume of at least [ADDRESS_848401] shipper is recommended. These 
shippers may be ordered at the SAF -T-PAK website: www.saftpak.com. The following 
instructions below are for use with the recommended STP -210 shipper. If using another 
federally approved diagnostic shipper, please follow instructions provided for that specific shipper. 
NOTE:  Specimens MUST BE SHIPPED Sunday  through Thursday  as an OVERNIGHT 
PRIORITY shipment. Specimens are NOT ACCEPTED ON SATURDAYS  OR 
SUN DAYS  in the AMC biorepository. 
B. INSTRUCTIONS FOR PERIPHERAL BLOOD SPECIMENS FOR PLASMA AND 
PBMCS (FOR RESEARCH) COLLECTED ON SUNDAY – THURSDAY  
From study participant, draw:  
One 8.5 cc (mL) yellow top [acid citrate dextrose (ACD)] tube at two time points: prior to 
initiation of study drug (enrollment visit and prior to first dose, timing not important); and at each biweekly study visit while on high dose nelfinavir treatment.  
With a black, water resistant, sharpie pen, label each specimen with the following information: 
• AMC Protocol # 098 
• AMC Participant ID#  
• Date and time of collection  
 
AMC 098 (Version 4 .0) 08DEC2020 86 
NCI Version Date 08DEC2020  • Specimen type, i.e., WB = Whole Blood 
• Specimen purpose: Research  
Specimen Shipment  
• Seal the tops of the tube(s) with Parafilm.  
• Place the sealed tube(s) into bubble wrap (provided in STP-210 kit). 
• Tape around the bubble wrap so that the roll stays together and the tubes cannot fall 
out or break. 
• Place absorbent material sheet around the bubble wrapped tubes and slip into a biohazard poly- bag and “self -seal.”  
• Place poly -bag containing tubes into the white TYVEK bag and seal.  
• Place the TYVEK bag into the STP -[ADDRESS_848402] shipper with clear packing/shippi[INVESTIGATOR_45295]. 
• Affix the FEDEX air bill on blank side of the shipper making sure that it is marked 
“FEDEX PRIORITY OVERNIGHT.”  
• Mark “OTHER” in the air bill under “Packaging.” Please use the FedEx #  available on 
the AMC member’s only website. 
• Under air bill  section “Special Handling” indicate “YES -SHIPPERS DECLARATION 
NOT REQUIRED.”  
• Place “From/To” information onto areas provided on the shipper. 
DOMESTIC BLOOD SPECIMENS  should be shipped by [CONTACT_635045]: 
Sylvia Silver , DA 
AMC Bior epository 
George Washington Medical Center  
Ross Hall, Room [ADDRESS_848403], NW Washington, DC [ZIP_CODE] Phone: [PHONE_13223] Fax: 202- 994-5056 
Email: [EMAIL_12110]  
• Make certain that shipper is already either pre- labeled with ‘UN#3373’ stamp or  make 
a paper label with ‘UN#3373” and affix it to the shipper. 
• Make certain that the net volume of the specimen being shipped is written in the space provided on the shipper or make a separate label with the volume in mL and affix to the shipper. 
• Affix air bill to shipper so that the ‘UN’ and ‘VOLUME’ labels are visible.  
• RETAIN THE TOP COPY OF THE AIRWAY BILL FOR YOUR RECORDS.  
• Place the box in the FedEx pi[INVESTIGATOR_86899] a package pi[INVESTIGATOR_9107]. 
 
AMC 098 (Version 4 .0) 08DEC2020 87 
NCI Version Date 08DEC2020  Please Note: The shippers will be mailed back to each AMC site.  
Specimens should be sent by 24- hour shipment at room temperature. If collecting on a 
Friday  through Saturday where 24 -hour shipment is not possible, please see Section C  
below for instructions regarding separation of Plasma and PBMCs from blood. In this case 
separation will need to occur on site and within 2 hours of blood collection. 
C. INSTRUCTIONS FOR SEPARATION OF BLOOD FOR PLASMA AND PBMCS 
(FOR RESEARCH) COLLECTED ON FRIDAY  - SATURDAY  
In the event that blood samples are drawn on Friday  through Saturday, the samples must 
be processed into plasma and peripheral blood mononuclear cells (PBMC) immediately to maintain their viability for analysis.  
From study participant, draw:  
One 8.5 cc (mL) yellow top [acid citrate dextrose (ACD)] tube for PBMCs and plasma (see 
below for PBMC and plasma separation directions) at two time points: prior to study drug initiation (enrollment and prior to first drug dose acceptable, exact timing not important);  
and at each biweekly study visit while on nelfinavir treatment.  
With a black, water resistant, sharpie pen, label each specimen with the following information: 
• AMC Protocol # 098 
• AMC Participant ID#  
• Date and time of collection  
• Specimen t ype, i.e., WB = Whole Blood 
• Specimen purpose: Research  
Preparation of plasma and peripheral blood mononuclear cells (PBMCs)  
Blood is to be processed on site within 6 hours of collection. 
Materials  
• Lymphocyte Separation Medium (LSM Solution, Ficoll -Hypaque - sterile) 
• 15 mL conical centrifuge tubes (sterile)  
• PBS (sterile) 
• 1 mL , 5 mL and 10 mL  serologic pi[INVESTIGATOR_6343] (sterile) 
• 1.5 mL NUNC tubes 
• Alcohol- saturated, control rate freezer container  
• DMSO freezing media  
• Lonza BioWhittaker TM Cryoprotective Medium (catalog BW12-132A)  
• 50% Heat Inactivated Fetal Bovine Serum  
Plasma separation and freezing procedures 
 
AMC 098 (Version 4 .0) 08DEC2020 88 
NCI Version Date 08DEC2020  1. The 10 mL tubes of whole blood in acid citrate dextrose should be rotated gently two 
or three times before being centrifuged. Do not transfer before centrifugation.  
2. Separate the cells by [CONTACT_128934] 500 g for 10 minutes. 
3. Remove 0.5 mL aliquots of plasma and put into separate 1.5 mL NUNC tubes and transfer to liquid nitrogen storage. 
PBMC separation and freezing procedures 
1. The cel ls and plasma remaining from the previous step are transferred into a 15 mL 
conical tube or 50 mL centrifuge tube depending on volume. 
2. Sterile PBS should be added to the suspended whole blood cells in an equal volume and pi[INVESTIGATOR_406998] (1:1). 
3. The whole blood- PBS mixture should be carefully overlaid onto 4- [ADDRESS_848404] between the LSM and the whole blood mixture. (If the layer of  LSM gets mixed with the blood- PBS, the tube should be gently rotated to mix 
the blood, PBS, and LSM, and transfer to a 50 mL sterile conical tube. An equal volume of PBS is added, and the cells are separated at 600 g for 15 minutes. After removal of LSM -PBS supernatant, return to Step 2). 
4. Centrifuge the 15 mL conical tube for 30 minutes at 900 g at room temperature. The mononuclear leukocytes (principally lymphocytes and monocytes) will band at plasma/LSM interface.  
5. The fluffy white layer just below the plasma layer should be aspi[INVESTIGATOR_634985] [ADDRESS_848405] supernatant, taking care not to disturb pellet. 
9. Resuspend in 12 mL of PBS. Take 10 µ l of suspension for cell counting (dilute 
accordingly whether using a hemocytometer or automated cell counter). Centrifuge again for 10 minutes at 500g to wash cells. 
10. Using a 1 ml pi[INVESTIGATOR_8462], the *DMSO freezing mixture should be added dropwise to the cell pellet suspension. Gently finger -tap between drops to resuspend cells. If the cell 
pellet is small, only 0.5 mL of freezing media is added (and only one aliquot of cells is frozen). If the cell pellet is large, up to 2 mL of freezing media can be added in a drop wise fashion. (Cell densities of 1 -10 million PBMC/ml are best for cryopreservation. 
If a hemocytometer is available, the optimal concentration is 5 x 10
6 PBMC/mL).  
*Important: Do not put the DMSO containing media on the cell button all at once . 
Freeze the cell suspension in 0.5 mL aliquots in sterile NUNC vials by [CONTACT_86977] a room temperature, alcohol saturated, control rate freezer container and store in 
 
AMC 098 (Version 4 .0) 08DEC2020 89 
NCI Version Date 08DEC2020  the - 80°C freezer overnight. Transfer the cell suspension into the liquid ni trogen 
temperature freezer for long -term storage the next working day. 
GENERAL  
Plasma and PBMC specimens may be shipped in batches monthly. To ship blood 
specimens, use a diagnostic shipper approved for a volume of at least [ADDRESS_848406] shipper is recommended. These shippers may 
be ordered at the SAF -T-PAK website www.saftpak.com. The following instructions 
below are for use with the recommended STP -210 shipper. If using another federally 
approved diagnostic shipper, please follow instructions provided for that specific shipper. 
NOTE: Specimens MUST BE SHIPPED Sundays through Thursday  as an OVERNIGHT 
PRIORITY shipment. Specimens are NOT ACCEPTED ON SATURDAYS OR 
SUNDAYS . 
SPECIMEN PREPARATION, PACKAGING, AND SHIPMENT  
Blood specimens 
With a black, water resistant, sharpie pen, label each specimen with the following information:  
• AMC Protocol #098 
• AMC Participant ID#  
• Date and time of collection  
• Specimen type: i.e., P = Plasma; PBMCs= Peripheral Blood Mononuclear Cells 
• Specimen purpose: Research  
Specimen shipment 
• Seal the tops of the tube(s) with Parafilm.  
• Place the sealed tube(s) into bubble wrap (provided in STP-210 kit). 
• Tape around the bubble wrap so that the roll stays together and the tubes cannot  fall 
out or break. 
• Place absorbent material sheet around the bubble wrapped tubes and slip into a 
biohazard poly- bag and “self -seal.”  
• Place poly -bag containing tubes into the white TYVEK bag and seal. 
• Place the TYVEK bag into the STP -[ADDRESS_848407] shipper with clear packing/shippi[INVESTIGATOR_45295]. 
• Affix the FEDEX airbill on blank side of the shipper making sure that it is marked “FEDEX PRIORITY OVERNIGHT.”  
• Mark “OTHER” in the airbill under “Packaging.” Please use the FedEx #  available on 
the AMC member’s only website. 
• Under airbill section “Special Handling” indicate “YES -SHIPPERS DECLARATION 
NOT REQUIRED.”  
 
AMC 098 (Version 4 .0) 08DEC2020 90 
NCI Version Date 08DEC2020  • Place “From/To” information onto areas provided on the shipper. 
***PLEASE DOUBLE CHECK PACKAGING OF SHIPP ER AND DO NOT DEVIATE 
FROM REQUESTED LABELING. Shippi[INVESTIGATOR_634986] 9 label with weight of dry ice written on package. 
Mail to:  
Sylvia Silver , DA 
George Washington Medical Center  
Ross Hall,  Room [ADDRESS_848408], NW 
Washington, DC [ZIP_CODE] Tel: 202- 994-2945 
Fax: 202- 994-5056 
D. PREPARATION OF TISSUE SAMPLES  
From KS study participant, obtain: 
Skin biopsy; formalin- fixed  
Three will be obtained: 1). One at baseline; 2). Another at [ADDRESS_848409] dose NFV; and 3). A third at 2 weeks after beginning high dose NFV. Tissue specimens (punch biopsies) must  be placed into no more than 5 mL buffered formali n and processed 
locally to  FFPE. Please refer to the MOP for processing instructions . 
Skin biopsy; RNA later  
Three will be obtained: 1). One at baseline; 2). Another at [ADDRESS_848410] dose NFV; and 3). A third at 2 weeks after beginning high dose NFV. Tissue specimens (punch biopsies) should be placed into 1 mL RNA later ( locally sourced or provided to 
each site by [CONTACT_635046] 20). 
*NOTE: Specimens can only be accepted Monday through  Friday . Therefore, specimens 
can only be shipped Sunday -Thursday  for delivery the next day. Samples in RNA later  
are to be shipped on cold packs and FFPE block  is to be shipped in ambient temperature.  
TISSUE specimens from U.S. sites should be shipped to:  
Sylvia Silver , DA 
George Washington Medical Center  
Ross Hall, Room [ADDRESS_848411], NW Washington, DC [ZIP_CODE] Phone: [PHONE_13223] Fax: 202- 994-5056 
 
AMC 098 (Version 4 .0) 08DEC2020 91 
NCI Version Date 08DEC2020  TISSUE specimens from internatio nal sites should be shipped to: 
Johann Schneider, MMed Anat Path 
Division of Anatomical Pathology  
National Health Laboratory Service  
10th Floor Green Avenue, Room 52 
Tygerberg Hospi[INVESTIGATOR_634946] 7535 South Africa Phone: 27- 21-938-4041 
Fax: 27-21-938-6559 Email: [EMAIL_12114]  
E. ORAL SWAB SAMPLES  
Oral swabs will be self -collected by [CONTACT_635047] 14 days prior to starting study 
drug (14 baseline swabs) and twice weekly beginning on high dose nelfinavir (14 on-treatment swabs) for quantification of KSHV, EBV, CMV and HSV by [CONTACT_62865]. Swabs and 
tubes containing buffer will be provided to the sites. 
Swabs: Puritan Swabs, Fisher Scientific Polyester; Plastic shaft; 6 x 1/10 in.; 10 pack 
sterile; 1000/CS Catalog #25-806 1PD. Buffer: 5X recipe as follows (500 mL): 
• KCL, ACS Reagent  Sigma  #P3911-500G  18.65g 
• Tris-HCl, 1M, pH8  Sigma  #T3038  25 mL 
• EDTA, 0.5M, PH8 Sigma  #3690   125 mL 
• Igepal CA_630 Sigma  #l3021-500mL 25mL 
With a black, water resistant, sharpie pen, label each tube with the following information: • AMC Protocol # 098 
• AMC Participant ID#  
• Date and time of collection  
• Specimen type: Oral swabs 
Participants will be instructed how to collect swabs in the following manner (See 
Appendix 
XIII): 
• Rub the tip of the swabs over the inside of the both cheeks (buccal mucosa), along the 
upper and lower gum -lines inside and outside of the teeth, around the hard palate and 
across the soft palate; end with the posterior wall as tolerated by [CONTACT_2299].  
• Place the swab into opened buffer tube labeled with the participant ’s identification 
number. 
• Break off the long cardboard handle so that the lid can be put on tightly.  
• Complete the swab collection portion of the visit CRF.  
 
AMC 098 (Version 4 .0) 08DEC2020 92 
NCI Version Date 08DEC2020  • Place the buffer tubes from one participant in one plastic bag.  
Swabs should be stored and shipped at room temperature.  
SWAB specimens from U.S. sites should be shipped to: 
Sylvia Silver , DA 
George Washington Medical Center  
Ross Hall, Room [ADDRESS_848412], NW Washington, DC [ZIP_CODE] Phone: [PHONE_13223] Fax: 202- 994-5056 
SWAB specimens from intern ational sites should be shipped to:  
Johann Schneider, MMed Anat Path Division of Anatomical Pathology  
National Health Laboratory Service  
[ADDRESS_848413], Room 52 
Tygerberg Hospi[INVESTIGATOR_634946] 7535 South Africa Phone: 27- 21-938-4041 
Fax: 27-21-938-6559 Email: [EMAIL_12114]  
F. RECORD OF SPECIMENS  
This study will track specimens via GlobalTrace
SM, a component of the AMC Advantage 
eClinical system. The GlobalTraceSM shipment manifest must accompany all specimen 
shipments.  
 
 
AMC 098 (Version 4 .0) 08DEC2020 93 
NCI Version Date 08DEC2020  APPENDIX XI: DRUGS KNOWN TO BE METABOLIZED BY [CONTACT_584383]450 ISOENZYMES  
When drugs classified as “substrates” are co -administered with nelfinavir there is the potential for higher concentrations of the 
“substrate.” When nelfinavir is co -administered with compounds classified as “inhibitors,” increased plasma concent rations of nelfinavir 
is the potential outcome. The co -administration of “inducers” would potentially lower plasma nelfinavir concentrations. See Section 
3.2.[ADDRESS_848414] Potential Interactions  
CYP3A4 Substrates  
Albuterol  
Alfentanil  
Alprazolam  
Amlodipi[INVESTIGATOR_634987], conj., synthetic  
Estrogens, conj., equine  
Estrogens, conj., esterified  Ketoconazole  
Lansoprazole  
Letrozole  
Levomethadyl acetate hydrochloride  
Levonorgestrel  
Lidocaine  
Losartan  
Lovastatin  
Medroxyprogesterone  
Mefloquine  
Mestranol  
Methadone  
Methylergonovine  
Methysergide  
Miconazole  
Midazolam  
Miglustat  Quetiapi[INVESTIGATOR_634988] 098 (Version 4 .0) 08DEC2020 [ADDRESS_848415]  
Moricizine  
Nateglinide  
Nefazodone  
Nelfinavir  
Nevirapi[INVESTIGATOR_634989] 098 (Version 4 .0) 08DEC2020 95 
NCI Version Date 08DEC2020  CYP3A4 Substrates  
Diltiazem  
Disopyramide  Itraconazole  
Ketamine  Progesterone  
 
CYP3A4 Inhibitors  
Acetominophen  
Acetazolamide  
Amioderone  
Amlodipi[INVESTIGATOR_634990] 098 (Version 4 .0) 08DEC2020 [ADDRESS_848416]  
Ziprasidone  
 
AMC 098 (Version 4 .0) 08DEC2020 97 
NCI Version Date 08DEC2020   
CYP3A4 Inducers  
Aminoglutethimide  
Carbamazapi[INVESTIGATOR_634991] (high dose)  
Dexamethasone (high dose)  
Efavirenz  
Fosphenytoin  Hydrocortisone (high dose)  
Methylprednisolone (high dose)  
Modafinil  
Nevirapi[INVESTIGATOR_634992] (high dose)  
Primidone  
Rifabutin  
Rifampin  Rifapentine  
St. John’s wort  
 
CYP2C19 Substrates  
Amitriptyline  
Celecoxib  
Diclofenac1 
Fluoxetine  
Fluvastatin  
Glibenclamide  Glimepi[INVESTIGATOR_634993]  
S-naproxen→Norpi[INVESTIGATOR_634994]-4- OH2  
Rosiglitazone  Suprofen  
Tamoxifen  
Tolbutamide1 
Torsemide  
Valproic acid  
S-warfarin1 
Zafirlukast  
 
CYP2C19 Inhibitors  
Amiodarone  
Efavirenz  
Fenofibrate  
Fluconazole  
Fluvastatin  Fluvoxamine2 
Isoniazid  
Lovastatin  
Metronidazole  
Paroxetine  Phenylbutazone  
Probenicid  
Sertraline  
Sulfaphenazole1 Teniposide  
Voriconazole  
Zafirlukast  
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848417]. John's Wort  
 
Adapted from Cytochrome P -450 Enzymes and Drug metabolism. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL eds. Drug 
Information Handbook 12TH ed. Hudson, OH; LexiComp Inc. 2004: 1619-1631. 
(1). Malhorta et al . (2000). Clin Pharmacol Ther. 69:14-23 
(2). Mathijssen et al . (2002). J Natl Cancer Inst. 94:1247-1249 
(3). Frye et al . (2004). Clin Pharmacol Ther. 76:323-329 
 Additional information for drug interactions with cy tochrome P450 isoenzymes can be found at http://medicine.iupui.edu/flockhart/. 
 
 
AMC 098 (Version 4 .0) 08DEC2020 99 
NCI Version Date 08DEC2020  APPENDIX XII: DRUGS KNOWN OR SUSPECTED TO INHIBIT KSHV 
REPLICATION 
 
Direct Acting Antivirals  
acyclovir  
adefovir  
cidofovir  
foscarnet  
ganciclovir  
valacyclovir  
valganciclovir  
 
HIV Protease Inhibitors  
atazanivir  
darunivir  
fosempranavir  
lopi[INVESTIGATOR_634995] 098 (Version 4 .0) 08DEC2020 100 
NCI Version Date 08DEC2020  APPENDIX XIII: PARTICIPANT INSTRUCTIONS FOR ORAL SWABS  
YOU MUST KEEP THIS DIARY AND BRING IT TO YOUR APPOINTMENT  
Study Participant ID #: _______________ 
You will collect one oral swab on 14 separate days before you start nelfinavir (14 swabs total). If you begin taking a higher dose  of nelfinavir, you will collect more oral swabs after one week of 
taking the higher dose. You will collect two oral swabs every week for seven weeks (14 swabs 
total).  
How to collect the oral swabs 
1) Collect the oral swabs in the morning before brushing your teeth or eating. 
If you not able to collect the swab in the morning , wait one hour after eating, drinking, or 
brushing your teeth to collect the oral swabs. 
2) Rub the tip of the swab over each of these areas in your mouth as shown below: 
A. The inside of the both cheeks 
B. Along the upper and lower gum- lines inside and outside of the teeth  
C. Around the hard palate and across the soft palate 
D. End with the posterior wall  (if you are able ) 
 
  
 B. 
Upper and 
Lower Gums, 
Inside and 
Outside Teeth  D. 
Posterior 
wall 
 
AMC 098 (Version 4 .0) 08DEC2020 101 
NCI Version Date 08DEC2020  Study Participant ID #: _______________ 
 
3) Place the swab into an opened tube.  
4) Break off the long cardboard handle so that the lid can be put on 
tightly. 
5) Place the tubes into the plastic bag and keep the swabs at room temperature  to bring to your next study visit. 
Please record in the diary below the date that oral swab was done. Be sure to record the swabs when you do them  and avoid writing entries for several days at once. 
When you are finished, bring this diary with you to your next study visit. In the “Comments” section write any problems you are having collecting the swabs or if you missed a swab. 
 
Oral Swab Collection Before Starting Nelfinavir  
Day of Collection  Date  
MM/DD/YY YY Time  
Swab Collected  
(circle AM/PM)  Comments  
1 ___/___/______  ___:___ AM  PM  
2 ___/___/______  ___:___ AM  PM  
3 ___/___/______  ___:___ AM  PM  
4 ___/___/______  ___:___ AM  PM  
5 ___/___/______  ___:___ AM  PM  
6 ___/___/______  ___:___ AM  PM  
7 ___/___/______  ___:___ AM  PM  
8 ___/___/______  ___:___ AM  PM  
9 ___/___/______  ___:___ AM  PM  
10 ___/___/______  ___:___ AM  PM  
11 ___/___/______  ___:___ AM  PM  
12 ___/___/______  ___:___ AM  PM  
13 ___/___/______  ___:___ AM  PM  
14 ___/___/______  ___:___ AM  PM  
Please return the swabs to your doctor with your diary at your next study visit.  

 
AMC 098 (Version 4 .0) 08DEC2020 102 
NCI Version Date 08DEC2020  Study Participant ID #: _______________ 
 
Please record in the diary below the date that oral swab was done. Be sure to record the swabs 
when you do them  and avoid writing entries for several days at once. When you are finished, bring 
this diary with you to your next study visit. In the “Comments”  section write any problems you 
are having collecting the swabs or if you missed a swab. 
 
Oral Swab Collection on High Dose Nelfinavir  
Weeks  Swabs  Date  
MM/DD/YYYY  Time  
Swab Collected  
(circle AM/PM)  Comments  
Week 1  No Swabs  
Week 2  Swab 1  ___/___/______ ___:___ AM  PM  
Swab 2  ___/___/______ ___:___ AM  PM  
Week 3  Swab 1  ___/___/______ ___:___ AM  PM  
Swab 2  ___/___/______ ___:___ AM  PM  
Week 4  Swab 1  ___/___/______ ___:___ AM  PM  
Swab 2  ___/___/______ ___:___ AM  PM  
Week 5  Swab 1  ___/___/______ ___:___ AM  PM  
Swab 2  ___/___/______ ___:___ AM  PM  
Week 6  Swab 1  ___/___/______ ___:___ AM  PM  
Swab 2  ___/___/______ ___:___ AM  PM  
Week 7  Swab 1  ___/___/______ ___:___ AM  PM  
Swab 2  ___/___/______ ___:___ AM  PM  
Week 8 Swab 1  ___/___/______ ___:___ AM  PM  
Swab 2  ___/___/______ ___:___ AM  PM  
Please return the swabs to your doctor with your diary at your next study visit.  
 
AMC 098 (Version 4 .0) 08DEC2020 103 
NCI Version Date 08DEC2020  APPENDIX XIV: PARTICIPANT DRUG INFORMATION HANDOUT AND WALLET 
CARD  
Information for Participants, Their Caregivers and Non -Study Healthcare Team on Possible 
Interactions with Other Drugs and Herbal Supplements  
The participant ___________________ is enrolled on a clinical trial using the experimental study 
drug, nelfinavir . This clinical trial is sponsored by [CONTACT_29630]. This form is 
addressed to the patient, but includes important information for others who care for this patient.  
These are the t hings that you as a healthcare provider need to know: 
Nelfinavir interacts with certain specific enzymes in your liver* and may affect the heart’s electrical activity (QTc prolongation)**.  
* The enzyme(s) in question is/are CYP3A and CYP2C19 . Nelfinavir is  broken down by 
[CONTACT_635048]. 
** The heart’s electrical activity may be affected by [CONTACT_635049]. The study doctor may be concerned about QTc prolongation and any other medicine that is associated with greater risk for having QTc prolongation. 
To the participant: Take this paper with you to your medical appointments and keep the attached information card in your wallet . 
Nelfinavir  may interact with other drugs which can cause side effects . For this reason, it is very 
important to tell your study doctors of any medicines you are taking before you enroll onto this clinical trial. It is also very important to tell your doctors if you stop taking any regular medicines, or if you start taking a  new medicine while you take part in this study. When you talk about your 
current medications with your doctors, include medicine you buy without a prescription (over -the-
counter remedy), or any herbal supplements such as St. John’s Wort. It is helpful to bring your medication bottles or an updated medication list with you. 
Many health care providers can write prescriptions. You must tell all of your health care providers 
(doctors, physician assistants, nurse practitioners, pharmacists) you are taking part in a clinical 
trial. 
These are the things that you and they need to know:  
Nelfinavir must be used very carefully with other medicines that use certain liver enzymes or that may affect your heart’s electrical activity. Before you enroll onto the clinical tr ial, your study 
doctor will work with your regular health care providers to review any medicines and herbal supplements that are considered strong inducers/inhibitors or substrates of CYP3A or CYP2C19, or any medicine associated with greater risk for havin g QTc prolongation. 
• Please be very careful! Over -the- counter drugs (including herbal supplements) may contain 
ingredients that could interact with your study drug. Speak to your doctors or pharmacist to determine if there could be any side effects.  
• Your regular health care provider should check a frequently updated medical reference or call your study doctor before prescribing any new medicine or discontinuing any medicine. 
• Your study doctor’s name [CONTACT_832] ________________________ and he or she can be contact[CONTACT_6811] _____________________________________. 
 
AMC 098 (Version 4 .0) 08DEC2020 [ADDRESS_848418] with drugs that are processed by [CONTACT_6813], or affects 
the electrical activity of your heart . Because of this, it is very 
important to: 
 Tell your doctors if you stop taking any medicines or if you 
start taking any new medicines. 
 Tell all of your health care providers  (doctor s, physician 
assistants , nurse practitioner s, or pharmacists ) that you are taking 
part in a clinical trial.  
 Check with your doctor or pharmacist whenever you need to 
use an over -the- counter medicine or herbal supplement.  Nelfinavir interacts with a specific liver enzymes called 
CYP3A and CYP2C19, heart’s electrical activity (QTc 
prolongation) , and must be used very carefully with oth er 
medicines that interact with Nelfinavir . 
 Before you enroll onto the clinical trial, your study doctor 
will work with your regular health care providers to review 
any medicines and herbal supplements that are considered “strong inducers/inhibitors or substrates of CYP3A and 
CYP2C19 , or affect the heart’s electrical activity .” 
 Before prescribing new medicines, your regular health care providers should go to a frequently- updated medical 
reference  for a list of drugs to avoid,  or contact [CONTACT_51081].  
 Your study doctor’s name [CONTACT_832] ____________________ _ and 
can be contact[CONTACT_6811] _________________________________.  
AMC -098 (Version 4. 0) 08DEC2020 i 
NCI Version Date 08DEC2020  SUMMARY OF CHANGES  
A Pi[INVESTIGATOR_634937] 4.0 
 
NCI Protocol #: AMC -098 
Local Protocol #: AMC -098 
 NCI Version Date: 08DEC2020 Protocol Date: 08DEC2020  
I. Scientific and Substantive Changes  
# Section  Comments  
1.  WHAT EXTRA 
TESTS AND 
PROCEDURES 
WILL I HAVE IF 
I TAKE PART IN 
THIS STUDY?  Added statements communicating that if previously submitted 
baseline tissue samples are inadequate to perform IHC studies, additional slides from the diagnostic punch biopsy may be requested to perform such studies. 
See protocol summary of changes item 3 
regarding this change. 
II. Administrative and Editorial Changes:  
# Section  Comments  
2.  Global  Version number and version date were updated from v3.0 dated 
13FEB2019 to v4.0 dated 08DEC2020 
3.  HOW LONG 
WILL I BE IN 
THIS STUDY?  Participants will be followed for 8 weeks after discontinuing 
nelfinavir unless in the opi[INVESTIGATOR_021], the 
participant should start an alternative therapy sooner for treatment of 
KS. Instructions were added requiring follow -up evaluations to be 
completed before participants start a new therapy to treat KS.  
4.  WHERE CAN I 
GET MORE 
INFORMATION?  [CONTACT_635059] ’s (Protocol Chair) address and contact [CONTACT_635050]. 
AMC -098 (Version 4. 0) 08DEC2020 1 
NCI Version Date 08DEC2020  AMC- 098 MODEL INFORMED CONSENT FORM  
Study Title for Study Participants : A Study of Nelfinavir for Treating Kaposi Sarcoma  
Official Study Title for Internet Search on http://www.ClinicalTrials.gov : A Pi[INVESTIGATOR_634996]  
A Clinical Trial of the AIDS Malignancy Consortium (AMC) 
WHAT IS THE USUAL APPROACH TO MY CANCER?  
People with Kaposi sarcoma who are not in this study are usually treated with intravenous 
chemotherapy (cancer fighting drugs given through a needle in a vein), cryotherapy (freezing of the cancer), radiation, or other treatments depending on how severe the disease is. Somet imes 
combinations or sequences of these treatments are used, and your doctor can explain which may be best for you. These treatments can reduce symptoms and may stop the tumor from growing for several months or more.  
WHAT ARE MY OTHER CHOICES IF I DO NOT TAKE PART IN THIS STUDY?  
If you decide not to take part in this study, you have other choices. For example: 
• you may choose to have the usual approach described above 
• you may choose to take part in a different study, if one is available, or 
• you may choose not to be treated for cancer  
WHY IS THIS STUDY BEING DONE?  
You are being asked to participate in this study because you are an adult with Kaposi sarcoma that 
has not been improving. The purpose of this study is to test the good and bad effects of the medicine called nelfinavir. Nelfinavir could shrink or cure your cancer, but it could also cause side effects. 
Nelfinavir is FDA approved to treat HIV, but it has not yet been tested or FDA approved to treat people who already have Kaposi sarcoma . Nelfinavir has also been shown to kill the Kaposi 
sarcoma- associated herpes virus (KSHV) that causes Kaposi sarcoma, and has been found to be 
safe when used at higher doses to treat people with other cancers.  
We will test whether regular or higher doses of nelfinavir help shrink your Kaposi sarcoma or cause any side effects. Another purpose of this study is for researchers to learn how well nelfinavir blocks the KSHV virus in people taking the study medicine. There will be about 36 people taking part in this study. 
WHAT ARE THE STUDY GROUPS?  
All people in the study will get the same study treatment with nelfinavir in the form of pi[INVESTIGATOR_3353]. Some 
of the people in the study will have HIV and some will not have HIV. If you join the study, you will first get the regular approved dose of nelfinavir (1250 mg by [CONTACT_104744]). If the regular dose of nelfinavir does not cause your Kaposi sarcoma to shrink enough then you will be given a higher dose of nelfinavir (3125 mg by [CONTACT_104744]). If nelfinavir causes bad side effects, the dose might be lowered or stopped. 
Nelfinavir should be taken with a moderately high fat meal, for example that includes oil, butter, 
eggs, or meat. If you cannot swallow the tablet whole, you may dissolve the tablet in a small amount of water. Drink all of the mixture after the tablet diss olves. Then refill your glass with 
AMC -098 (Version 4. 0) 08DEC2020 [ADDRESS_848419]. Do not mix with acidic food or juice (apple juice, 
applesauce, or orange juice) because it will make it taste bad. Someone in the clinic will talk with you about the diet requi rements.  If you vomit after taking nelfinavir, do not take more pi[INVESTIGATOR_634997]. 
HOW LONG WILL I BE IN THIS STUDY?  
You will be given the regular dose of nelfinavir for up to [ADDRESS_848420] IF I TAKE PART IN THIS 
STUDY?  
Most of the tests that you will have done are part of the usual way people with Kaposi sarcoma are treated. However, there are some extra tests and exams that you will need to do if you join in this study. 
Before the study: 
• You will need to take a HIV test unless you have had one recently or your usual doctor  knows 
for sure that you do have or do not have HIV. 
• If your Kaposi sarcoma was diagnosed without a biopsy (small pi[INVESTIGATOR_634998]) we will ask your doctor to take a biopsy to make sure that you have Kaposi sarcoma.  
• We will as k questions related to the risk of getting HIV, including drug use and sexual 
behavior. 
• You will have an electrocardiogram (EKG) within 4 weeks of starting the study  
• You will have a chest X-ray within 4 weeks of starting the study 
• If you are a female who may become pregnant, you will have a pregnancy test  
During the study: 
• You will come to the study clinic every 2 weeks. 
• You will have a nutrition assessment in addition to routine physical examinations.  
• You will have an EKG  two weeks after starting standard dose nelfinavir and two weeks after 
starting high dose ne lfinavir.  
• You may receive chest X -rays while on treatment if the doctor thinks you need them. 
• If you are a female who may become pregnant you will have a pregnancy test  prior to starting 
standard dose nelfinavir and again prior to starting high dose nelfinavir  
• Two Kaposi sarcoma biopsies will be taken before you start nelfinavir, during the regular dose 
AMC -098 (Version 4. 0) 08DEC2020 [ADDRESS_848421] to biopsies done for cancer diagnosis. Local anesthesia will be used for your comfort.  If the tissue from the biopsy is not adequate, the study doctors may need to 
use some additional the tissue left over from your biopsy when you were diagnosed with cancer to perform these tests.  
• The biopsies will be very small (only a few millimeters across). Adverse effects from these biopsies are very uncommon and include mild pain, bruising, bleeding and low risk of infection . 
• We will ask you to collect saliva with a swab in your mouth daily for [ADDRESS_848422] the KSHV virus that causes Kaposi sarcoma. This virus is found in the saliva of many people with Kaposi sarcoma. Collecting these swabs is painless.  
• Before you start nelfinavir, we will draw blood samples (about 2 tablespoons total) at separate 
screening visits for research tests. While you are taking nelfinavir, we will draw about [ADDRESS_848423] for other viruses that 
occur with HIV infection and Kaposi sarcoma.  
Neither you nor your health care plan/insurance carrier will be billed for the collection of the biopsies, saliva swabs, or any blood tests that are not part of usual care for Kaposi sarcoma. Results 
from these tests will not be shared with you or your study doctor.  
WHAT POSSIBLE RISKS CAN I EXPECT FROM TAKING PART IN THIS STUDY?  
If you choose to take part in this study, there is a risk  that:  
• You may lose time at work or home and spend more time in the hospi[INVESTIGATOR_90782]’s office than usual. 
• You may be asked sensitive or private questions which you normally do not discuss. 
If you are taking certain medicines, you may not be able to take part in the study. 
If you have HIV, you will continue taking your regular HIV medications throughout the course of 
the study. If you are on certain HIV medications, you may need to change regimens for safety with the nelfinavir during the time you are in the study and for a short time after. If you choose not to switch to one of the allowed regimens, you may not be able to take part in the study.  
If you take part in the study, you will be given a Participant Drug Information and Wallet Card 
that has information about drugs may interact with nelfinavir which can cause side effects. 
It is possible that your Kaposi sarcoma could get worse while taking nelfinavir. Nelfinavir may 
affect how different parts of your body work such as your liver, kidneys, heart, and blood. The study doctor will be testing your blood and will let you know if changes occur that may affect your health.  
AMC -098 (Version 4. 0) 08DEC2020 [ADDRESS_848424] other side effects from nelfinavir or the tests that will be 
done. 
Here are important  points about side effects:  
• The study doctors do not know who will or will not have side effects. 
• Some side effects may go away soon; some may last a long time.  
• Some side effects may be serious and may even result in death.  
Here are important points about how you and the study doctor can make side effects less of a 
problem: 
• Tell the study doctor if you notice or feel anything different so they can see if you are having 
a side effect.  
• The study doctor may be able to treat some side effects.  
• The study doctor may adjust nelfinavir to try to reduce side effects.  
The tables below show the most common and the most serious side effects that researchers know about. There might be other side effects that researchers do not yet know about. If important new side effect s are found, the study doctor will discuss these with you. 
COMMON, SOME MAY BE SERIOUS  
In [ADDRESS_848425]: 
• Diarrhea  
• Low red blood cell count (anemia) 
• Low white cell blood cell count 
 
OCCASIONAL, SOME MAY BE SERIOUS  
In [ADDRESS_848426]:  
• Fatigue  
• Dehydration 
• Heartburn  
• Nausea  
• Bloating or gas  
• Rash  
• Low platelets  
• Increase in cholesterol and triglycerides  
• High blood sugar or diabetes  
 
RARE, AND SERIOUS  
In [ADDRESS_848427]:  
• Infection, especially when white blood cell count is low  
• Electrical changes in the heart causing abnormal or dangerous heart rhythm  
Let your study doctor know of any questions you have about possible side effects. You can ask the study doctor questions about side effects at any time. 
AMC -098 (Version 4. 0) 08DEC2020 5 
NCI Version Date 08DEC2020  Reproductive risks: Reproductive risks have not been seen with nelfinavir. However, higher doses 
of nelfinavir have not been studied in pregnant or breastfeeding women. You should not get pregnant or breastfeed a baby [CONTACT_305350]. Check with the study doctor about what types of 
birth control, or pregnancy prevention, to use while in this study. If you are a woman who could 
become pregnant and are taki ng hormonal birth control, talk to the study doctor. Nelfinavir can 
cause hormonal birth control to fail, and may lead to unplanned pregnancy. To take part in this study, you will need to agree to use other non- hormonal birth control methods like condoms or 
abstinence while taking nelfinavir.  
WHAT POSSIBLE BENEFITS CAN I EXPECT FROM TAKING PART IN THIS STUDY?  
It is not possible to know at this time if nelfinavir is better than the usual ways Kaposi sarcoma is treated, so this study may or may not help treat  your Kaposi sarcoma. This study will help 
researchers learn things that will help people in the future.  
CAN I STOP TAKING PART IN THIS STUDY?  
Yes. You can decide to stop at any time. If you decide to stop for any reason, it is important to let the study doctor know as soon as possible so you can stop safely. If you stop, you can decide whether or not to let the study doctor continue to provide your medical information to the organization running the study. 
The study doctor will tell you about new information or changes in the study that may affect your 
health or your willingness to continue in the study. 
The study doctor may take you out of the study: 
• If your health changes and the study is no longer in your best interest, 
• If new information becomes available,  
• If you do not follow the study rules, 
• If the study is stopped by [CONTACT_456], IRB, or (insert as appropriate: FDA/National Drug 
Authority of Uganda). 
WHAT ARE MY RIGHTS IN THIS STUDY?  
Taking part in this study is your choice. No matter what decision you make, and even if your 
decision changes, there will be no penalty to you. You will not lose medical care or any legal rights.  
For questions about your rights while in this study, call the ________________________ (insert name [CONTACT_29094])  Institutio nal Review Board at __________________ (insert telephone number). 
(Note to Local Investigator: Contact [CONTACT_539052] a local institution who are not on the IRB or research team but take calls regarding clinical trial questions can also be listed here.) 
WHAT ARE THE COSTS OF TAKING PART IN THIS STUDY?  
Nelfinavir will be supplied to you at no charge by [CONTACT_4618], Inc. while you take part in this study. It 
is possible that the nelfinavir may not continue to be supplied while you are on the study. Although 
not likely, if this occurs, your study doctor will talk to you about your options. 
You and/or your health plan/insurance company will not be billed  for the tumor biopsies, saliva 
AMC -098 (Version 4. 0) 08DEC2020 6 
NCI Version Date 08DEC2020  swabs, or extra research blood tests that are not part of usual cancer care.  
You and/or your health plan/insurance company will need to pay for all of the other costs of 
treating your cancer while in this study, including the co st of usual tests, procedures, or medicines 
to manage any side effects, unless you are told that certain tests are supplied at no charge. Before you decide to be in the study, you should check with your health plan or insurance company to find out exactly what they will pay for.  
You will receive $(insert amount) for each study visit you attend. (Note to Local Investigator: retain this information and insert amount as applicable in the local consent. If your site will not 
be compensating the participant, please use the following language instead: There will not be any monetary compensation for participation in this study.) 
WHAT HAPPENS IF I AM INJURED OR HURT BECAUSE I TOOK PART IN THIS 
STUDY?  
If you are injured or hurt as a result of taking part in this stud y and need medical treatment, please 
tell your study doctor. The AIDS Malignancy Consortium will not offer to pay for medical 
treatment for injury. (Note to SSA site: add appropriate language for coverage of research- related 
injury costs). Your insurance company may not be willing to pay for study- related injury. If you 
feel this injury was a result of medical error, you keep all your legal rights to receive payment for this even though you are in a study. 
WHO WILL SEE MY MEDICAL INFORMATION?  
Your privacy i s very important to us and the researchers will make every effort to protect it. Your 
information may be given out if required by [CONTACT_2371]. For example, certain states require doctors to 
report to health boards if they find a disease like tuberculosis. However, the researchers will do 
their best to make sure that any information that is released will not identify you. Some of your health information, and/or information about your specimen, from this study will be kept in a central database for research. Your nam e or contact [CONTACT_305352]. 
There are organizations that may inspect your records. These organizations are required to make sure your information is kept private, unless required by [CONTACT_139207]. Some of these organizations are:  
• The sponsor, the AIDS Malignancy Consortium (AMC) 
• The drug company supporting the study, [COMPANY_007] Inc. 
• The Institutional Review Board (IRB) is a  group of people who review the research with the 
goal of protecting the people who take part in the study. 
• The Food and Drug Administration (FDA) and the National Cancer Institute (NCI) in the U.S., 
(international sites: insert name [CONTACT_635057]/or local regulatory authorities who will 
review study records)  
WHERE CAN I GET MORE INFORMATION?  
You may visit the NCI Web site at http://cancer.gov/ for more information about studies or general information about cancer. You may also call the NCI Cancer Information Service to get the same information at: 1 -800-4- CANCER (1 -[PHONE_421]). 
 
AMC -098 (Version 4. 0) 08DEC2020 7 
NCI Version Date 08DEC2020  A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search  this Web site at any time.  
WHO CAN ANSWER MY QUESTIONS ABOUT THIS STUDY?  
You can talk to the study doctor about any questions or concerns you have about this study or to report side effects or injuries. Contact [CONTACT_39635] __________________ (insert name [CONTACT_539071][s])  at __________________ (insert telephone number). 
You can also contact [CONTACT_079] [INVESTIGATOR_634999]- Chairs for the AIDS Malignancy 
Consortium: 
[CONTACT_635060] de recherche du CHU Sainte- Just 
3175 Côte Sainte-Catherine Montréal Qc H3T 1C5, Canada  
Tel: ([PHONE_13224] Emai l: [EMAIL_12107] 
 [CONTACT_635061] &  Family Research Institute  
[ADDRESS_848428] N, Mailstop E2- 112 
Seattle, WA [ZIP_CODE] Tel: (206) 667 -4628 
Email: [EMAIL_12109] 
 
[CONTACT_635062] 389, Cancer Research Building [ADDRESS_848429] Baltimore, MD [ZIP_CODE] Tel: (410)- 955-8839 
Email: [EMAIL_12118]  
 OPTIONAL SAMPLE COLLECTIONS FOR LABORATORY STUDIES AND DONATION OF LEFTOVER TISSUE SAMPLES TO THE AIDS AND CANCER SPECIMEN RESOURCE (ACSR)  
This section is about optional studies you can choose to take part in 
Researchers are trying to learn more about cancer, HIV/AIDS, and other health p roblems. Much 
of this research is done using samples from your tissue, blood, urine, or other fluids. Through these 
studies, researchers hope to find new ways to prevent, detect, treat, or cure health problems. Some of these studies may be about genes. Gen es carry information about features that are found in you 
and in people who are related to you. Researchers are interested in the way that genes affect how your body responds to treatment. 
If you choose to take part in this study, the study doctor for the main study would like to collect 
unused blood and biopsy tissue left over after the study is done. The researchers ask your permission to store and use your samples and related health information (for example, your response to cancer treatment, results of study tests and medicines you are given) for medical 
research. The research that may be done is unknown at this time. Storing samples for future studies is called “biobanking.” The Biobank is being run by [CONTACT_635051]. 
What is involved? If you agree to take part, here is what will happen next: 
AMC -098 (Version 4. 0) 08DEC2020 8 
NCI Version Date 08DEC2020  1) Your sample and some related health information will be stored in the ACSR Biobank, along 
with samples and information from other people who take part. The samples will be kept until 
they are used up. Information from your medical record may be updated after the study is over. 
2) Qualified researchers can submit a request to use the materials stored in the ACSR. A science committee at the ACSR will review each request. There will also be an ethics review to ensure 
that the request is necessary and proper. Researchers will not be given your name [CONTACT_305358]. 
3) Neither you nor your study doctor will be notified when research will be conducted or given reports or other information about any research that is done using your samples.  
4) Some of your genetic and health information may be placed in central databases that may be public, along with information from ma ny other people. Information that could directly 
identify you will not be included. 
What are the possible risks?  
1) There is a risk that someone could get access to the personal information in your medical records or other information researchers have stored about you. 
2) There is a risk that someone could trace the information in a central database back to you. Even without your name [CONTACT_39648], your genetic information is unique to you. The researchers believe the chance that someone will ident ify you is very small, but the risk may 
change in the future as people come up with new ways of tracing information. 
3) In some cases, this information could be used to make it harder for you to get or keep a job or insurance. There are laws against the misuse of genetic information, but they may not give full protection. There can also be a risk in knowing genetic information. New health information about inherited traits that might affect you or your blood relatives could be found during a study. The researchers believe the chance these things will happen is very small, but cannot promise that they will not occur.  
How will information about me be kept private?  
Your privacy is very important to the researchers and they will make every effort to protect it. Here are just a few of the steps they will take:  
1) When your sample(s) is sent to the researchers, no information identifying you (such as your name) will be sent. Samples will be identified by a unique code only. 
2) The list that links the unique code to your nam e will be kept separate from your sample and 
health information. The ACSR and AMC staff with access to the list must sign an agreement to keep your identity confidential. 
3) Researchers to whom the ACSR and the AMC send your sample and information will not know who you are. They must also sign an agreement that they will not try to find out who you are. 
4) Information that identifies you will not be given to anyone, unless required by [CONTACT_2371]. 
5) If research results are published, your name [CONTACT_635058] n will not be used. 
What are the possible benefits?  
You will not benefit from taking part. The researchers, using the samples from you and others, might make discoveries that could help people in the future.  
AMC -098 (Version 4. 0) 08DEC2020 9 
NCI Version Date 08DEC2020  Are there any costs or payments?  
There are no ad ditional costs to you or your insurance for these optional studies. You will not be 
paid for taking part. If any of the research leads to new tests, drugs, or other commercial products, 
you will not share in any profits.  
What if I change my mind?  
If you decide you no longer want your samples to be used, you can call the study doctor, _________________, (insert name [CONTACT_116497])  at ________________________ 
(insert telephone number of study doctor for main trial) who will let the researchers know. Then, any sample that remains in the bank will no longer be used and related health information will no longer be collected. Samples or related information that ha ve already been given to or used by 
[CONTACT_116486].  
What if I have more questions?  
If you have questions about the use of your samples for research, contact [CONTACT_39635], ________________, (insert name [CONTACT_116497]), at _____________________  
(insert telephone number of study doctor for main trial) . 
Please circle your answer to show whether or not you would like to take part in each option: 
Samples for future research studies:  
My samples and related information may be donated to ACSR Biobank for use in future 
health research.  
 YES    NO 
I agree to have my samples undergo genetic testing to learn about, prevent, diagnose, or treat HIV -related diseases and cancer.  
 YES    NO 
This is the end of the section  about optional studies. 
  
AMC -098 (Version 4. 0) 08DEC2020 [ADDRESS_848430] been answered. I will be given a signed copy of this form. I  agree to take part in 
the study. 
 Participant’s signature: ________________________________  Date of signature: _____________________________________  Signature [CONTACT_52943](s) conducting the informed consent discussion: _______________________  Date of signature: _____________________________________ 
AMC -098 (Version 4. 0) 08DEC2020 11 
NCI Version Date 08DEC2020  ATTACHMENT 1: AMC CERTIFICATE OF CONFIDENTIALITY STATEMENT  
The NIH has given the AMC a Certificate of Confidentiality. The Certificate does not mean that 
the NIH or the U.S.  Government recommend that you take part in this study. This Certificate helps 
us keep your health information private. 
Your records for this study will have information that may identify you. This Certificate lets us 
turn down legal demands for your study records. We can use the Certificate to turn down demands 
for records from a U.S. court. The Certificate can be used in any federal, state, or local legal matters. We will use the Certificate to turn down any demands for your study records. The cases where  we cannot use the Certificate are explained below.  
We cannot use the Certificate to turn down a demand from the U.S. Government for study records. This applies to audits or reviews of the AMC. This also applies to study records that we have to report to the FDA.  
The Certificate does not stop you or your family members from sharing your health information. It does not stop you from talking about taking part in this study. You may give written permission for an insurer, employer, or other person to get copi[INVESTIGATOR_89890]. If you give permission, we cannot use the Certificate to say  no to a request for your study records. 